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Patient preferences refer to the idea that patients evaluate elements of healthcare based upon their experiences, values, 
and attitudes, and these preferences can influence their healthcare decisions [1]. These elements can include the 
relative benefits, harms, costs, and important outcomes resulting from different medical treatments, products 
situations, and decisions. According to the Federal Drug Association (FDA), patient preference information is defined 
as information resulting from “assessments of the relative desirability or acceptability to patients of specified 
alternatives or choices among outcomes or other attributes that differ among alternative health interventions” [2]. 
Patient preferences are a critical and meaningful conception within the field of health research. Health is a complex 
concept with varying definitions across different social groups, with the World Health Organization defining it as “a 
state of complete physical, mental, and social well-being” and “not merely the absence of disease or infirmity” [3]. 
More contemporary definitions have included “the ability to adapt and to self-manage, in the face of social, physical 
and emotional challenges” [4] emphasising how health is both deeply personal and highly subjective from person to 
person. ‘Good’ health is essentially an ideological construction, influenced by socio-cultural norms and values, and 
enacted by a variety of different behaviours and activities. There are global variations in health behaviours, both in 
perception and expression. Therefore, how patients view and assess biomedical products or treatments is pertinent 
issue that must be examined in order to better support healthcare policy. Global and public health policy is heavily 
founded in the practices of empirical data collection, inferring complex interactions between risk factors and states of 
morbidity, mortality, and disability. However, it is also vital to examine the individual’s interaction with their 
healthcare choices. Patients who use any elements of healthcare, therefore, are the “co-producers of their health and 
… represent the only consistent fact throughout the care pathway” [4].  
Furthermore, the examination of patient preferences has wide-reaching practical implications for healthcare policy 
and economics, with many possible applications. For example, before healthcare professionals can attempt to establish 
health intervention campaigns in local populations, they must first determine whether their strategies will be 
successfully recognised, supported, and followed by individuals. Global health interventions are more successful if 
they “target behaviour change in a manner that is appropriate and acceptable to the populations in which they are 
implemented” [5]. This has global implications: from a Tanzanian population’s willingness to pay for cataract 
surgeries [6] to a British population’s acceptance of a measles-mumps-rubella vaccine [7]. Patient preferences have 
significant contribution to the development, regulation, and reimbursement of medical products. In addition to 
encouraging treatments that are effective, safe, and cost-effective, the incorporation of the patient voice is essential to 
improving lives and delivering medical products that are actually used or wanted within patient populations. They can 
help establish a better understanding of the disease, discern personal experiences of the patients with the disease, and 
anticipate the acceptability of various benefits and risks. This can be particularly use for the predicting the reception, 
acquirement, and dissemination of a medical product across national or international populations.  
 
Patient Preference Studies 
The attention given to patient preference studies has increased exponentially in recent years [8],  not just as an effective 
tool for patient engagement, but a legitimate method for advancing evidence-based product development. Patient 
preference studies are being recognised as being the cornerstone of patient-centric healthcare and clinical care, and 
that their applications will only increase in the coming years [9]. Notable organisations have promoted their 
importance, both in terms of improving medical products and treatments and to healthcare systems as a whole, and 
have issued high-profile reports guiding how they should be conducted, assessed, and incorporated into decision-
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making. This includes guidance from the FDA [2], the European Medicines Agency (EMA) [10], and the Medical 
Device Innovation Consortium (MDIC) [11], as well as previous Innovative Medicines Initiative (IMI) projects [12].  
Patient preference information can be identified through both qualitative and quantitative research methods, including 
social surveys, experiments, case studies, interviews, and other forms of participant observation [11]. However, it is 
still unclear what constitutes a methodologically sound patient-preference study, and how different methods compare 
to one another [8]. This is especially relevant for determining how the functions of their methodologies can influence 
the manner in which data is obtained, analysed, and reported. In order for patient preference studies to be sufficiently 
acknowledged within the field of healthcare research, and for their role in the MPLC to be enhanced, greater clarity 
is needed concerning how patient preference information is investigated.  
More examination is also required on the composition of quantitative and qualitative data produced by patient 
preference studies, and the most effective uses for these data. Although patient preference information can be used to 
inform a variety of different decision-points, this may largely depend on the stage of the MPLC.    
 
The Medical Product Lifecycle 
Benefit-risk assessments are often described as the ‘foundation’ for medical product decision-making [13] and patient 
preferences can significantly contribute towards their input [14, 11, 15, 16]. Other applications for patient preferences 
include the identification of new medical products [17], identifying unmet medical needs [14, 11, 17], regulatory 
approval submissions [18], and health technology assessments [19, 20, 21].  
Therefore, the successful identification and analysis of patient preference information is relevant to many stakeholders, 
including (but not limited to) the pharmaceutical industry, regulators, health technology assessment bodies, health 
insurance agencies or reimbursement bodies, clinicians, academics, patient advocates, caregivers, and patients 
themselves. As these stakeholders conduct vital functions across many different stages of the medical product lifecycle 
(MPLC), this illustrate how patient preference information can influence the production of medical products on both 
the micro- and macro- level.  
The MPLC can be summarised in the following way:  
Figure 1: Medical product lifecycle (MPLC) 
 
A complete overview of the influence and impact of patient preference information at every stage of the MPLC is 
necessary to determine when it can have the greatest effect and to whom. Additionally, this would help determine 
where patient preference information is needed, but not currently implemented, and which phases stand to benefit 








Thesis Aims and Objective 
This thesis aims to critically examine how patient preference studies are performed, and how this can affect their 
systematic integration into the MPLC. These aims can be specified in three detailed objectives:  
1. To examine the current systematic integration of patient preference studies into the MPLC, as well as barriers 
and opportunities to their inclusion 
2. To appraise different preference exploration and elicitation methods and their suitability to meet decision-makers 
needs across the MPLC 
3. To critically examine different elicitation methods through empirical evidence by comparing their executions 
and results within the same patient population  
 
Thesis Outline 
This thesis will begin with a general introduction explaining the theoretical justifications for undertaking this research, 
the impact of patient preference information on the medical product development, and the importance of examining 
patient preference research methods.  
In Part 1 of this thesis, the systematic integration of patient preferences throughout the medical lifecycle will be 
examined. In Chapter 1, an overview of critical decision-points within the medical product lifecycle (MPLC) will be 
identified, as well as the potential for including patient preferences. Chapter 2 examines the current factors and 
situations influencing the value of patient preference studies throughout the MPLC through a literature review. 
Chapter 3 examines these factors and situations affecting the value of patient preference studies in the MPLC through 
semi-structured interviews in Europe and the US.  
In Part 2 of this thesis, the methods used for examining patient preferences are critically examined. In Chapter 4, 
methods for eliciting and exploring patient preferences are identified through an extensive systematic review. Chapter 
5 appraises and empirically compares these identified methods in order to identify which are most suitable for meeting 
decision-makers needs throughout the MPLC.  
In Part 3 of this thesis, patient preference methods are examined through case studies administering surveys to real 
patients. Chapter 6 compares two preference elicitation methods through a study examining what is most important 
to diabetes patients when choosing glucose monitoring technologies.  
In Part 4 of this thesis, the future of patient preference integration is explored. Chapter 7 looks at the challenges 
facing the integration of patient preferences into a critical decision point, health technology assessment (HTA), 
through a systematic literature review.  
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Abstract   
Background: Patient preference (PP) information is not effectively integrated in decision-making throughout the 
medical product lifecycle (MPLC), despite having the potential to improve patients’ healthcare options. A first step 
requires an understanding of existing processes and decision-points to know how to incorporate PP information in 
order to improve patient-centric decision-making. 
Objectives:  The aims were to: 1) identify the decision-making processes and decision-points throughout the MPLC 
for industry, regulatory authorities, and reimbursement/HTA, and 2) determine which decision-points can potentially 
include PP information.  
Methods: A scoping literature review was conducted using five scientific databases. Semi-structured interviews were 
conducted with representatives from seven European countries and the US, including industry (n=24), regulatory 
authorities (n=23), reimbursement/HTA (n=23). Finally, validation meetings with key stakeholders (n=11) were 
conducted.  
Results: Six critical decision-points were identified for industry decision-making, three for regulatory decision-
making, and six for reimbursement/HTA decision-making. Stakeholder groups agreed that PP information is not 
systematically integrated, either as obligatory information or pre-set criteria, but would benefit all the listed decision-
points in the future.  
Conclusion: Currently, PP information is not considered as obligatory information to submit for any of the MPLC 
decision-points. However, PP information is considered an important component by most stakeholders to inform 
future decision-making across the MPLC. The integration of PP information into 15 identified decision-points needs 





The pharmaceutical industry, regulatory authorities, and reimbursement/Health Technology Assessment (HTA) 
bodies (including payers) generally agree that the use of patient preference information (PP information) could be 
beneficial to decision-making throughout the medical product lifecycle (MPLC) in Europe and the US [1, 2, 3]. PP 
information is defined as information resulting from “assessments of the relative desirability or acceptability to 
patients of specified alternatives or choices among outcomes or other attributes that differ among alternative health 
interventions” [4]. PP information can be determined through qualitative and quantitative methods, and includes the 
relative importance of what matters most to patients, enabling the examination of trade-offs that patients are willing 
to make between benefits and harms. Therefore, PP information is different to patient reported outcomes (PROs), but 
it can provide through which outcomes can be prioritised. It not only captures patient needs and concerns, but it also 
provides a significant opportunity for patients to express important preferences and have this information incorporated 
into decision-making [5]. Patient-centric decision-making not only results in better transparency and accountability of 
medical product development, but may also result in better outcomes for patients, improved quality of research and 
study outcomes more relevant to patients, more products developed in line with patients’ needs, and increasing overall 
well-being [5, 6, 7].  
Before PP information can be formally integrated within decision-making, a clear overview of the current decision-
making processes, including critical decision-points, along the MPLC must be formulated. We define a critical 
decision-point as an identified fixed moment where a decision influences the course of the medicine development, 
authorisation or reimbursement process. These are essentially “go-or-no-go” decisions. Therefore, this study will be 
focusing on stakeholders that directly affect the progression of medical products along the MPLC (i.e. industry, 
regulatory authorities, and reimbursement/HTA). In addition, it needs to be determined which decisions can 
potentially benefit from the inclusion of PP information. To date, there is no consolidated, published overview 
concerning the critical decision-points along the MPLC for the different stakeholders involved, as well as how, and 
based on what information and criteria, these stakeholders make their decisions.  
The current study aims to: 1) identify the decision-making processes and critical decision-points throughout the MPLC 
for industry, regulatory authorities, and reimbursement/HTA, and 2) determine which of these critical decision-points 
have the potential to include PP information.   
 
Materials and Methods 
A four-step approach was used in this study, including a scoping literature review (step 1), semi-structured interviews 














Figure 1 Overview of methodology 
 
 
Scoping literature review 
In step 1, a literature search was performed to identify relevant white and grey literature [8]. White literature included 
relevant, peer-reviewed articles published in scientific/academic journals. The literature was retrieved via five 
scientific databases: Guidelines International Network, Embase, PubMed (including Cochrane Central and Medline), 
PsycINFO and EconLit. Search queries consisted of MeSH terms and free text words in order to optimise the breadth 
of results (e.g. decision making, patient preference, decision-point, and drug life cycle). The databases were searched 
for relevant titles and abstracts published between January 2011 and April 2017. Grey literature was collected in order 




Three researchers (CW, KSB, JV) independently reviewed the abstracts of the literature and applied inclusion and 
exclusion criteria. Inclusion criteria were: conceptual or applied descriptions of (i) decisions made by industry or 
regulatory authorities or reimbursement/HTA related to medical products; (ii) the use of patient preferences in 
decision-making by industry or regulatory authorities or reimbursement/HTA regarding medical products. The 
following exclusion criteria were applied: (i) not written in English, (ii) no full text article available, (iii) published 
before 2011, (iv) country outside of US/EU because of the focus on EU decision-processes and differences compared 
to the US, (v) conference abstracts, conference notes, book reviews, and presentations. Data extraction was conducted 
by four researchers (CW, KSB, JV, SW), by assessing the full texts of white and grey literature based on the same 
inclusion and exclusion criteria as the abstract screening. Through this process, key decision-points and decision 
processes were identified for each stakeholder group, making a preliminary list to be confirmed in the next steps of 
the methodology.  
Semi-structured interviews 
In step 3, interviewees representing one of the stakeholder groups (industry, regulatory authorities and 
reimbursement/HTA) were recruited via purposive sampling and snowballing (i.e. asking confirmed interviewees to 
suggest others) (see Appendix 1.4).  The interviews were conducted between April 2017 and August 2017 in Sweden, 
the UK, Italy, the Netherlands, France, Germany and Romania which provided representation from all different 
cardinal regions in Europe. Interviews were also conducted in the US to examine perspectives outside the EU. Potential 
interviewees received information on the study and provided informed consent. This study was approved by the Ethics 
Committees in each of the countries where interviews were conducted. 
An interview guide was developed based on topics that had emerged from the literature review detailed in step 1. 
Interviews were conducted by five researchers and took approximately one hour and were conducted via telephone or 
face-to-face. Interviews were conducted in English, audio recorded, and transcribed verbatim. Transcripts were 
analysed through framework analysis [9] using NVivo software [10], where the data were interpreted for consensuses 
and observations across the stakeholder groups, which created thematic ‘codes’. After a ‘familiarisation process’ [9] 
in which the coders (CW, KSB, RH) examined transcripts from each stakeholder group, open-coding was applied to 
three transcripts, along with deductive codes reflecting key stages of the MPLC identified from the scoping review. 
The success of these codes encapsulating the themes within each transcript were compared, and then served as the 
basis of the codes that were then applied to the entire 70 transcript sample. The sections of transcript that corresponded 
to a code were indexed into a chart that identified the coded material for each participant’s stakeholder group and 
country. These charts were analysed by four researchers (CW, KSB, JM, SW) for common attitudes and opinions of 
the respondents, comparing similarities between stakeholder groups and countries.  
Validation meetings 
In steps 2 and 4, meetings with representatives from each of the stakeholder groups (industry, regulatory authorities, 
reimbursement/HTA) were scheduled to validate the results from both the literature review and the semi-structured 
interviews. These stakeholder representatives, from both the EU and US, were not participants in the semi-structured 
interviews. During this step, information was retrieved on differences in decision-making processes between EU and 
US. The first round of meetings with each stakeholder group (one meeting with two industry representatives, four 
meetings with four regulatory representatives, one meeting with one reimbursement/HTA representative) was 
conducted after the scoping literature review to confirm the identified decision-making processes. The second round 
of separate meetings with each stakeholder group (two meetings with two industry representatives, two meetings with 
two regulatory representatives, one meeting with two reimbursement/HTA representatives) took place after the semi-






During step 1, A total of 723 records were screened on title, and abstract, or table of contents (Figure 1). From these, 
223 records were selected for full- text screening (of which 32 related to industry, 89 to regulatory authorities, and 
102 to reimbursement/HTA) and 57 records were selected from the full text screening (of which 10 related to industry, 
14 to regulatory authorities and 33 to reimbursement/HTA). General decision processes, chronology of decision-
making, and type of information required during these processes, was extracted. These articles were used in a first 
stage to map out decision processes for all stakeholders. Not all works are directly cited in the results, because most 
articles named the decision-points but did not describe the content of the decision-points, or the required information, 
in detail. During step 2, seven validation meetings were conducted (n=2 industry, n=4 regulatory, n=1 
reimbursement/HTA). The decision-making processes from step 1 were confirmed, the differences between EU and 
US decision-making processes was examined. During step 3, A total of 70 interviews were conducted with 
representatives from industry (n=24), regulatory authorities (n=23) (including US regulators, European-level 
regulators, and national EU regulators) and reimbursement/HTA (n=23). In this step, six industry decision-points, four 
regulatory decision-points, and six reimbursement/HTA decision points were identified. During step 4, six validation 
meetings were conducted (n=2 industry, n=2 regulatory, n=2 reimbursement/HTA). The decision-points identified in 
step 3 were confirmed, and one regulatory decision-point was removed. Experts confirmed that ‘orphan designation’ 
is a designation process which creates separate processes and timelines, and not a decision-point (go-or-no-go 
decision) that exists for every medical product.  
Conclusively, six industry decision-points, three regulatory decision-points, and six reimbursement/HTA decision 
points were identified. 
 
I.  Decision-points within industry decision-making 
We identified six critical decision-points in the industry processes (Figure 2). These decision-points start immediately 
after pre-discovery, and run through the MPLC, with the final decision-point concluding in post-approval. In general, 
product development and decisions whether to proceed are in the context of regulatory requirements, which may differ 
between products or regulatory designations (e.g. orphan status). The most commonly followed decision-points are 
described below. 
Figure 2 The core industry decision-making process, including the critical decision-points (in black arrows), along the medical 
product lifecycle. 
 
Select & prioritise targets and leads: this decision-point is generally based on biology data such as the extent to which 
human and animal disease pathology overlap. The candidate selection decision is based on animal efficacy and 
toxicity, pharmacology, pharmacokinetics, and drug metabolism characterised using in vitro assays and efficacy using 
animal models of disease or in vitro tests on human cells or tissue [11, 12]. The semi-structured interviews with 
industry representatives in the EU and US revealed a positive perspective towards patient preference information (PP 
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information) in early stages of the MPLC. An EU interviewee suggested early integration of PP information will help 
“[identify] fields in which new therapies, whether it be medical devices or medicines, should be developed” 
(Netherlands).  
Prioritise studies (Early clinical development): data and conclusions on whether to enter clinical development are 
peer-reviewed by technical and operational management committees that verify safety, quality, regulatory 
documentation and resource availability. The decision to enter clinical development is based on pre-clinical evidence 
supporting confidence in the biologic target, literature data, manufacturing data, operational feasibility and verification 
that the medicine candidate could meet the needs of the target product profile [13, 14]. Representatives from the US 
and EU suggested that companies which routinely engage patients better inform and communicate their decisions. 
One representative from EU said “patient preference on, for example, target product profiles […] inform go/no-go 
[development] decisions” (UK). 
Prioritise assets (Early clinical development): data and conclusions on whether to enter Phase 2 of clinical 
development are peer reviewed by technical and operating management committees to ensure safety, quality and 
favourable medical benefit-risk to support continued development in a larger clinical trial [14]. The decision to enter 
Phase 2 development is based on evidence that the medicine is having a pharmacologic effect on the target organ of 
normal health volunteers (or in patients for oncology products) operational feasibility, and confidence the medicine 
candidate’s performance could hit the target product profile [13, 14]. During the interviews, a number of industry 
representatives said that PP information informs trials by “look[ing] at the endpoints of your study, defining them” 
(Netherlands), by assessing “clinical trial feasibility” (US), and by translating PP information “into an outcome 
measure” (UK).  
Optimise & Prioritise assets (Late clinical development): data and conclusions on whether and how to enter Phase 3 
of clinical development are peer reviewed by technical and operating committees to ensure safety, quality and 
favourable medical benefit-risk to support continued development in a substantially larger Phase 3 patient study. The 
benefit-risk profile is further developed and may include risk management planning to mitigate safety risks and 
increase the probability that the benefit-risk profile remains positive [15]. Technical performance includes data from 
Phase 2 with sufficient dose-response evidence to support Phase 3 dose-selection, safety, quality and favourable 
medical benefit-risk in the appropriate patient population [13, 14]. Widespread PP information integration by industry 
will improve healthcare by increasing resource allocation efficiency and by developing products with stronger value 
propositions, or as one EU industry representative explained “better decisions will be taken and […] patient value will 
increase” (Sweden).   
Regulatory Submission & Launch: committees review efficacy and safety data to ensure evidence supports a 
favourable medical benefit-risk profile and planned label claims. Technical performance includes Phase 3 data from 
pivotal registration studies demonstrating efficacy and safety. The decision to apply for regulatory marketing 
authorisation typically requires: Phase 3 technical performance that supports the target product profile; desired label 
claims; and commercial opportunity or considerations [13]. An industry representative stated that including PP 
information in “the dossiers that you put together for regulatory authorities or HTAs[…] provides context to either the 
company narrative or company conclusions around the datasets” (UK). 
Manage MPLC & Prioritise opportunities: includes decisions that are made after commercialisation. Products may be 
enhanced to further satisfy medical needs. Ideas may arise from many potential sources including observational studies 
(e.g., to comply with regulatory commitments), investigator-initiated studies, patient advisory boards, focus groups, 
surveys, and structured patient interviews [16]. A number of representatives identified the value of PP information to 
inform decisions in the post-approval setting, including reimbursement, comparative effectiveness, addressing new 
safety signals and informing shared-decisions between a patient and their health care provider. An EU industry 
representative suggested that “if patient preferences are taken into account, the cost effectiveness of a therapy might 
be better and reimbursement might be easier to decide on” (Netherlands).  
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II. Decision-points within regulatory decision-making 
Three critical decision-points were identified within regulatory decision-making, defined as a fixed moment where a 
decision is taken that influences the course of the authorisation process (Figure 3). The identified critical decision-
points are submission and validation, scientific opinion, and commission decision. Other regulatory processes, defined 
as activities that do not need a go-or-no-go decision, but are conducted in order to inform future decision-points, were 
also identified (in white in Figure 3). Depending on the product, as well as whether the medical product will go through 
the centralised procedure of the EMA or the FDA`s regulatory decision-making, some decision-points may vary. For 
example, separate processes and timelines exist for products that are designated to be orphan products for rare diseases 
or paediatric products. A comparison of the decision-points of the FDA and EMA can be found in Figure 4.  




Figure 4 Comparison of EMA and FDA decision-points, including the critical decision-points (in black arrows), along the 
medical product lifecycle.  
 
Submission & validation happens when companies submit a Marketing Authorisation Application dossier for the 
approval of a medicine. Specifics depend on the application: for new applications, a full dossier (electronic Common 
Technical Document (eCTD)) needs to be completed, for a variation, new changes need to be submitted only. If 
applicable, a renewal confirms that all information is up to date and a Periodic Safety Update Report adds new 
information to the original dossier. For medicines to go through to scientific evaluation, submitted materials are 
assessed for completeness (eCTD) and they have to meet all the legal requirements [18]. Regulatory representatives 
in the EU and US said that they occasionally get PP information when pharmaceutical companies apply for Marketing 
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Authorisation and that their agency supports this information: “We get them occasionally, less frequently than I would 
like […]. So if we get them, we have to take them into account” (Germany). 
Scientific opinion is a positive or negative recommendation given by the Committee for Medical Products for Human 
Use (CHMP), on whether to authorise a medicine based on the scientific evaluation [17, 18]. All information gathered 
during the pre-submission is needed to make a scientific opinion, including a complete submission dossier (eCTD). A 
positive opinion is issued when a positive benefit-risk balance, including efficacy, is sufficiently demonstrated and 
when the dossier meets all legal requirements [5]. A 'summary of opinion' is immediately published after the opinion 
is submitted to the European Commission [18]. During the interviews, regulatory representatives recognised the value 
of including patients as experts in discussions that lead to the scientific opinion. However, representatives in both the 
EU and US were sure that there are no formal or systematically integrated protocols for including PP information in 
the regulatory process at this moment: “There are not formal protocols for that, I think much yet. But I think that that 
will be important to provide” (US). 
A commission decision, is when the European Commission, grants, refuses, changes, suspends or revokes marketing 
authorisation. The commission decision is based on the ‘summary of opinion’ and legal requirements [18]. The 
summary is replaced by a full European Public Assessment Report (EPAR) once the European Commission has 
decided to approve marketing authorisation or not [18]. The safety monitoring and the ongoing benefit-risk 
assessments might feedback to submission and validation if there is; a variation, a renewal, need for a periodic safety 
update report (PSUR), a referral or switch to Over the Counter (OTC) for the medicine [18]. Some of the 
representatives in both the EU and US expressed a limited acceptance for PP information and that there is a need for 
a structured way to include PP information in commission decisions. One respondent stated, “All these things are very 
important but you have to create a way of measuring the impact of taking into account patient preference” (Italy). 
 
III. Decision-points within reimbursement/HTA decision-making  
There are six critical decision-points during the reimbursement/HTA decision-making processes (Figure 5). These 
include filtration, prioritisation, and appraisal, and also when these three decision-points are repeated for reassessment. 
Other HTA processes, defined as activities that do not need a go-or-no-go decision, but are conducted in order to 
inform future decision-points, were also identified (in white in Figure 5). The process by which different countries 
conduct these decision-points is generally similar in practice, although also depends on the country’s unique healthcare 
system [26]. EU countries operate under procedural rules and timelines set by the European Commission, although 
methodological and procedural differences exist between nation states [27, 28]. In the US, health payers and 
organisations, including both commercial health payers and government payers make their own decisions regarding 
reimbursement [29].  
The filtration of potential assessment topics is often conducted in order to narrow down prospective assessment topics 
to a manageable number, although not always relevant to reimbursement/HTA bodies that address all medicines  [1, 
30, 31, 32]. Medicines that are expected to have a limited impact on the healthcare system or patients are considered 
to be a lower priority. Filtration selects products by applying pre-established criteria, which do not vary widely across 
the EU and North America [33]. The criteria often address whether the technology is new and innovative, is a 
modification of an existing product, or is an existing product being used for a new indication. Further criteria are often 
related to the associated disease burden; whether there are existing treatments for the condition; the anticipated clinical, 
economic, or societal impacts; the appropriateness for relevant stakeholders or healthcare system; or the timeframe 
that it would take the product to be commercialised and incorporated into practice [34].  
The prioritisation of potential assessment topics, if applicable to the particular reimbursement/HTA body, aims at 
determining the significance of the filtered technologies for the healthcare system, and deciding which technologies 
will be invested in with limited assessment resources [35]. Filtration and prioritisation are often conducted through 
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horizon scanning or early awareness and alert activities. In the US, this is often the AHRQ (Agency for Healthcare 
Research and Quality), or private sector companies [29]. The majority of explicit criteria utilised by 
reimbursement/HTA concern patient group sizes and the burden of disease; the potential clinical benefit on morbidity, 
mortality or quality of life; the cost or economic impact, both to the patient and to stakeholders; social impact including 
ethical or legal concerns; the anticipated speed of adoption; and the availability of evidence or additional input from 
patient groups [36]. However, one EU representative stated that frequently “one patient is sitting in one big HTA big 
[sic] decision-making body and they don't believe them because – ‘oh yeah one single patient’” (Germany), indicating 
that one patient might not carry much weight for decision-makers.  
After evidence is obtained during the assessment step, the critical decision-point of the appraisal occurs, where the 
evidence is reviewed and a decision is made regarding reimbursement. Generally, assessments collect scientific 
clinical and economic evidence: safety and efficacy information (often relative to available alternatives), clinical 
effectiveness (often relative to available alternatives), time required for diffusion, costs, or financial impact [30, 36, 
37]. This can be included in form of literature reviews, clinical evidence from clinicians or manufacturers, cost-
effectiveness analysis, estimated QALYs, observational studies, or combined sources. Additional evidence from 
patients and patient organisations can also be submitted. The appraisal committee can consider social or ethical 
impacts, equity issues, the product’s degree of innovation, the burden of disease and projected epidemiological trends, 
and other patient issues [38]. All stakeholder representatives mentioned that PP information is not required or 
implemented systematically, with cost-effectiveness and efficacy given priority instead. An EU representative said, 
“By the time it comes to HTA bodies it's a bit too late to start thinking about patient preferences” (UK). There is 
limited guidance for PP information inclusion, as an EU representative indicated, “We don’t have anything, any 
explicit criteria […] that specifies “this is the weight of patient preference we should take in the decision” (France). 
Although all representatives accurately understood the concept of PP information, many had a misconception that 
patient preferences are sufficiently accommodated through QALYs, despite their calculation frequently incorporating 
public preferences, and not patient preferences. An EU participant described QALYs as “implicit” patient preferences 
and stated, “we suppose that patient preferences are included in this tool” (France).  
 




This paper represents a significant first attempt to identify 15 critical decision-points from key stakeholders with the 
objective to incorporate patient preference information (PP information) in the MPLC. An overview of all identified 
critical decision-points is given in Appendix 1.5. Each of the critical decision-points requires different information, 
based on pre-determined decision criteria, to be submitted to the decision-makers. A description of the information 
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needs and decision criteria for each decision-point can be found in Appendix 1.1-1.3. Some decision criteria already 
allow for PP information to be incorporated more readily than others, but PP information is currently not routinely 
considered one of the requirements for decision-making. However, within all stakeholder groups this has been 
recognised as a valuable component to inform decision making across the MPLC in the near future. 
In general, industry representatives spoke positively about increasing the integration of PP information to inform 
decision-making throughout the MPLC, especially in the development of a new medicines since it provides context 
which informs and helps communicate their decisions. Regulatory representatives expressed that there is limited 
acceptance for PP information within their decision-making processes since there is currently no recognised nor 
structured way to include and/or value such information. However, some regulators stated that PP information could 
be more important in specific situations, like for rare diseases. The EMA and FDA value the perspectives of patients 
and are committed to encouraging patient input throughout medicine development and product reviews [4, 39, 40]. 
Both EMA and FDA play an important role in providing guidance to industry and reimbursement/HTA on how to best 
incorporate PP information in future assessments [4, 39]. All reimbursement/HTA representatives agreed that PP 
information is sometimes included in assessment dossiers, but not required. According to representatives from 
EUPATI (European Patients Academy on Therapeutic Innovation) and HTAi (Health Technology Assessment 
international), mechanisms exist to collect preferences from patients that help identify and select potential 
reimbursement/HTA topics that are most important or pressing. 
Greater discussion and collaboration is required between key stakeholders, especially regulators and 
reimbursement/HTA, in order to consolidate efforts to integrate PP information. Despite PP information having the 
potential to be integrated at numerous stages of the MPLC, there still are various barriers preventing its inclusion. The 
integration of PP information into industry decision-making appears readily feasible, whereas reimbursement/HTA 
and regulatory authorities first need to decide how much weight should be given to PP information compared to other 
required information. Although not the objective of this paper, timelines, budgets, and other issues of feasibility (e.g., 
method selection) need to be appraised and resolved by these stakeholders before PP information can be integrated. 
Recommendations are needed to inform all decision-makers about how best to capture patient preferences, which 
methods to use, who should best conduct patient preference studies in order to avoid potential bias, how to interpret 
the results, and satisfy particular decision criteria for each decision-point. It was also not the objective of this study to 
determine where PP information should be integrated, or assess at which decision-points it would be more valuable. 
However, identifying decision-points where PP information can be integrated serves as an important first step.  
Our results focused on medicines instead of medical devices, although the latter adds other important dimensions and 
nuances to this discussion. Within industry, medical device development is highly variable with different company 
procedures, depending on regulatory authorities’ assigned risk level and the intended use of the device. However, 
decisions are governed by the same principles as medicine development. High risk-level medical device development 
can be analogous to medicine decision-making from Phase III onwards [17]. For reimbursement/HTA in the EU, most 
international guidelines for economic evaluation are written to be applicable to both medicines and medical devices. 
Some EU countries appraise medical devices through specialist reimbursement agencies, separate from medicines. 
The US appraises medical devices similar to medicines, but has separate processes: private and government payers 
decide upon reimbursement decisions of medical devices by conducting a technology assessment which is largely 
dependent on clinical impact or utility and cost-effectiveness [29]. The starkest difference between medicines and 
medical devices occurs during regulatory decision-making. All devices are classified based on the risk level. A clinical 
investigation can be assigned and approved by the applicable authority before submission. For all devices in EU, a 
European CE Marking Certificate is issued for the device after successful completion of a Notified Body audit [18]. 
In the US, the probable benefits should outweigh the risks with oversight from an Institutional Review Board or an 
appropriate local committee [22]. Current literature suggests PP information should be seen as additional data in the 




Strengths and weaknesses 
This study included a comprehensive four-step approach where international representatives (n=70) from all the three 
stakeholder groups in the MPLC were included, creating a novel and highly representative overview that has not been 
outlined in previous literature. The scoping literature review included grey literature which enriched the collected 
information with current knowledge and practices. The literature review only included English papers and documents, 
which could be a potential limitation. However, the validation meetings confirmed the findings of both the literature 
review and the semi-structured interviews, while clarifying differences between EU and US. A potential limitation 
was the snowballing recruitment technique of the interviewees, the majority of whom were found through connections 
with the PREFER consortium, which may inadvertently introduce a sampling bias. Some participants may have 
wanted to participate because they already found the topic interesting or valuable. In addition, five interviewers 
conducted the interviews in eight different countries, meaning there could be variation in the conduct of the interviews. 
We expect this variation to be minimal, however, because all interviewers used the same interview guide and 
instruction manual. This study examined three stakeholders directly involved with PP information integration because 
it was focusing on policy and MPLC decision-making. However, the perspectives of patients, patient organisations, 
academics, clinicians, and other stakeholders are also vital in the successful use and integration of PP information.  
  
Conclusion  
Patient preference (PP) information is currently not routinely considered one of the requirements for decision-making. 
With support already being generated by all these stakeholders, this study provides an overview of 15 decision-points 
with the potential to include PP information. This roadmap, combined with continued discussion between key 
stakeholders, is needed to successfully implement PP information into decision-making, and strengthen a crucial path 
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- Secondary market 
research 
- Competitor Analysis 
/events 
Project assessment criteria: 
- Validated Target 
- Unmet healthcare need 
- Target activity 
- Structure 
- Novelty 
- Unmet need 
Portfolio assessment criteria: 














- Competitive intelligence 
(CI) /events 
Project assessment criteria: 
- Animal pharmacology; absorption, distribution, metabolism and elimination (ADME), 
and toxicity 
- Manufacturing scalability 
- Unmet need 
Portfolio assessment criteria: 
- Assets are prioritized using unmet need, technical & operational feasibility, 














- Primary qualitative 
research 
- Competitive intelligence 
(CI) /events 
Project assessment criteria: 
- Pharmacokinetic and pharmacodynamics (PK/PD), Maximum Therapeutic Dose, 
Safety 
- Manufacturing commercial formulation 
- Competition 
Portfolio assessment criteria:  




















 - Primary qualitative & 
quantitative research 
- Competitive intelligence 
(CI) /events 
Project assessment criteria: 
- Proof of Concept 
- Dose range 
- Safety 
- Competition 
- Economic trade-offs between development alternatives 
Portfolio assessment criteria: 

























 - Competitive intelligence 
(CI) /events 
Project assessment criteria: 
- Phase 3 supports commercially acceptable label 
































- Competitive intelligence 
(CI) /events Investigator 
Initiated Trials (IIT) 
- Observational data 
- Primary research 
Project assessment criteria: 
- Phase 4 
- Observational data 
- IIT 
- Economics 
Lifecycle portfolio assessment criteria: 





Appendix 1.2: Critical decision points, information needs and decision criteria for regulatory decision-making regarding 






























Based on pre-authorisation guidance 
 
Specifics depend on application: 
- New application fill in full dossier, electronic Common 
Technical Document (eCTD) 
- Variation, submit to the changes 
- Renewal confirm up to date, add new information to 
dossier 
- Periodic safety update reports (PSURs) add what is 
collected 
- The drug, or the class or drugs, is ‘referred’ to the Agency 
so that it can make a recommendation for a harmonised 
position across the EU  
- Formal completeness of the submitted 
dossier (eCTD) 
















- All information gathered at the pre- submission 
- Complete submission dossier (eCTD) 
- Positive risk-benefit balance 
- Efficacy and safety sufficiently 
demonstrated 
- Legal requirements (e.g. on 


















- Scientific opinion 
  
- Positive scientific opinion 
- Legal requirements   
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Appendix 1.3: Critical decision points, information needs and decision criteria for HTA decision-making regarding early HTA, 

















- Assessment topics identified 
through identification stage  
- Potential identification 
sources include: commercial 
or medical media, trial 
registries, scientific journals, 
commercial developers,  
specialized horizon scanning 
databases (eg. EuroScan) 
and early awareness and 
alert (EAA) systems 
- Determine if the drug is: 
• New/innovative 
• Appropriate for stakeholders 
• Relevant for the health system 
• A modification of an existing product 
• The same product being used for a new indication 
• Within the time frame of the horizon scanning system 
• Potentially impacting the healthcare system  
- Further determine: 
• The associated disease burden  
• If there are existing treatments for this condition  















- Information collected during 
identification stage and 
narrowed down during the 
filtration stage 
Must satisfy one or more criteria before being considered for further consideration or 
assessment, or otherwise will be put on a monitoring list    OR 
Conducted without criteria (based on the prior knowledge of organizational memory an 
awareness of policy) 
Most agencies use prioritization criteria which can include:  
- Patient numbers/burden of disease  
- Potential clinical benefit 
- Possible economic impact and anticipated seed of adoption 
- Unmet medical or healthcare needs 
- Level of available evidence 
- Existence of alternative product 
- Safety profile of the product 
- Social, ethical and legal aspects 
- Potential impact 
- Patient (e.g., impact on morbidity, mortality, quality of life, diagnosis)  
- Cost (increased costs or savings, large capital outlay, direct and indirect costs for patients 
and society)  
- Service/organizational (e.g., increased or decreased use, service reorganization, structural 
changes, staff training)  
- Societal (e.g., ethical issues, controversial methods) 
- External emphasis—policy-related, patient groups, experts  




















- All information gathered 
during the health technology 
assessment phase: overview 
and critical assessment of 
the safety, relative 
effectiveness, cost, budget 
impact, cost-effectiveness, 
societal impact, impact on 
the organisation of 
healthcare and patient issues 
related to the product  
- Evidence whether the medical product is: 
• Safe 
• Clinically effective (Compared to an active comparator and standard of care)  
• Cost-effective (Not all HTA bodies ask, some focus more on added 
clinical benefit and budget impact) 
• Positive relative efficacy and relative clinical effectiveness  
• Innovative 
• Have a place in current available therapies 
- Further determine: 
• The costs (budget impact) 
• The potential social, ethical, and legal impacts  
• The current stage of diffusion  
• If there are equity issues 
• What is the burden of disease 
• What is the target patient population 
• What is the trial quality 
• What would be the public health impact 
• What are the projected epidemiological trends of the disease 
• How do patients value the outcomes of the therapy 
- Inputs can include: 
• Local health policies  
• Literature reviews 
• Clinical evidence (safety, efficacy, added clinical benefit) from clinicians, 
specialists, pharmaceutical manufacturers, and patient groups  
• Economic evidence and/or models (cost-utility, cost-effectiveness analysis) 
• Estimated QALYs (Quality-adjusted-life years) (either through direct elicitation of 
patient preferences or indirectly (e.g. EQ-5D)  
• Primary evidence can be commissioned (ex. observational studies) or integrative 
methods (combining sources)  
• Input from patients, caregivers, and patient organisations: impacts, expectations, 




Appendix 1.4: Recruitment Protocol 
 






N=2 Representatives of Swedish Medical Products Agency 
with i) a formal role in healthcare products regulation process 
AND ii) experience in regulatory affairs as well as knowledge 
of national regulations 
N=2 Swedish representatives with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=4 Representatives of i) a Swedish Health 
Technology Assessment Organization or a 
Swedish reimbursement agency; OR ii) who 
are involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=2/3 persons whose 
activities are focused on 
pharmaceuticals  
n=1/2 persons whose 









N=2 Representatives of Romanian National Agency for 
Medicines and Medical Devices with i) a formal role in 
healthcare products regulation process AND ii) experience in 
regulatory affairs as well as knowledge of national regulations  
N=2 Romanian representatives with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=4 Representatives of i) a Romanian Health 
Technology Assessment Organization or a 
reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=2/3 persons whose 
activities are focused on 
pharmaceuticals  
n=1/2 persons whose 






N=2 Representatives of Italian Medicines Agency (AIFA) with 
i) a formal role in healthcare products regulation process AND 
ii) experience in regulatory affairs as well as knowledge of 
national regulations 
N=2 Italian representatives with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=4 Representatives of i) an Italian Health 
Technology Assessment Organization or an 
Italian reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=2/3 persons whose 
activities are focused on 
pharmaceuticals  
n=1/2 persons whose 





N=2 Representatives of Medicines & Healthcare Products 
Regulatory Agency with i) a formal role in healthcare products 
regulation process AND ii) experience in regulatory affairs as 
well as knowledge of national regulations 
N=2 UK representatives with a role or official position within 
EMA OR ii) collaborations and/or interactions with European 
regulatory agencies for the Evaluation of Medicinal Products 
AND ii) knowledge of European legislation 
N=4 Representatives of i) an UK Health 
Technology Assessment Organization or a 
reimbursement agency OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures 
n=2/3 persons whose 
activities are focused on 
pharmaceuticals  
n=1/2 persons whose 










N=1 Representative of Medicines Evaluation Board (CBG) 
with i) a formal role in healthcare products regulation process 
AND ii) experience in regulatory affairs as well as knowledge 
of national regulations  
N=1 Dutch Representative with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=2 Representatives of i) a Dutch Health 
Technology Assessment Organization or a 
reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=1/2 persons whose 
activities are focused on 
pharmaceuticals  
n=0/1 persons whose 









N=1 Representative of Federal Institute for Drugs and Medical 
Devices (BfArM) or Paul-Ehrlich-Institut (PEI) - with i) a 
formal role in healthcare products regulation process AND ii) 
experience in regulatory affairs as well as knowledge of 
national regulations  
N=1 German representative with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=2 Representatives of i) a German Health 
Technology Assessment Organization or a 
reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=1/2 persons whose 
activities are focused on 
pharmaceuticals  
n=0/1 persons whose 







N=1 Representative of French National Agency of Medicine 
and Health Products Safety (ANSM)  with i) a formal role in 
healthcare products regulation process AND ii) experience in 
regulatory affairs as well as knowledge of national regulations  
N=1 French representative with a role or official position 
within EMA OR ii) collaborations and/or interactions with 
European regulatory agencies for the Evaluation of Medicinal 
Products AND ii) knowledge of European legislation 
N=2 Representatives of i) a French Health 
Technology Assessment Organization or a 
reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=1/2 persons whose 
activities are focused on 
pharmaceuticals  
n=0/1 persons whose 





N=1 Representative of US Food and Drug Administration 
(FDA) FDA from the Center for Drug Evaluation and Research 
(CDER) or the Center for Biologics Evaluation and Research 
(CBER)  
N=1 Representative of US Food and Drug Administration 
(FDA) from the Center for Devices and Radiological Health 
(CDRH). 
N=2 Representatives of i) an American Health 
Technology Assessment Organization or a 
reimbursement agency; OR ii) who are 
involved in the evaluation of a health 
technology OR in the prescription drugs and 
health care reimbursement decision-making 
procedures. 
n=1/2 persons whose 
activities are focused on 
pharmaceuticals  
n=0/1 persons whose 
activities are focused on 
medical devices 
* Ensure a mix of males and females whenever possible 
1 Ensure the inclusion of bodies with differing scope and budget responsibilities 
2 Includes consultants for industry/representatives of general associations of pharmaceutical industry. Ensure the inclusion of 
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Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of patient 
preferences in their decision-making processes. In general, experience in conducting and assessing patient preference 
studies is limited. Here, we performed a systematic literature search and review to identify factors and situations 
influencing the value of patient preference studies, as well as applications throughout the medical product lifecyle. 
Factors and situations identified in 113 publications related to the organization, design, and conduct of studies, and to 
communication and use of results. Although current use of patient preferences is limited, we identified possible 





The importance of incorporating patient needs and perspectives into decision making through-out the lifecycles of 
drugs and medical devices, for the purpose of this study collectively called the medical product lifecycle (MPLC), is 
receiving increasing recognition [1–4]. Recognition of the value of patients’ perspectives has led to a shift in drug 
development and assessments, from only looking at clinical outcomes to taking into account the judgements of patients 
on how these outcomes affect their lives. This shift originates from the notion that patients should be at the center of 
the MPLC, because they are the ones not only gaining the benefits, but also being exposed to the risks [5]. One option 
to better understand the patient perspective is through exploring and eliciting patient preferences (see Glossary). The 
US Food and Drug Administration (FDA) refers to patient preferences by defining patient preference information as 
‘qualitative or quantitative assessments of the relative desirability or acceptability to patients of specified alternatives 
or choices among outcomes or other attributes that differ among alternative health interventions’ [4]. Patient 
preferences can be obtained through the use of different exploration (qualitative) and elicitation (quantitative) methods 
[6]. Preference exploration methods can be defined as qualitative methods that collect descriptive data through 
participant or phenomenon observation, and examining the subjective experiences and decisions made by participants. 
Examples of preference exploration methods include semi-structured interviews and focus groups. Preference 
elicitation methods can be defined as quantitative methods collecting quantifiable data that can be reported through 
statistical inferences or analysis. Examples of preference elicitation methods include discrete choice experiments 
(DCE), analytical hierarchy process (AHP), and standard gamble. Although methods can be classified as exploration 
or elicitation methods, they can also be classified as structured-weighting, health-state utility, stated-preference, or 
revealed-preference methods, as described in the Medical Device Innovation Consortium (MDIC) Patient Centered 
Benefit-Risk Project report [3,7]. Stakeholders, including the pharmaceutical and medical device industry, regulatory 
authorities, HTA bodies, payers, clinicians, academia, and patient organizations, generally agree that there is value in 
using patient preferences to inform assessments and decision making [1,3,4,8–13]. In addition, patients themselves 
have expressed interest in decision-making processes [14]. Patient preferences are found to provide additional 
information on medical products, such as insights into the relative importance of clinical outcomes and safety issues, 
and to help in transparent communication regarding the incorporation of patient views in regulatory decision making 
[1,3,15,16]. Moreover, they can lead to more relevant, well-informed, transparent, publically trusted, and patient-
centric decisions [3,13,17,18]. In HTA specifically, patient preferences are believed to provide a health condition 
perspective and to improve the usefulness, appropriateness, and acceptability of the assessments [2,8,19,20]. Also, 
consideration of patient preferences in clinical trial design can lead to a lower burden for patients participating in the 
trial, and could result in improved recruitment, retention, and compliance of patients. Moreover, it could lead to more 
real-world clinical outcomes if preferences of patients are considered during the establishment of treatment arms 
[4,21–25]. European and US industry, regulators, HTA bodies, and payers are currently exploring the use of patient 
preferences in their processes and decision making. However, in general, these stake-holders have limited experience 
in conducting and assessing these studies. Moreover, they are generally not familiar with factors influencing the value 
of these studies, the situations in which these studies are most valuable, and possible applications of patient preferences 
in their processes and decision making [26– 28]. By performing a systematic literature search and review (see 
Appendix 2.1) focused on the current measurement and use of patient preferences in Europe and the US, here we 
provide an overview of factors and situations that influence the value of patient preference studies. We also 
investigated applications of patient preferences in assessments and decision making along the MPLC.  
 
Overview of applications of patient preferences along the medical product lifecycle  
A total of 113 publications were included in the literature review (see Appendix 2.2). Before we explore the factors 
and situations that influence the value of patient preference studies in assessments and decision making along the 
MPLC, first we give a short overview of how patient preferences can be used in MPLC phases. Several publications 
described that patient preferences can be used in every phase of the MPLC, from discovery until post marketing [3,29]. 
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Here, we describe the applications of patient preferences following the structure of the MPLC (Fig. 1). An overview 
of the availability of guidelines and frameworks on the use of patient preferences throughout these phases is given in 
Table 1. Currently, the Innovative Medicines Initiative (IMI) Patient Preferences in Benefit– Risk Assessments during 
the Drug Life Cycle (PREFER) project is working on providing recommendations on how patient preferences can 
inform decision making throughout the MPLC [9].  
Figure 1: 
 
Abbreviations: HTA, Health Technology Assessment; PRO, patient-relevant outcomes; QALY, quality-adjusted life year. 
 
Table 1: 
Availability of guidance on the use of patient preferences along the MPLC 
Phase of the MPLC Availability of guidance 
Discovery Lack of guidance reported [98] 
Pre-clinical development No guidance identified 
Clinical development No guidance identified 
Marketing Authorization Patient Preference Information – Voluntary Submission, Review in Premarket Approval 
Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion 
in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration 
Staff, and Other Stakeholders. U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation 
and Research [4] 
MDIC Patient Centered Benefit-Risk Project Report: A Framework for Incorporating Information 
on Patient Preferences regarding Benefit and Risk into Regulatory Assessments of New Medical 
Technology [3] 
ICH Harmonised Guideline: Revision of M4E Guideline on Enhancing the Format and Structure of 
Benefit-Risk Information in ICH [127] 
HTA & reimbursement Kleme et al. Patient perspective in health technology assessment of pharmaceuticals in Finland [107] 
Kievit et al. Taking patient heterogeneity and preferences into account in health technology 
assessments [20] 
Lack of guidance reported [10, 128] 
Post-marketing No guidance identified 
Abbreviations: HTA, Health Technology Assessment; ICH, International Council for Harmonisation of Technical Requirements for 





Patient preferences are used in the discovery of new medical products [30,31]. They can inform ideation and 
prototyping. During ideation, the elicitation of patient preferences can help to identify unmet medical needs, also 
referred to as unmet health-care needs. For instance, this is demonstrated by the patient preference study on fragile X 
syndrome (FXS) by Cross et al. [32], described in the report of Selig [3,4,30]. Selig described how stakeholders sought 
to get a better understanding of unmet needs in FXS. Caregiver preferences were quantified for six treatment outcomes. 
Caregivers found the ability of patients to control their psychological, gestural, and verbal behavior to be the most 
important treatment outcome. Cross et al. [32] stated that these results would have the potential to inform future drug 
development in FXS [30]. In addition to identifying unmet medical needs, they can lead to a better understanding of 
the disease, personal experiences of patients with the disease, and the acceptability of benefits and risks [3,4,30,33]. 
Patient preferences can even be used to inform the design of the target product profile, ensuring that patient needs are 
met [34]. During prototyping, patient preferences can inform adaption of the design of the medical product [3,4,11].  
Preclinical development  
Almost no evidence was found on applications of patient preferences in preclinical development. Patient preference 
were suggested to ensure that the patient needs are addressed by the medical product in design validation during 
preclinical testing [3]. No literature was retrieved demonstrating the actual use of patient preferences during preclinical 
development.  
Clinical development  
Patient preferences can be elicited during clinical development to inform clinical trial design, product design 
validation, and benefit- –risk assessment [3]. Patient preferences are currently taken into account in clinical trial design 
[3,4,11,30], during which patient preferences can be used to identify patient-relevant outcomes that can inform the 
selection of clinical endpoints [4,22,35–37]. Also, patient preferences can inform the development of reasonable 
inclusion and exclusion criteria. Moreover, they can be used to define experimental or control treatment arms in doubly 
randomized preference trial (DRPT) designs. In DRPT designs, the effect of preferences on clinical outcomes can be 
analyzed [24,25,38–44]. Patient preferences can also be used in clinical trial designs to calculate the acceptable level 
of uncertainty (significance level and power) in clinical trials [45,46] and to inform development of information that 
will be provided to patients during clinical trials, including background information and study results [23].  
Marketing authorization  
The use of patient preferences in regulatory marketing authorization was discussed in 46 out of 113 (41%) 
publications. Regulatory authorities such as the FDA [4] and the European Medicines Agency (EMA) [1] are currently 
exploring the use of patient preferences [11– 13]. However, they do not require the submission of patient preferences 
[16]. The FDA accepts the submission of patient preference information in approval applications for medical devices 
either as supporting evidence or for informational purposes [4,47]. Patient preferences can be used at the marketing 
authorization stage in benefit–risk assessment, assessment for early access [11], and for optimizing labeling that will 
inform patients on benefits and risks [3,4]. Use of patient preferences in benefit–risk assessment has given rise to 
patient-centered benefit–risk (PCBR) assessments [48,49]. Several initiatives are working on incorporating patient 
preferences in benefit–risk assessments, such as the MDIC Patient Centered Benefit-Risk Project, IMI PREFER, and 
the FDA’s Center for Devices and Radiological Health (CDRH) Patient Preference Initiative [9,50]. In benefit–risk 
assessments, patient preferences can provide information on maximum acceptable risk, minimum acceptable benefit, 
net clinical benefit, quality-adjusted time without symptoms and toxicity, and relative value-adjusted number needed 
to treat through multiple-criteria decision analysis, benefit–less-risk analysis, the Gail assessment, and probabilistic 
simulation methods [49,51–56]. These assessments are informed by patient preferences through understanding the 
trade-offs that patients make between benefits and risks [36]. Moreover, the results of patient preference studies can 
not only show a range of preferences, but also be used to identify subpopulations for whom the benefits outweigh the 
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risks [3,4,16,52,57]. Finally, patient preferences can help to weigh the benefits and risks in benefit–risk assessments 
based on the relative importance of out-comes, benefits, and risks for the patients [51,58].  
 
Health technology assessment & reimbursement  
Although different publications described that patient preferences can inform reimbursement decisions during the 
HTA and reimbursement stage [3,59–62], Dirksen et al. [63] reported that not much evidence is available on the actual 
use of patient preferences in reimbursement decision making and that multiple countries do not consider patient 
preferences as an explicit prioritization criterion. The use of patient preferences in HTA was discussed by 49 out of 
113 (43%) publications. Although cases have been described where HTA bodies are reluctant towards considering 
patient preferences in their assessments, European and US HTA bodies and payers have increasingly shown interest 
in using patient preferences in their assessments (Table 2) [2,8,10,11,31,64–67]. Twelve publications specifically 
mentioned the use of patient preferences in economic evaluations, including cost-effectiveness, cost–benefit, and cost–
utility analyses [60,61,68–77]. In these analyses, patient preferences can inform the identification of patient-relevant 
outcomes, and the identification of subpopulations for whom the benefits outweigh the risks [20,52,61,75]. In addition, 
patient preferences can help to weigh outcomes according to their relative importance to patients [20,61,75,78]. This 
could be done by incorporating patient preferences and other evidence into a multicriteria decision analysis [52,55]. 
Lastly, Bewtra et al. [76] described that the utility values resulting from patient preference studies can be used as 
quality-of-life weights in the calculation of quality-adjusted life years (QALYs). QALYs and EuroQol five dimensions 
(EQ-5D) utilities are frequently used in HTA, but their classical use has been criticized by some, because they only 
cover benefit for generic quality-of-life dimensions rather than for all factors that important to patients [73,79,80].  
Table 2: 
Main US and European HTA bodies and payers interested in patient preferences  
Country Organization 
Belgium Belgian Health Care Knowledge Centre (KCE) 
England & Wales (United 
Kingdom) 
National Institute for Health and Care Excellence (NICE) 
Finland Finnish Medicines Agency (Fimea) 
France High Authority of Health (HAS) 
Germany Institute for Quality and Efficiency in Health Care (IQWiG) 
Netherlands Care Institute Netherlands (CVZ) 
Scotland (United Kingdom) Scottish Medicines Consortium (SMC) 
United States Centers for Medicare & Medicaid Services (CMS) 
Based on references [19, 29, 61, 62, 65, 66, 78, 81, 129] 
 
Post marketing  
Although some applications of patient preferences described above might also be applicable to the postmarketing 
phase, some additional postmarketing-specific applications were identified in the MDIC report [3] and the FDA 
guidance [4]. During the post-marketing phase, patient preferences could inform product acceptance by patients, 









Figure 2: Factors and situations influencing the value of patient preference studies. Factors and situations were mapped along the 
organization, design, conduct, and communication and use of results of patient preference studies. Stages and steps of patient 
preference studies and their organization were identified as they emerged from the literature.  
Abbreviations: MPLC, medical product lifecycle. 
 
Factors and situations influencing the value of patient preference studies  
Many factors and situations were identified that can influence the value of patient preference studies (Fig. 2) [18,81]. 
Factors were defined by the researchers as a fact or influence that occurs during the organization, design, conduct, or 
communication of results of the study and that contribute to, or affect, the value of results from patient preference 
studies. Situations were defined as a circumstance or condition that occurs during the use of results and that contributes 
to, or affects the value of, results from patient preference studies. Situations were considered to be external to the 
preference study and not controllable by the researcher. These factors and situations are described below following 
the different stages and steps of a patient preference study. Although there are alternative ways to describe the stages 
of patient preference studies and the different steps that they encompass, we identified steps and their organization as 
they emerged from the literature, in addition to the organizational context (see Appendix 3.3). Stages included study 
design, study conduct, and communication and use of the results.  
Organizational context  
Multiple organizational factors were identified that determine the value of patient preference studies, as discussed 
below.  
Expertise: Clinical, medical product development, patient, methodological, and statistical expertise of the conducting 
parties will have con-siderable impact on whether and how a preference study is per-formed [2,3,12,28,30,50,82,83]. 
Partnerships between industry, academia, and patient organizations can be established to acquire the needed expertise 
[28], but agreements on sharing and using the data need to be established [28,30]. Expertise must be shared between 
parties to ensure appropriate conduct by trained staff and common understanding [4,28,30].  
Patient centeredness: Patient centeredness of patient preference studies is an important factor for success. The FDA 
guidance [4] states that the patient should be ‘the central focus of the study’. Patients and patient representatives can 
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participate in the study design to guarantee comprehensibility of the information and questions provided to patients, 
to improve recruitment, and to ensure correct interpretation and communication of results [4,16,28].  
Good practices: Following good research practices, similar to Good Clinical Practices [84] and Good 
Pharmacoepidemiology Practices [85], will ensure a correct design and conduct of the study and the value of the 
results [30,86]. However, patient preference study-specific guidance is often lacking (Table 3). Different initiatives 
are working on addressing methodological issues and providing recommendations and guidance on the design and 
conduct of patient preference studies (Table 4).  
Table 3: 
Availability of guidance on design and conduct of patient preference studies 
Topic Availability of guidance 
Good research practices ISPOR method specific good research practices [4, 78, 103] 
Choice of preference exploration/elicitation method Lack of guidance reported [3, 18, 98] 
Selection of attributes Lack of guidance reported [3] 
Whose preferences should be measured Lack of guidance reported [3, 60] 
Validity assessment Janssen et al. Improving the quality of discrete-choice experiments in 
health: how can we assess validity and reliability? [109] 
Lack of guidance reported [3] 
Abbreviations: ISPOR, International Society for Pharmacoeconomics and Outcomes Research. 
Table 4: 
Initiatives working on addressing methodological issues and providing guidance on the design and conduct of patient 
preference studies 
Initiative Website 
Innovative Medicines Innitiative (IMI) - Patient Preferences in 
Benefit-Risk Assessments during the Drug Life Cycle (PREFER) 
https://www.imi-prefer.eu  
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) - Patient Preferences Special Interest Group 
https://www.ispor.org/sigs/Stated-Preference-Methods.asp  
International Academy of Health Preference Research (IAHPR) http://iahpr.org  
International Health Economics Association (iHEA) - Health 
Preference Research Special Interest Group  
https://www.healtheconomics.org/page/HealthPreference 
 
Ethics: Compliance with ethics requirements associated with questioning patients is necessary in setting up a patient 
preference study, and different measures have to be taken to meet these ethics requirements [14,60]. This process is 
time consuming. Obtaining ethics and/or institutional review board (IRB) approval when questioning patients can 
especially be challenging for industry, and will not always give direct access to patients and their data [31,83]. Postmus 
et al. [16] described that they did not collect demographic and clinical data in their patient preference study to avoid 
the complexity of data protection, but stated that not having these data limited their analysis.  
Financial resources: Conducting patient preference studies comes with a financial burden that can differ among 
methods. Budgets of US$100 000– 400 000 (€90 000 to €370 000) have been quoted for quantitative patient preference 
studies [2,3,12,30,31,50,82,83,87].  
Study duration: The conduct of a patient preference study is time-consuming, ranging from 6 months to 2 years in 
complex cases [2,12,30,82,83]. The recruitment of patients can particularly take more time than is anticipated [82,83].  
Timing along MPLC: It is not clear when patient preference studies should be conducted because the submission of 
patient preferences is currently not required by regulatory authorities and HTA bodies and/or payers, but can be 
accepted as supporting evidence in a submission dossier [3,4,50,55]. Currently, the study sponsor themselves needs 




Patient preference study design  
If patient preferences are elicited in well-designed and well-con-ducted patient preference studies, patient preferences 
are considered to be valid scientific evidence that can be valuable in informing decision making [4]. Thus, the design 
phase of a patient preference study is a crucial phase. Inadequate design will negatively influence the value of the 
study and make it unlikely that outcomes will be considered by decision makers [12]. Design factors that could 
influence the value of the study are discussed below per step in the design process (Fig. 2).  
Research question  
The formulation of the research question will influence the value of the study and choice of preference elicitation, or 
exploration method, because the applicability of measuring patient preferences depends on the research question being 
asked [3,30] 
Patient versus other preferences 
Decision making might not be sensitive to patient preferences when preferences of other stakeholders, such as the 
general public or clinicians, or other evidence, are found to be more important than those of the patient [3]. This might 
be particularly important when setting up a study to inform HTA because some reimbursement decision-makers might 
wish to take the preferences of the general public, as a healthcare payer, into account [55,63,88].  
Sample definition  
Besides obtaining ethics and/or IRB approval and access to patients as described above, additional factors can 
influence the value of patient preference studies during sample definition:  
Clarity: Clearly defining the patient sample will ensure inclusion of the right patients and value of results. Setting up 
inclusion and exclusion criteria can safeguard a clear definition of the patient sample [3].  
Ensuring representativeness: Ensuring heterogeneity in the patient sample will result in generalizable results that are 
representative of the preferences of the full patient population for which the medical product is intended to be launched 
[3,4,21,30,36,50,89,90]. Generalizability of the results might be limited because of the eligibility criteria of the sample, 
especially when patient preference studies are performed along-side clinical trials [39,72,89,91–96].  
Ability to participate: In the following patient populations, it might be more difficult to measure preferences and it 
might be necessary to pay more attention to the design of the exploration or elicitation instrument: (i) low reading 
level or vision difficulties; (ii) not able to use a pencil or a computer mouse; (iii) no access to the internet; (iv) 
physically disabled; (v) cognitive impairments; and (vi) pediatric patient populations [3,4,70,83,97]. If preferences 
cannot be elicited directly from patients themselves, preferences can be elicited from informal care- givers, including 
parents and family members [3,4,33]. Parents can be included to represent their children and family members to 
represent older relatives [3,4,30,49,70,93,98]. However, their preferences might differ from those of the patients 
because they might not assign the same values to various risks and benefits [4,99].  
Sample size: During the design phase of patient preference studies, sample size and power calculations can be made 
to allow for statistical analyses later on [14,100]. If sample size calculations do not take heterogeneity into account, it 
might be impossible to do subpopulations analysis when results are available [89,90,93,95,97]. Required sample sizes 
differ among methods. For example, in general, smaller samples are required for swing weighting compared with 
DCEs [87].  
Method selection  
Many different types of preference exploration (qualitative) and elicitation (quantitative) methods exist and can be 
used in patient preference studies [3,4,14,81]. Factors that determine the value of patient preference studies are 
discussed below.  
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Match to research question: The optimal method for patient preference elicitation or exploration will depend on the 
study objective and primary use of results, and can be discussed with the stakeholders affected by, or evaluating, the 
results in advance to increase the value of the study [4,12,18,81,101]. Elicitation methods can quantify personal 
preferences, are structured, have clearly defined data types, have limited response options, allow for statistical 
analysis, and are recommended to be used when the aim is to explore preference heterogeneity in different patient 
profiles [3,4,45,56]. Exploration methods, such as interviews and focus groups, are recommended for concept 
exploration and gaining in-depth knowledge of the value of medical products [3,10,18]. Although it is important to 
match the method to the research question, this specificity and lack of standard measures is also what makes it hard 
to compare preference studies across conditions, limiting their value for some HTA agencies or reimbursement 
decision-makers [55].  
Match to MPLC stage: The appropriate choice of the method depends on the phase in the MPLC. During discovery, 
interactive exploration methods, such as focus groups, have been described as being particularly useful [4]. In 
informing clinical trial design, both exploration and elicitation methods have been used [24,25,35–37,39,102]. For 
benefit–risk assessments, elicitation methods, such as DCE and AHP, as well as exploration methods can be useful 
[12,53,59,103]. In HTA, elicitation methods that can examine willingness to pay are also described as being useful 
[59,60,69,70,81,104,105]. However, until now, HTA has mainly focused on patient involvement using preference 
exploration methods [55,106,107].  
Validity of the method: Given that participant responses might depend on the preference elicitation method used 
[105,108], weights or values obtained through different methods might not be comparable [82]. Therefore, guidance 
on which methods to use are of important to ensure the value of patient preference studies in decision making. There 
is a lack of guidance on how to assess the validity of a patient preference study [3] (Box 5). However, work is underway 
on approaches to assess the validity of patient preference studies. For example, Janssen et al. [109] created a conceptual 
model for the assessment of validity in DCEs. The manner in which internal validity can be ensured or assessed 
depends on the method used. Tervonen et al. [87] compared swing weighting (SW) to DCEs and stated that internal 
validity is automatically enforced with SW because of the exact nature of the collected preferences, whereas the 
internal validity of DCE results needs to be assessed manually. Assessment of external validity of stated-preference 
methods, requiring a comparison between stated and actual choices, is difficult to perform because of the use of 
hypothetical choices [3,100].  
Instrument design  
Depending on the objective of a patient preference study, the preference exploration or elicitation instrument can be 
designed to explore or elicit preferences for health states, treatment attributes, or treatment alternatives [81]. Different 
factors related to the design of the instrument influence the value of the study, as discussed below.  
Capturing demographics and clinical baseline data: Collecting demographic and clinical data is important if subgroup 
analysis is planned to be performed [16].  
Attribute development: Attributes could be identified through patient and caregiver involvement, via a combination 
of literature reviews, interviews, and meta-analyses of clinical data, and possibly via trial economic evaluations 
[49,73,89,110]. Identifying attributes and their levels that are relevant and do not overlap is necessary to produce 
results that can be used to assess trade-offs [4,16,49]. When the real-life attributes and levels are not sufficiently 
different and do overlap, hypothetical choices can be included. This inclusion is often mentioned as a limitation, 
because hypothetical choices can reflect benefit and risk profiles other than of the actual therapies that will be approved 
[3,36,91,93,96]. The number of attributes that can be included in the instrument differs among methods. For example, 
DCEs have been argued to not allow the inclusion of many attributes and, thus, their applicability to contexts with 
many attributes is limited [87].  
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Cognitive burden: Cognitive burden varies among methods, and minimization of this burden will assure the value of 
the results [4,87]. In patient preference elicitation studies, the cognitive burden for participants can be high because 
of the use of hypothetical choices and the large number and representation of questions, attributes, and levels 
[3,4,14,52,59,82,83,89,91,111]. Exploration methods, including interviews and focus group discussions, have a low 
cognitive burden for participants [61]. The patient population should be able to perform the method-specific tasks and 
understand the questions to realize results that can be used to assess meaningful trade-offs [3,4,16,49,83,112]. Survey 
administration via interviews or work- shops instead of online administration could provide support to patients in 
understanding the questions [87,112].  
Patient education: The extent to which patients are informed on the benefits and risks of the medical product when 
participating in a patient preference study is a determining factor for the value of the results [4,16]. Effective 
communication on benefits, risk, uncertainties, and probabilities [30] can overcome cognitive burden [96] through the 
use of appropriate numeric, verbal, and graphic representations [4,52,82]. Effective communication is especially 
important when the instrument is designed on a self-administered basis [4,30]. The amount of, and how, information 
is provided to patients on the disease, risks, and benefits can influence their preferences and the validity of the study 
[24,30,63,83,98,110,11–115]. In describing outcomes to patients, Hockley et al. [83] recommend defining the name 
of the outcome, the description, recurrence, duration, and whether the outcome is treatable. Although no further 
guidance on patient education in patient preference studies was found, other sources that might provide information 
on how to educate patients include the guidance of the FDA on communicating benefits and risks [116], the IMI 
EUPATI project [117], and the criteria for judging the quality of patient decision aids from the International Patient 
Decision Aid Standards (IPDAS) [118].  
Question framing: When eliciting patient preferences, the framing of the questions can influence preferences and the 
validity of the study [119,120]. Bowling et al. [119] stated that ‘patients’ perceptions of risk and preferences for 
treatment are difficult to measure because of the large influence of question framing and presentation effects 
(positive/negative question wording biases)’. In addition, Howard et al. [120] demonstrated in a DCE study that 
attribute framing can influence patient preferences.  
Appeal of the instrument: The selection of a method and design of the instrument can depend on how engaging the 
instrument is to prevent dropout. Minimal dropout can be achieved when the instrument is engaging through inclusion 
of engaging stimuli and exclusion of complex formats and difficult to answer questions [3,83].  
 
Patient preference study conduct  
Relevant factors influencing the value of the study and related to the study conduct are discussed below, based on 
each step of study conduct (Fig. 2).  
Participant recruitment  
Besides obtaining ethics and/or IRB approval and access to patients, as described above, another factor related to the 
recruitment of participants that will influence the value of the study is representativeness. Obtaining a representative 
sample of the patient population is a recruitment challenge for many patient preference studies [2,100]. Sample bias 
can be caused by over-inclusion of motivated patients, for example because of the recruitment of patients via a sole 
patient organization [16,36,49,78,93,121]. However, even in case of sample bias, the results of patient preference 
studies might still be meaningful for subpopulations [16].  
Piloting and data collection  
Testing validity and reliability: Performing pilot studies before the main data collection is done will allow testing of 
validity and reliability of the preference method and instrument [78,83]. Protocol compliance During data collection, 
compliance with the protocol is a crucial determinant of the validity and reliability of the results [4,30].  
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Analysis and interpretation  
Robustness: When the robustness of the analysis is ensured, results of the analysis will lead to appropriate 
interpretation [4,30]. However, the value of the analysis can be reduced if the design of the study was not well set up 
[82]. In quantitative patient preference studies, statistical analysis can be performed, resulting in estimates and 
uncertainties (confidence intervals or standard errors), which can create a value model [4,16,33]. A sensitivity analysis 
can be per-formed to assess the importance of the different values in the model [4,33]. It might be necessary to use 
advanced regression techniques in quantitative patient preference studies, such as the mixed logit model [89,93]. For 
qualitative patient preference studies, statistical analysis is not appropriate [92].  
Preference heterogeneity: Given that individual preferences are measured in patient preference studies, it is possible 
that there are differences between patients in how they perceive and weigh the attributes [4,50,60,95,122]. Some 
patients might accept higher risks for a certain benefit than other patients [3,4,50]. The detection of these differences 
could not only reveal population-level preferences for the medical product, but might also lead to the identification of 
subpopulations tolerating the risks [3,4,50,52,62]. Using statistical analysis tools that allow for detection of variation 
and distribution of preferences, for example latent class analysis, makes subgroup analysis possible [48,78,89,123]. 
However, the number of sub-groups that can be evaluated is limited [48]. Allowing for the identification of 
subpopulations for whom the benefits outweigh the risks will increase the value of the study for benefit–risk 
assessments and HTA [3,4,16,20,52,57].  
 
Communication and use of the results from patient preference studies  
The results of patient preferences studies can be communicated to, and used by, different stakeholders in decision 
making during the MPLC. Besides the communication of results to stakeholders for use in decision making, results 
can also be communicated back to patients. However, the communication of results to patients should be done in a 
different manner than communication to assessors. During the use of the results, stakeholders’ attitudes toward the 
use of patient preferences, but also clinical and market situations can influence the value of patient preferences studies.  
Factors arising in communication of results  
Tailoring of communication: Results of patient preference studies can inform many stake-holders, including industry, 
regulators, HTA bodies, payers, physicians, patient organizations, and patients. However, these stakeholders have 
different needs and, therefore, tailoring of the language, format, and venue of the study results to the stakeholder group 
can enhance the value of the results to the stakeholders. Patient organizations can participate in the communication of 
results to patients to ensure comprehensibility of the disseminated results [28].  
Presentation of results: Visualizing results can prevent their misinterpretation, and can be achieved through the use of 
tables, forest plots, and bar charts [82].  
Situations influencing the value of patient preference studies  
Patient population characteristics: Patient preferences might be especially useful in a population with unmet medical 
needs or in rare diseases [3,4,49]. However, if the medical product is developed for an unmet medical need with severe 
symptoms and high mortality, or if the outcomes of treatment with the medical product are more favorable than the 
outcomes of the disease treated with best-available care, it might be less valuable to elicit patient preferences [3].  
Product characteristics: The characteristics of the investigational product and its alternatives influence the value of 
patient preferences in decision making [3,4,50]. Patient preferences can be useful for decision making when: (i) it 
concerns a self-use medical product; (ii) there are significant benefits and risks compared with alternatives; (iii) there 
are different alternatives with different profiles (preference-sensitive situations); (iv) the importance of the benefits 
and risks is similar (uncertain benefit–risk profiles); (v) benefits and harms do not occur simultaneously; (vi) 
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technologies new to a certain disease area are used; (vii) risks can be identified for which no benefit can compensate; 
and (viii) clinical experiences and end-points are subjective [3,4,45,50,89,105,110]. When approval is likely because 
of important benefits and non-severe risks or because of superiority compared with alternatives, patient preferences 
might become less valuable [3].  
Familiarity of assessors: Eliciting patient preferences might be especially valuable in patient populations with which 
regulators are not familiar [50]. When sponsors and regulators know the disease area and technologies well, patient 
preferences become less valuable [3]. In addition, the value of elicited quantitative patient preferences for decision 
making can be limited by unfamiliarity with preference methods among assessors interpreting the results [82,98].  
Attitudes of assessors: There is no consensus on the role of patient preferences in decision making along the MPLC. 
A consensus on this role might be difficult to achieve because of distrust in the use of patient preferences resulting 
from the false impression that preferences can only be used as averages, fear that patient preferences will replace 
existing clinical evidence, barriers to ‘cultural change’, the lack of consensus on the definition of patient preferences, 
and disappointment risk (i.e., the possibility that patient preference studies might yield unexpected results; e.g., some 
patients might not want to accept the risks of a new product) [1,3,4,12,30,31,36,47,50,63,64,66,70,81–83,98,124,125].  
New competitors: If new treatment options become available, or if new benefits and risks are identified, the results of 
previously performed patient preference studies might no longer be valid and might need to be reconducted [82].  
 
Concluding remarks  
Although limited evidence was found on the actual use of patient preferences in decision making, they are gaining 
attention in processes along the MPLC. We believe that additional guidance on the use of patient preferences in 
assessments and decision making is necessary to increase their use. Moreover, use of patient preferences could 
increase if regulatory authorities, HTA bodies, and payers would inform the industry about whether and how they 
would use patient preferences in their processes, or would state in what situations they find patient preferences 
valuable or even require the submission of results from patient preference studies. Many factors and situations have 
to be taken into account when designing and conducting a patient preference study to obtain valuable results that can 
be used in assessments and decision making. The main trends among the factors that we described here that will 
contribute to the value of a patient preference study are: (i) having a multidisciplinary team; (ii) ensuring patient 
centeredness in the design as well as the conduct and communication of results; (iii) matching the sample and the 
method to the research question; (iv) safeguarding validity in the method selection and instrument design; (v) reducing 
cognitive burden; (vi) providing adequate patient education; (vii) guaranteeing that preference heterogeneity can be 
measured and interpreted; and (viii) tailoring communication of results to the audience. Further research should focus 
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Appendix 2.1: Systematic literature search and review: methods 
 
Systematic literature search strategy 
White and grey literature1 was consulted. White literature was retrieved through a sensitive2 systematic literature 
search in PubMed, Embase, PsycINFO, EconLit, and Guidelines International Network. Search terms were developed 
through PICO analysis of the research question (Table I.I). Several terms were used to exclude drugs and medical 
devices with no direct therapeutic effect, and to exclude the process of shared decision making. The consulted 
databases specifically searched titles and abstracts, filtering for articles published between 2011 and March 2018 in 
English of which the full-text publication were available. Guidelines International Network did not permit a complex 
search query and only the term “patient preferences” was used for this database. Grey literature was collected through 
interaction with industry, patient representative, academic, regulatory, and HTA stakeholders. Grey literature included 
reports of patient-centered projects and guidelines from regulatory agencies such as the EMA and FDA, as well as 
national HTA agencies and payers from Europe or the US. 
 
Selection process and data extraction 
After removing duplicates, three researchers (EvO, CW, and RJ) independently reviewed the titles and abstracts of 
potentially relevant white literature, as well as titles, summaries, and content tables of identified grey literature. Every 
publication was independently reviewed by two reviewers, and excluded if it did not meet all of the following criteria:  
• Mention of factors and situations influencing the value of patient preferences in context of the MPLC; OR 
indication of how patient preferences can be used in processes and decision making along the MPLC 
• On European or US context 
• Published after 2011 
• Written in English 
• Full text available (conference abstracts, letters to the editor, book reviews, presentations, conference notes, 
and workshop presentations were excluded) 
 
The full texts of white and grey literature were assessed by one researcher (EvO) based on the same inclusion and 
exclusion criteria as during the title and abstract screening. Additional articles were included through snowballing. 
Data extraction was done by the same researcher. 
 
Table I.I Search query: A AND B AND C AND D NOT E 
A: Factors/situations 
Concept MeSH Emtree Free text (searched in title and abstract) 
Process     process, processes 
Condition     condition, conditions 
Factor     factor, factors 
Influence     influence, influences, influencer, influencing 
Utility     Utility 
Weight     Weight 
Value     Value 
Application     application, applications 
Decision making     assessment, assessments, criteria, criterias, "decision making", 
"decision making", critertion, "decision point" 
B: Patient preferences 







"patients preference", "patients preferences", "preference of patients", 
"preferences of patients", "patient preference", "patient preferences", 
"preference of a patient", "preference of the patient", "preferences of a 
patient", "preferences of the patient" 
 
1 Adams RJ, Smart P, Huff AS. Shades of Grey: Guidelines for Working with the Grey Literature in Systematic Reviews for Management and 
Organizational Studies. International Journal of Management Reviews. 2016:n/a-n/a. 









“methodology” "elicitation methods", method, methodology, empirical, "qualitative 
method", qualitative, "quantitative method", quantitative, technique, 
techniques 
Measuring     Measuring 
Assessment     measurement, measurements, assessment, assessments 
Inclusion     inclusion, including, include, incorporate, incorporating, incorporation, 
involving, involvement, involve 
D: Medical Product LifeCycle 
Concept MeSH Emtree  Free text (searched in title and abstract) 
Drug life cycle     "life cycle of a drug", "life cycle of a medical device", "medical device 
life cycle", "lifecycle of a drug", "lifecycle of a medical device", 
"medical device lifecycle", "drug life cycle" 
"drug lifecycle"  
Development     "drug development", "medical device development", "development of 
drugs", "development of a drug", "development of medical devices", 
"development of a medical device" 
Benefit and risk "risk 
assessment" 
“risk assessment” "benefit and risk" 
"risk and benefit"  
Benefit-risk     "benefit-risk" 
"risk-benefit"  
Reimbursement     "reimbursement" 
Research     "drug research", "medical device research", "clinical trials", "clinical 
trial" 
HTA     "health technology assessment", "health technology assessments" 
E: NOT terms 
Concept MeSH Emtree  Free text (searched in title and abstract) 
NOT terms     "shared decision making", "shared decision making", monitoring, 
biomarker, biomarkers 
 
Strengths and limitations 
 
Literature search 
While one of the strengths of this literature review was the systematic search, this search also had some limitations. 
The terms used in this search were very specific to the MPLC context. While the use of these terms ensured a sensitive 
search regarding the research question on the processes used to incorporate patient preferences in decision making, 
this sensitivity might have led to loss of information on factors that influence the quality of patient preference studies 
outside the MPLC context. In addition, only English literature was consulted, limiting the possibility of finding 
information specific to processes in non-English speaking European countries. Moreover, it is possible that relevant 
research outside peer-reviewed literature was not consulted. More information might have been discovered concerning 
the actual inclusion of patient preferences in decision making on medical products by reviewing assessment reports 
of single treatments. Lastly, since the literature was performed in two parts (January 2011 till November 2016 and 
December 2016 till March 2018), it is possible that some literature that was published but not yet available in the 
databases before November 2016 might not have been retrieved. 
 
Definition of patient preferences 
During the screening of publications, we soon discovered that in literature there is no consensus on the definition of 
patient preferences. In addition to the existence of different definitions of the term patient preferences, also other terms 
were used as synonyms for patient preferences, such as “attitudes towards […]”, “patient input”, or “patient 
perspective”. In this study, the search strategy only included “patient preference” and “patient preferences” as search 
terms for the concept of patient preferences, but no other synonyms were included, possibly resulting in an 
underestimation of the current use of patient preferences. Because of the ambiguity of terms such as “patient input” 
and “patient perspective”, it was sometimes difficult to assess when statements were referring specifically to patient 
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preferences or to broader attitudes. Moreover, since patient preferences were a key term in our search query, it is 
possible that some informative publications not containing the term patient preferences or not falling under the MeSH 
or Emtree term “patient preference” were not included in this literature review. This might also explain why more 
information on quantitative patient preference studies using elicitation methods was found and rather limited 
information was found on qualitative patient preference studies using exploration methods. 
 
Selection process and data extraction 
A strength of this literature review was the independent inclusion and exclusion of publications based on titles and 
abstracts by two researchers, reducing subjectivity of this process. However, studies were not formally appraised 
through the use of existing appraisal techniques. The researchers tried to apply existing appraisal techniques, but no 
technique was found that would be able to appraise all the different types of literature included, from single studies to 
systematic reviews and guidelines. Another limitation of the literature review was that the extraction of information 





Appendix 2.2: Overview of included literature and themes identified in the literature 
 
The number of retrieved publications was 1033 (Figure II.I). In total based on inclusion and exclusion criteria, 665 
publications were excluded during title and abstract screening, and 94 during full text screening. An additional 8 
publications were included via snowballing. In the end, 113 publications were included. These publications covered 
different factors, situations and applications (Table II.I). 
 
 
Figure II.I Flowchart of the literature search and inclusion of publications 
 
Table II.I Overview of included literature and themes covered in the literature 
# Reference (reference #) Phases of PP studies in which conditions 
and contextual factors were identified 
MPLC phases in which applications 
were identified or that was the 
context of the paper 
1 Abelson et al.[2] Organization, Conduct HTA 
2 Beresniak et al.[80] / HTA 
3 Bewtra et al.[76] / HTA 
4 Bilvick et al.[68] / HTA 
5 Bloom et al.[22] / Clinical 
6 Brennan[124] Use of results Other 
7 Brazier et al.[128] / HTA 
8 Breckenridge et al.[11] / R&D, Clinical, MA, HTA 
9 Brooker et al.[125] Use of results HTA 
10 Chaudhuri et al.[45] Conduct, Use of results Clinical 
11 Danner et al.[129] / HTA 
12 Dirksen et al.[63] / HTA 
13 Egbrink et al.[18] Design, Use of results MA 
14 Eliasson et al.[111] Design MA 
15 EMA benefit-risk 
standards[122] 
Conduct MA 
16 EMA patient’s voice report[1] Conduct, Use of results MA 
17 EPF survey[8] / HTA 
18 Ervin et al.[35] / Clinical 
19 Facey et al.[10] Design, Use of results MA, HTA 
20 FDA guidance[4] Organization, Design, Conduct, Use of 
results 
R&D, Clinical, MA, Post-marketing, 
other 
21 Finnell et al.[77] / HTA 
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# Reference (reference #) Phases of PP studies in which conditions 
and contextual factors were identified 
MPLC phases in which applications 
were identified or that was the 
context of the paper 
22 Franco et al.[24] Design Clinical 
23 Fraenkel et al.[113] Design Other 
24 Gagnon et al.[106] / HTA 
25 Gaudiano et al.[21] Conduct Clinical 
26 Gold et al.[101] Design Other 
27 Goto et al.[74] / HTA 
28 George et al.[44] / Clinical 
29 Gries et al.[90] Conduct HTA 
30 Gryczynski et al.[39] Design, Conduct Clinical 
31 Gutknecht et al.[81] Design, Conduct, Use of results MA, HTA, other 
32 Hailey et al.[67] / HTA 
33 Hauber et al.[53] / MA 
34 Hernandez Alva et al.[123] Conduct HTA 
35 Ho et al.[50] Organization, Design, Conduct, Use of 
results 
MA 
36 Ho et al.[96] Design, Conduct Use of results MA 
37 Hockley et al.[83] Organization, Design, Conduct, Use of 
results 
MA 
38 Hockley et al.[14] Design, Conduct MA 
39 Hollin et al.[49] Design, Conduct MA 
40 Hughes et al.[82] Organization, Design, Conduct, Use of 
results 
MA 
41 ICH Harmonised Guideline on 
Benefit-Risk Information[127] 
/ MA 
42 Ijzerman et al.[108] Design HTA 
43 IQWiG AHP Pilot[61] Design HTA 
44 IQWiG CA pilot[62] Conduct HTA 
45 Irony et al.[57] / MA 
46 Janssen et al.[48] / MA 
47 Janssen et al.[109] / MA 
48 Janssen et al.[88] / HTA 
49 Johnson et al.[103] Design, Use of results MA 
50 Johnson et al.[43] / Clinical 
51 Katz et al.[91] Design, Conduct MA 
52 Kay et al.[79] / HTA 
53 Kievet et al.[20] / HTA 
54 King et al.[41] / Clinical 
55 Kleme et al.[107] Use of results HTA 
56 Lim et al.[23] / Clinical 
57 Louviere[115] Design / 
58 Lowe et al.[31] Organization, Design, Use of results R&D, HTA 
60 MacLean et al.[105] Design, Conduct HTA 
61 Marcus et al.[25] / Clinical 
62 Marrone et al.[54] / MA 
63 Marsh[29] Design HTA 
64 Marsh et al.[51] / MA 
65 Marsh et al.[52] Design, Conduct HTA, MA 
66 Martin-Fernandez et al.[72] Conduct HTA 
67 MDIC PCBR report[3] Organization, Design, Conduct, Use of 
results 
R&D, Pre-clinical, Clinical, MA, HTA, 
Post-marketing, other 
68 Menon et al.[13] / MA 
69 Menon et al.[19] / HTA 
70 Minion et al.[36] Design, Conduct, Use of results Clinical 
71 Moes et al.[64] Use of results HTA 
72 Mol et al.[15] Conduct, Use of results MA 
73 Montazerhodjat et al.[46] / Clinical 
74 Morel et al.[33] Conduct R&D, MA 
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# Reference (reference #) Phases of PP studies in which conditions 
and contextual factors were identified 
MPLC phases in which applications 
were identified or that was the 
context of the paper 
75 Mott et al.[60] Design, Conduct MA, HTA, other 
76 Mott[55] Design MA, HTA 
77 Mt-Isa et al.[17] Use of results MA 
78 Mühlbacher et al.[121] Conduct HTA 
79 Mühlbacher et al.[78] Design, Conduct HTA 
80 Mühlbacher et al.[66] Use of results MA, HTA 
81 Mühlbacher et al.[75] / HTA 
82 Nafees et al.[97] Design, Conduct HTA 
83 Olschewski et al.[40] / Clinical 
84 PCRG[42]PCRG[42] / Clinical 
85 Peay et al.[93] Design, Conduct MA 
86 Pisa et al.[65] / HTA 
87 Postmus et al.[16] Design, Conduct, Use of results MA 
88 Postmus et al.[112] Design MA 
89 PPVF framework[47] Use of results MA, other 
90 Puhan et al.[56] Design MA 
91 Puhan et al.[58] Use of results MA 
92 Rodriguez et al.[69] Conduct HTA 
93 Roy et al.[94] Conduct HTA 
94 Sanchez-Martinez et al.[104] / HTA 
95 Selig[30] Design, Conduct, Use of results R&D, Clinical, MA 
96 Silverman et al.[95] Conduct Other 
97 Smith et al.[98] Design, Conduct, Use of results MA 
98 Svedsater et al.[92] Conduct MA 
99 Stamuli et al.[37] Design Clinical 
100 Stewart et al.[102] / Clinical 
101 Stewart et al.[34] / R&D 
102 Swinburn et al.[110] Design, Conduct Other 
103 Terris-Prestholt et al.[71] / HTA 
104 Tervonen et al.[87] Organization, Design MA 
105 Thebaut et al.[70] Conduct, Use of results HTA 
106 Tinelli et al.[89] Design, Conduct HTA 
107 Tinelli et al.[73] Design, Conduct, Use of results HTA 
108 Torgerson et al.[86] / Clinical 
109 van Til et al.[12] Organization, Design, Use of results MA 
110 von Arx et al.[114] Design MA 
111 Walter et al.[38] / Clinical 
112 Weernink et al.[59] Design MA, HTA 
113 Wolka et al.[28] Organization, Design, Conduct, 
Communication and use of results 
MA 
Abbreviations: HTA, Health Technology Assessment; MA, Marketing Authorization; MDIC PCBR, Medical Device Innovation Consortium’s Patient 
Centered Benefit-Risk Project; MPLC, Medical Product Lifecycle; PCRG, Preference Collaborative Review Group; PP, Patient preference; R&D, 




Appendix 2.3: Steps of a patient preference study 
 
Figure III.I Steps of a patient preference study 
 
While there are alternative ways to describe and group steps of patient preference studies, we identified steps and their 
organization as they emerged from the literature (Figure III.I): 
Organization – The organization and management of patient preference studies, including the management of 
resources such as budget, staff, and time management. 
Study design – The setup of patient preference studies, including defining the: 
Research question – A research question is defined. It is described why patient preferences should be elicited, for what 
treatment alternatives or health states they should be elicited, and in what patient population the study will be 
conducted. 
Sample definition – The patient population is defined and inclusion and exclusion criteria are setup for the selection 
of the sample. 
Method selection – A choice is made for one or multiple preference exploration (quantitative) or elicitation 
(qualitative) methods. Examples of exploration methods are semi-structured interviews and focus groups. Examples 
of elicitation methods are Discrete Choice Experiment (DCE), Analytic Hierarchy Process (AHP), or Time-Trade-Off 
(TTO). 
Instrument design – The questions, attributes and levels are defined and thought is given to how the questions will be 
presented and displayed to the patient. 
Study conduct – The stage in which the study is performed and data are collected. 
Participant recruitment – Participants are recruited based on inclusion and exclusion criteria, and the full-scale study 
is started. 
Piloting and data collection – Pretesting surveys, coding of the survey, testing that the coded survey meets 
specifications and making revisions based on the testing is done during piloting. A pilot study, a small scale 
preliminary study, may also be conducted to evaluate feasibility, time, cost, clarity of the questions, functioning of the 
method, and statistical variability. An appropriate sample size can be calculated and study design can be improved 
prior to the initiation of the full-scale study. In data collection, data is collected through exploring and eliciting the 
participants’ preferences with the predefined method. 
Analysis and interpretation – Data is analyzed using different (non-)statistical tools and tests. Results are interpreted 
and presented in a meaningful way. 
Communication and use of results – The results of the patient preferences study can be communicated to and used by 
stakeholders in decision making during the MPLC. 
Communication to patients – Besides communication of results to inform decision making, results should also be 
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Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical industry, regulatory 
authorities, and Health Technology Assessment (HTA) bodies/payers for use in assessments and decision-making 
along the medical product lifecycle (MPLC). This study aimed to identify factors and situations that influence the 
value of patient preference studies (PPS) in decision-making along the MPLC according to different stakeholders. 
Methods: Semi-structured interviews (n=143) were conducted with six different stakeholder groups (physicians, 
academics, industry representatives, regulators, HTA/payer representatives, and a combined group of patients, 
caregivers, and patient representatives) from seven European countries (the United Kingdom, Sweden, Italy, Romania, 
Germany, France, and the Netherlands) and the United States. Framework analysis was performed using NVivo 11 
software. 
Results: Fifteen factors affecting the value of PPS in the MPLC were identified. These are related to: study 
organisation (expertise, financial resources, study duration, ethics and good practices, patient centeredness), study 
design (examining patient and/or other preferences, ensuring representativeness, matching method to research 
question, matching method to MPLC stage, validity and reliability, cognitive burden, patient education, attribute 
development), and study conduct (patients’ ability/willingness to participate and preference heterogeneity). Three 
types of situations affecting the use of PPS results were identified (stakeholder acceptance, market situations, and 
clinical situations).  
Conclusion: The factors and situation types affecting the value of PPS, as identified in this study, need to be considered 






Recently, the use of patient preference information (PPI) in drug development and assessments has gained attention 
[1]. PPI is defined by the United States (US) Food and Drug Administration (FDA) as: “qualitative or quantitative 
assessments of the relative desirability or acceptability to patients of specified alternatives or choices among outcomes 
or other attributes that differ among alternative health interventions” [2]. Key stakeholders, including the 
pharmaceutical and medical device industry, regulatory authorities, health technology assessment (HTA)/payers, 
reimbursement agencies, academia, health care professionals, and patient representatives, are recognizing the value of 
PPI in assessments and decision-making along the medical product lifecycle (MPLC) [3, 4].   
PPI can be used in every phase of the MPLC [4, 5]. Some examples of applications include: identifying unmet medical 
needs [2, 4, 6], informing the selection of endpoints, inform benefit-risk assessments [2, 4, 7, 8] and in HTA [9, 10, 
11]. PPI can give insights into the trade-offs that patients make between benefits and risks, and show the relative 
importance of outcomes for patients [12, 13, 14]. 
PPI can be obtained through many different preference exploration (qualitative) or elicitation (quantitative) methods 
[2, 4, 15, 16]. Exploration methods are recommended for concept exploration and gaining in-depth knowledge on the 
value of medical products [4, 17, 18]. Elicitation methods can quantify personal preferences, allow for statistical 
analysis, and possibly the detection of preference heterogeneity among patients [2, 4, 19]. 
Despite prior guidance on the review and research practices of patient preference studies (PPS) [2, 4, 20], systematic 
integration and acceptance of PPI into decision-making is still pending. Most industry, HTA/payers and regulators 
“have key uncertainties regarding the validity, representativeness, and robustness of preference studies to inform 
deliberative decision-making” [21]. Therefore, structured insights from all relevant stakeholders on the design and 
conduct of PPS, is currently needed. This study aimed to gather stakeholders’ views on important factors and situations 
that influence the value and role of PPS in assessments and decision-making. By addressing these factors and 
situations, decision-makers can be advised how to conduct and integrate more robust PPS, increasing the potential for 




Interviews were conducted with six stakeholder groups: industry, HTA/payers, regulators, academia, physicians, and 
a combined group of patients, patient representatives, or patients’ caregivers. Interviews were conducted in eight 
countries with heterogeneous healthcare systems. Interviews with patients, patient representatives, caregivers and 
physicians were conducted in different disease contexts (Table 1). Higher interview quota (n=24) were set for 
“primary” countries than represented four different regions of Europe. A smaller quota (n=12) were set for “auxiliary” 
countries, which served to confirm observations from the primary countries (Table 1). 
 
 
Table 1: Planned design of the interviews 
Country classes Country Interview quota 




(with a 24 interviewee 
quota) 
Italy 24 4 Lung cancer 
Romania 24 4 Cardiovascular disease 
Sweden 24 4 Rheumatoid arthritis 
United Kingdom 24 4 Muscular dystrophy 
52 
 
Country classes Country Interview quota 




(with a 12 interviewee 
quota) 
France 12 2 Lung cancer 
Germany 12 2 Rheumatoid arthritis 
Netherlands 12 2 Muscular dystrophy 
United States 12 2 Cardiovascular disease 
* Six stakeholder groups were interviewed in every country. These stakeholder groups included the pharmaceutical and medical device industry, 
HTA/payers, regulators, academia, physicians, and the combined group of patient representatives, patients and patients’ careg ivers 
**Only for interviews with patients, patient representatives, caregivers and physicians 
 
Participant Recruitment 
Participants were selected based on predefined inclusion criteria (Appendix 3.1-3.2) to enable selection of 
interviewees with the necessary experience or expertise to answer our research questions and promoting heterogeneity 
across the sample. Our interviewees were recruited through purposive sampling and snowballing recruitment 
techniques [22]. 
Conduct 
Two interview guides were developed based on the research questions and a literature review [23]. One guide using 
technical language was written for industry, regulators, HTA/payer representatives, and academics, and one using 
plain language for patients, caregivers, physicians and patient representatives. The interview guides were translated 
from English into six other languages. Interviews with patient representatives, patients, caregivers and physicians 
were conducted in their native language. These guides were translated back to English for a consistency check. 
Interviews with others were conducted in English, unless they only felt comfortable speaking their native language. 
To ensure comprehension of the guides, five reviews of the guide and pilot interviews were conducted by targeted 
stakeholder members. Written informed consent was obtained from all participants before the start of the interviews. 
The interviews were conducted via telephone, teleconference or face-to-face. Interviews were audio-recorded, 
transcribed verbatim and pseudonymised. Non-English transcripts were translated to English. 
Analysis 
Transcripts were analysed through framework analysis [24, 25] using NVivo [26]. The data were interpreted for 
patterns, consensuses, and critical observations across the stakeholder groups, which created thematic ‘codes’. First, 
two researchers (CW; EvO) examined 54 transcripts during a ‘familiarisation process’ [24] through which an overview 
of the collected data was established, and the researchers became aware of key themes and concepts which are made 
into thematic ‘codes’. Due to the volume of data, it is common for researchers conducting framework analysis to only 
familiarise themselves with a section of data [27]; in this case, roughly one third of the transcripts (n=54) was used 
for familiarisation. Next, a thematic framework was identified. Coding was applied to 6 transcripts (one from each 
stakeholder group) by two researchers (CW; EvO), in order to confirm the codes identified from the familiarization 
process, and also to confirm deductive codes formed from a previous systematic review regarding factors and 
situations influencing the value of patient preference studies [23]. Additional open-coding originating from these 6 
transcripts were combined with the familiarization process codes and the literature codes to create a final coding list 
(Appendix 3.3) , which was then applied to all 143 transcripts by five researchers (CW, EvO; KB; RH; MS). Portions 
or sections of text that corresponded to a theme were indexed, and placed in charts with headings reflecting these 
themes. These charts were then analysed and interpreted for common attitudes and opinions of the respondents, with 
comparisons being made inside stakeholder groups and countries.   
Results 
In total 143 interviews were conducted and interview quota were reached for all stakeholder groups and countries 
except for Romanian regulators (Table 2). Factors were identified along three stages of patient preference studies 
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(PPS): organisation, design, and conduct (Figure 1). In addition, challenges and solutions relating to these factors were 
identified (Table 3). Situations were identified during the last stage: communication and use of results. These stages 
were identified through literature [23] and confirmed through interview responses. 
 
Table 2: Characteristics of interviewees 















     
n % n % n % n % n % n % 
Country                         
  Italy (n=24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17% 
  Romania (n=23) 4 17% 4 17% 3 13% 4 17% 4 17% 4 17% 
  Sweden (n=24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17% 
  UK (n=24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17% 
  France (n=12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8% 
  Germany (n=12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8% 
  Netherlands (n=12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8% 
  US (n=12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8% 
Disease area*                        
  Lung cancer 6 25% NA NA NA 6 25% NA 
  Rheumatoid arthritis 6 25% NA NA NA 6 25% NA 
  Muscular dystrophy 6 25% NA NA NA 6 25% NA 
  Cardiovasc. disease 6 25% NA NA NA 6 25% NA 
Self-reported 
familiarity with PP                         
  Very familiar/      
     expert 1   4% 4 17% 3 13% 2   8% 0   0% 12 50% 
  Moderately familiar 7 29% 11 46% 13 57% 16 67% 6 25% 7 29% 
  Not familiar 16 67% 9 38% 7 30% 6 24% 18 75% 5 21% 
Abbreviations: Cardiovasc., cardiovascular; NA, Not applicable; PP, patient preferences; Reg., regulators; repr., representatives; HTA, Health 
Technology Assessment; UK, United Kingdom, US, United States; *, specific disease areas where only applicable to patients, patient 
representatives, caregivers and physicians. 
 
Factors relating to study organisation  
Five factors relating to the organisation of PPS were identified, namely: 1) Expertise of staff, 2) Financial resources, 
3) Study duration, 4) Ethics and good practices, and 5) Patient centeredness (Figure 1, Table 3). The first four factors 
were anticipated, and will not be exhaustively detailed in the results, because they are factors that influence the value 
of any scientific study. Although they are important factors, they are not unique to PPS. Further information about 
these factors’ current implementation in PPS is summarised in van Overbeeke et al., 2019 [23]. The fifth factor, patient 
centeredness, was more specific to PPS. Patient centeredness in study organisation is key to a successful PPS, since 
this should be the focus of the study. Patients are invaluable to informing the research questions, improving 
recruitment, and ensuring the comprehensibility of information and questions given to patients [23]. Interviewees 
across all stakeholder groups and countries, except for Romania, expressed the importance of having patients and/or 
patient representatives involved in the design and conduct, because they have the most real-life experience with their 
own condition.  
Factors relating to study design  
Eight factors relating to the design of PPS were identified (Figure 1). All stakeholder groups across all countries felt 






Figure 1  
Factors and situations influencing the value and role of patient preference studies (PPS) along the medical product 
lifecycle (MPLC) 






1. Examining patient and/or other preferences  
All interviewees were asked whose preferences should be measured, and their answers included patients, patient 
organisations, the public, caregivers, physicians, and combinations of these categories. Four interviewees discussed 
how the population must satisfy the research question. The preferences of family caregivers could be important in 
instances when caregivers make most of the medical decisions because patients cannot express themselves or their 
preferences may not be reliable (e.g. children or impaired cognitive abilities). Although caregiver preferences can 
sometimes reflect patient preferences, they also have their own preferences which could be different from the patient’s 
preferences. HTA/payer representatives, patients, industry representatives, and academics discussed preferring general 
public preferences instead of PPI, or a combination thereof, in the context of healthcare expenditure, budget allocation 
and reimbursement. A UK HTA/payer representative stated they must consider “all of the uses of the NHS [National 
Health Service] rather than just the particular patient group who is in front of them”. Five HTA/payer representatives 
assumed that patient preferences are incorporated satisfactorily and “built in” (UK) through QALYs or EQ5D 
measures, despite their calculation frequently incorporating public utility values for quality of life attributes as opposed 
to patient utilities for treatment outcomes. An EU industry representative stated that when it is the objective to elicit 
patient preferences, the general public should not be included.  
2. Ensuring representativeness 
Representatives from industry, HTA/payers, regulatory, academia, patients, and patient organisations across all 
countries expressed that it is crucial to have a patient sample representative of the actual patient population targeted 
with the treatment. All stakeholder groups across all countries had opinions about what constitutes as ideal 
characteristics of the patient sample, although this depends largely on the research question. Almost all participants 
agreed patients should have experience with the disease, although this is not as important in contexts like disease-
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prevention. Eighteen participants believed participants should have experience with treatment, stating that this results 
in more “reliable” (UK, regulator) preferences. Fourteen participants stated experience with treatment was less 
important. Other characteristics of an ideal sample included covering multiple countries of residence, if 
generalizability across countries is desired. Six interviewees (industry, regulatory, academia, and HTA/payer) 
expressed concern that the subjective nature of PPI generates a lower generalisability. US and EU academics, an EU 
HTA/payer representative, and an EU regulator explained how recruitment through patient organizations can lead to 
samples of highly motivated patients, and recruitment through clinical trials can give samples restricted by 
predetermined inclusion or exclusion criteria; both not representative of the patient population. A solution, according 
to the regulator, might be to recruit 50% patient organisations and 50% “everyday” patients. 
3. Matching the method to the research question  
The majority of industry, HTA/payer, regulators, and academic representatives mentioned that there is no single “gold 
standard” preference exploration (qualitative) or elicitation (quantitative) method. According to one academic, 
selecting a method is in itself “a trade-off” because “none of them are perfect… [or] offer you a guarantee of being 
better over any other one” (UK). The ability to quantify trade-offs was thought to be paramount in elicitation methods 
by many stakeholder groups, particularly academics. An EU physician was adamant that an elicitation method needs 
to be equipped to handle hypothetical scenarios, including drugs that are not yet available, and must include the option 
to not receive any treatment. This physician felt this was extremely applicable to conditions that have limited treatment 
options. One EU academic required elicitation methods to assess marginal rate of substitution to determine maximum 
acceptable risk. Five academics and one HTA/payer representative from Sweden and Germany advocated for 
elicitation methods that incorporate a monetary valuation, such as willingness-to-pay. EU academic and industry 
representatives indicated that elicitation methods are seen as more “robust” (US, industry), “objective” (Germany, 
industry), “acceptable by [sic] the medical… community” (Netherlands, academic) and more likely to “convince a 
payer” (France, academic). 
4. Matching the method to the MPLC stage 
Exploration methods were thought better suited for early MPLC phases for exploring heterogeneous data, defining 
value frameworks, or identifying endpoints or attributes, examining cultural heterogeneity and subjective experiences. 
Most interviewees from academia and industry argued that a mixed-methods approach is necessary, discovering 
attributes and levels early in the MPLC through exploration methods to “inform” (US, academia) elicitation studies 
during phase III or IV. Elicitation methods were thought to “refine quality […] with numbers” (Italy, regulator) by 
quantifying trade-offs, obtaining the strength of a preference, ranking or weighing an endpoint, and/or comparing 
decision pathways. Two UK HTA/payer representatives mentioned they are most familiar with elicitation methods 
during appraisals. 
5. Validity and reliability 
Most interviewees from all countries, especially HTA/payer representatives and academics, felt validity was extremely 
important, including method validity, criteria validity, internal validity, and external validity. EU HTA/payer 
representatives, a regulator and two industry representatives expressed a need for international scientific consensus 
regarding evaluating rigor of methodologies in a “standardized, validated way - accepted by everybody, all 
stakeholders” (France). One academic assured that studies published in articles undergo quality checklists for validity, 
but also suggested that piloting be conducted within studies for quality and validity checks. A US regulator pointed 
out that some methods have higher validity than others and suggested that the degree of rigor should be “fit for 
purpose”, meaning the level of validity should be proportional to the risk or invasiveness of the medical product. A 
US industry member explained how external validity is often not necessary for internal decision-making. An EU 
academic worried that use of hypothetical situations leads to low external validity. 
6. Cognitive burden 
All stakeholder groups emphasized that cognitive abilities of patients must be considered when designing preference 
studies, particularly for diseases associated with cognitive impairment or neuromuscular fatigue. This assures validity 
of the data, but also places value in the preferences of all patients, regardless of cognitive ability. Many interviewees 
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insisted that patients with cognitive issues should not be excluded, with an EU physician stating that stakeholders 
“have to get [sic] extra input to try and find out exactly what their views are” (UK). A physician, regulatory, and 
HTA/payer representative mentioned that survey fatigue should be avoided. Two patients said that patients often have 
different preferences depending on how they are feeling that particular day (UK patient and UK caregiver). Several 
cognitively burdensome situations were highlighted by academics, regulators, industry and HTA representatives, 
including 1) hypothetical scenarios, 2) complex probabilities or percentages, 3) complex stages of the drug life cycle, 
4) many repetitions of similar questions with different phrasing, 5) long surveys with no breaks, 6) absence of concrete 
examples and 7) surveys that cannot be completed at home. A US academic expressed, “a poorly designed study that 
was poorly understood by the users could result in a worse decision than if there had been no study what-so-ever”.  
7. Patient education 
Four EU and US industry members commented that patients’ knowledge is often not sufficient to contribute 
meaningful answers. However, other stakeholders, including patients themselves, recognised that the responsibility of 
patient education does not lie with the patients, but with the study designers, who should ensure comprehensibility. 
An EU industry member advised utilising educational tools, in video or other format, to instruct patient preference 
exercises. A US academic stated “we need to figure out how to make the instrument as comprehensible as possible to 
respondents who may have a very low educational attainment but still be accurate enough that we can map the 
attributes and levels to clinical outcomes,” expressing the need to strike a right balance. Two EU stakeholders 
recognised that informing patients without contributing bias or “influenc[ing]” the patient (Germany, physician) is “a 
challenge” (Sweden, regulator). 
8. Attribute development  
All stakeholders who expressed an ideal number of attributes for PPI elicitation studies thought it should be between 
3-6 attributes. Any more than 7, and the cognitive burden can become unmanageable, or the patients “[simplify] 
characteristics” (US, industry), affecting validity. Both EU and US interviewees mentioned standard attributes to 
incorporate like quality of life, overall survival rates, progression-free survival rates, or other symptomatic evaluations. 
An EU academic also advocated for the inclusion of ‘Willingness-to-Pay’ (WTP) features, as well as the level of 
convenience of managing conditions. An EU physician suggested to include the products’ administration frequency. 
Most representatives from different stakeholder groups emphasised the importance of constructing “easily 
interpretable” (Netherlands, regulator) and “patient-user friendly” (UK, regulator) questions, thereby measuring their 
preferences accurately. Two EU representatives spoke about making sure not to “steer certain answers” (UK, industry) 
and recognized that patients can be susceptible to the particular question ordering. A US academic strongly warned 
against using ambiguous attribute levels such as “mild, moderate, severe”. A US regulator explained “Patients who 
had experience of the disease should be essential in determining the type of questions, and for example, attributes […] 
also, the wordings and the communication part”. 
 
Factors relating to study conduct 
Two factors relating to the conduct of PPS will be examined (Figure 1), namely: 1. Patients’ ability and willingness 
to participate, and 2. Preference heterogeneity.  
1. Patients’ ability and willingness to participate 
Interviewees identified different hurdles to patient recruitment including lack of resources, the possibility of people 
dropping-out (or passing away) during the course of recruitment, fraudulent participants, and a hesitation of patients 
to discuss traumatic elements of their disease or condition. EU patients, a caregiver, and an industry representative 
said newly diagnosed patients or patients in severe, late stages of illness might not want to participate. In the context 
of myotonic dystrophy, an EU caregiver explained “It can take a long time for them to accept [the diagnosis] and to 
understand it” (UK). A US HTA/payer representative stated “One of the biggest issues is finding the patient” and 
explained that normally one month is given for recruitment, although two EU academics and two EU physicians stated 
it can take years for rare diseases. Multiple channels for recruitment were proposed by interviewees including health 
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care professionals, internet calls, patient organisations, national registries and clinical trials. To facilitate recruitment, 
two EU patients suggested to conduct studies from home or reimburse travel and hotel costs. 
2. Preference heterogeneity  
Almost all interviewees argued that preference heterogeneity, or the extent that preferences vary across individuals, is 
inevitable and “inherent” (UK, industry) due to differences in treatment experience, disease experience, cultures and 
countries, education, socio-economic status, family and support systems, beliefs and religions. Two regulators (EU), 
two academics (EU and US) and three industry representatives (EU) stated that capturing heterogeneity is complex 
and is often difficult to integrate into decision-making. Four industry representatives (EU and US), three regulators 
(EU), and three HTA/payers (EU) argued that heterogeneity is actually desirable and “a gift” (HTA/payer, Germany). 
It enables subgroup identification and exploration of opinions. An EU regulator stated that heterogeneity is only a 
problem if not taken into account. Three EU regulators, and a US industry representative stated that heterogeneity 
investigation requires larger sample sizes. A patient, academic and a regulator (EU and US) argued that PPI should be 
measured at multiple points in time to examine preference variation. An EU academic stated that preference studies 
should always conduct a latent class or other model of standard deviation to explore preference heterogeneity and 
allow for subgroup analysis.  
 
Situations relating to communication and use of PPS results 
Three types of situations were identified that may have an influence on the use of PPS results in decision-making 
along the MPLC (Figure 1), including 1. Stakeholder acceptance, 2. Clinical situations and 3. Market situations. 
Participants were asked directly whether there are any situations where the use of patient preferences could be more 
useful or less useful, and the following situations were discussed.   
1. Stakeholder acceptance 
Stakeholder acceptance, or the lack thereof, is a significant situation that can affect the use of PPS results along the 
MPLC. A patient representative, HTA/payer representative, and academics (EU, US) expressed that a “cultural 
change” (UK, HTA/payer) is needed to have assessors look at these data, because they are often “narrow-minded” 
(US, academia) about considering PPI. A patient and two regulators expressed the need for training assessors on the 
topic of PPI. Several interviewees, particularly HTA/payers and regulators, were reluctant towards PPI and gave more 
importance to other criteria, such as cost-effectiveness and clinical outcomes. Three interviewees questioned the 
ability of patients to provide valuable input since they are “not rational”, “too emotional” (Romania, academic) and 
“not able to make the best decisions for themselves” (US, HTA/payer). Almost half of Romanian interviewees 
mentioned that PPI do not have a place in the MPLC and were “never […] important in Romania” (Industry).  
2. Clinical situations  
PPI was perceived to be particularly useful in the context of chronic diseases, rare diseases, remission disorders, high 
unmet medical needs, unclear benefit-risk balance (both in terms of moderate benefits/high risks or heterogeneous 
drug profiles), limited availability of clinical (or other) information, end of life treatments, invasive treatments and 
treatments with subjective endpoints. Two EU regulators believed PPI is less important in the case of medical devices, 
especially the less invasive they are. An EU patient stated the opposite, explaining that patients have to use these 
devices every day. Two EU regulators and an EU academic believed that new or innovative products would benefit 
from PPI, although two other EU regulators disagreed, stating that patients would not be familiar enough with these 
products. Other contexts where PPI was perceived to be less useful include biological fluids, diagnostics, non-invasive 
treatments and medical devices, prevention medicine, surgical interventions, therapies with no clinical evidence (such 
as homeopathy), clear differences between new product and reference, new drugs with no added value compared to 





3. Market situations  
Two EU industry representatives and one US HTA/payer representative stated that PPI would be especially important 
in crowded therapeutic markets where trade-offs will be made between products, although one EU HTA/payer 
representative believed PPI would not add significant value in this situation. An EU industry representative stated that 
PPI would be less useful during significant changes in the therapeutic market. An EU regulator stated they would also 
not be as important when no medical alternatives are available, like for with orphan drugs, although patient acceptance 
to the treatment can still be measured. Another EU regulator stated that it might not be useful to examine PPI on 
sensitive topics with public controversy. 
 
Discussion 
Through 143 semi-structured interviews with six stakeholder groups in eight countries, we identified fifteen factors 
and three types of situations that can influence the value and role of patient preferences in assessments and decision-
making along the MPLC. Our results offer key insights into the barriers hindering the integration of patient preferences 
throughout assessments and decision-making in the MPLC, and our interviewees also expressed solutions as to how 
these challenges can be overcome (Table 3). Frequently cited factors included matching method to research question 
and MPLC stage, validity, cognitive burden, and preference heterogeneity.  
Table 3:  Challenges and solutions identified in the factors affecting the value of patient preference studies (PPS) 
 


















PP studies are complex and need to have 
correct analysis and interpretation. 
Have a multidisciplinary team that has experience with the disease in 
question and patient preference study conduct and/or methodologies. 
Financial resources 
PP studies are costly and funding is 
difficult to obtain. 
Ensure enough budget to not compromise recruitment and sample size. 
Study duration 
Patient recruitment is time consuming, 
particularly with rare diseases. 
Consider recruiting through many multiple channels (health care 
professionals, internet calls, patient organisations, national registries, 
and clinical trials) It is possible to conduct a complete patient 
preference study between 6-12 months.  
Patient centeredness 
Patient centeredness needs to be integrated 
into study design. 
Allow patients and/or patient representatives to be involved in the 
design of PP studies. 
Ethics and good 
practices 
Obtaining ethical approval is often a 
barrier for researchers. Privacy concerns 
might make patients hesitant to 
participate. Stakeholders are concerned 
about industry bias. 
Ensure ethical approval is always obtained. Ensure anonymous, 
confidential data collection and be transparent about how patient data 















It is not always known whose preferences 
need to be studied. 
This largely depends on the research question; if patient preferences 
need to be known, then the sample should consist out of patients. In 




Ensuring representativeness and 
generalisability is difficult when 
preferences are largely subjective. 
Where possible, examine a large sample size, and include patients that 
have experience with or sufficient knowledge about the disease, and 
are informed about treatments and/or drug development. 
Matching method to 
research question  
Selecting a method appropriate for a 
research question 
There is no “gold standard” method, and matching a method to the 
research question depends on what is attempting to be measured, and 
what form the results need to be. Some favour methods that can handle 
hypothetical scenarios, can quantify trade-offs, or include monetary 
valuations. 
Matching method to 
MPLC stage  
Selecting a method appropriate for an 
MPLC stage 
Qualitative methods are thought to be more appropriate for earlier 
stages, to identify attributes, and then followed up with quantitative 
methods to quantify these attributes at later stages. 
Validity and 
reliability  
Validity is important and needs to be 
maintained. 
Scientific consensus on an international level needs to standardise 
validity, including method, criteria, internal, and external validity. 
Despite there being no “gold standard” method, there still needs to be 
a standardised way to evaluate all methods.  
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 Factors Challenge Solution 
Cognitive burden  
Cognitive burden needs to be taken into 
consideration to involve patients with all 
ranges of abilities. 
Try to limit the use of elements that add greater cognitive burden: 
hypothetical scenarios, complex probabilities or percentages, 
describing complex stages of the MPLC, repeating the same type of 
question many times, long surveys/interviews with no breaks, abstract 
ideas without concrete examples, and surveys that cannot be 
completed at home. 
Patient education  
Patients’ knowledge is often not sufficient 
to contribute meaningful answers. 
Utilise educational tools, perhaps in video or other format, to instruct 
patient preference exercises. 
Attribute 
development  
Attributes need to contain important 
information for decision-makers, but also 
be comprehensible to patients. 
Too many attributes in one choice task in some elicitation methods, 
such as a DCE, can become burdensome to patients. Ensure easily 













s Patient ability and 
willingness to 
participate 
Participant recruitment is difficult if 
patients are unable or unwilling to 
participate. 
Recruit patients through multiple channels (health care professionals, 
internet calls, patient organisations, national registries, and clinical 
trials) and offer studies that patients can complete at home, or offer 
travel reimbursement schemes. 
Preference 
heterogeneity 
Heterogeneity in PP studies is difficult to 
address in decision-making. 
Heterogeneity is inherent, and must be sufficiently captured or 
quantified through PP exploration or elicitation or methods. 
 
Our results confirm the statements of the FDA guidance on PPI [2] and other studies [27, 28] regarding the 
involvement of patients and patient representatives in the design and conduct of preference studies. This leads to a 
better comprehensibility of the questions given to patients, improve recruitment, and ensure correct interpretation and 
communication of results. The FDA guidance on PPI [2] also indicates that exploration methods would be most useful 
during discovery, which is confirmed by our results. Our interviewees believed elicitation methods were suited for 
later phases in the MPLC although some argued that mixed-method studies would be beneficial. The use of elicitation 
methods are well documented in regulatory benefit-risk assessments [29] and HTAs [30]. However, HTA/payers often 
also utilise qualitative PPI or patient involvement [31], which was also supported by our results.  
Interviewees provided insightful guidance into the various elements of a patient preference study (PPS) that could 
increase cognitive burden, such as hypothetical scenarios and complex probabilities or percentages, which the FDA 
guidance on PPI also includes [2]. Some interviewees preferred at-home surveys, although several authors [33, 34] 
argue that survey administration via interviews or workshops can provide beneficial in-person support to patients. 
Some interviewees highlighted the importance of always using patient preferences instead of public utilities, except 
in situations where proxies to patients may be required. Others emphasised using public utilities in economic 
evaluations to ensure the applicability to more general allocation decisions. The issue of public versus patient 
preferences in health economic evaluations remains a pressing issue of debate [2, 35]. 
Interviewees indicated that there is a lack of guidance on the validity assessment of preference methods, confirming 
similar findings in the MDIC PCBR report [4]. Conceptual models created for validity assessments of some methods 
are currently being developed [36]. Capturing preference heterogeneity and allowing for the identification for 
subpopulations will increase the value of PPS for benefit-risk assessments and HTA [2, 4, 9, 28]. Interviewees 
suggested that capturing preference heterogeneity requires larger sample sizes and the use of latent class or other 
models of standard deviation. Janssen et al. [36] also concluded that advanced statistical methods might improve the 
understanding of preference heterogeneity in benefit-risk assessments, although the number of subpopulations that 
can be evaluated is limited.  
The identified market situations influencing the value of PPI support the concept of preference sensitive decisions, 
described by the  MDIC PCBR report as “[decisions]… in which there are multiple diagnostic or treatment options, 
and the decision which option to pursue depends upon the particular preferences of the decision maker” [4]. They 
encompass situations when no option is clearly superior over a plausible range of preferences and/or the evidence 
supporting one option over others is considerably uncertain. In addition, our findings confirm the statements of Hollin 
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et al. [37], the FDA guidance on PPI [2] and the MDIC PCBR report [4] that populations with unmet medical needs 
and rare diseases are specific situations where PPI is very valuable.  
Strengths and limitations 
This study’s fundamental strength originates from interviewing international experts in a variety of fields relating to 
every stage of the MPLC. Additionally, we interviewed patients, caregivers, and patient representatives, representing 
potential participants in PPS.  
Recruitment of interviewees was mostly done through the PREFER consortium and snowballing. Participants might 
have had an upfront interest PPI, creating a non-random sampling bias. A limited sample of each stakeholder group 
per country was interviewed, thus not representative of the whole stakeholder population. The self-reported familiarity 
with the topic of PPI differed among stakeholder groups and countries (Table 2). Participants with low self-reported 
familiarity may have provided less informative insights. In Romania, 74% of interviewees stated they were “not 
familiar” with PPI. However, all participants were recruited based on their significant experience as members of key 
stakeholder groups in the MPLC. Even if a participant had limited, direct experience with PPS, their experience with 
different stages of the MPLC, the incorporation of evidential data at these stages, or their interaction with patients, is 
highly relevant when considering the potential for PPI integration, and the factors that might be supporting or 
hindering this integration.  
The semi-structured nature of the interviews created a flexible rapport between interviewer and interviewee, allowing 
follow-up questions to be asked. However, not all factors and situations were discussed with every interviewee since 
some opted not to answer questions. For example, due to time constraints, participants were unable to elaborate on the 
reasons why PPI is useful in some clinical and market situations, and instead listed them.  
There was variation between interviews since eight interviewers conducted the interviews in seven different 
languages. Qualitative methodologies rely on subjective experiences and perspectives of participants in order to 
observe phenomena with context and detail.  Therefore, the results of these interviews represent the thoughts and 
opinions of the interviewees and may not always be objective or generalisable to every organisation or country. 
However, the large number of 143 interviews contributed to triangulating the data and examining an accurate account 
of the current status of PPI in the MPLC. Further research is recommended to contextualise these stakeholder 
comments with each country’s unique healthcare system and identify when PPI can be best integrated into the MPLC.  
 
Conclusions 
Many situations and factors need to be taken into account when designing and conducting PPS in order to obtain 
valuable results that can be used in decision-making. By examining the guidance given by 143 stakeholders with 
unique expertise, more robust PPS can be performed in order to incorporate PPI successfully into the MPLC. 
Moreover, these results can help medical product developers to decide, whether or not and how to include PPS in their 
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Appendix 3.1: Recruitment Protocol: Sweden, Romania, Italy, UK 
 Regulatory Authorities* HTA/payers*1 
Patient, caregivers and 
patient organisation* 






N=2 Representatives of Swedish 
Medical Products Agency with i) a 
formal role in healthcare products 
regulation process AND ii) 
experience in regulatory affairs as 
well as knowledge of national 
regulations 
N=2 Swedish representatives with a 
role or official position within EMA 
OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=4 Representatives of i) a 
Swedish Health 
Technology Assessment 
Organization or a Swedish 
reimbursement agency; OR 
ii) who are involved in the 
evaluation of a health 
technology OR in the 
prescription drugs and 
health care reimbursement 
decision-making 
procedures. 
Target disease: Rheumatoid 
Arthritis 
N=1 Swedish representative of 
one of the main (Swedish) 
Rheumatoid Arthritis patient 
organisations 
N=1 Patient over 18 newly 
diagnosed with RA (within 6 
months) 
N=1 Patient over 18 on at least 
one synthetic DMARD 
N=1 Patient over 18 on at least 




OR primary care 
provider OR physicians 
working with 
Rheumatoid Arthritis 
patients OR physicians 
as part of a medical 
team caring for 
Rheumatoid Arthritis 
patients in Sweden 
N=4 persons working 




in the drug life cycle 
OR patient preference 
methods 
n=2/3 persons whose 
activities are focused 
on pharmaceuticals  
n=1/2 persons whose 
activities are focused 








N=2 Representatives of Romanian 
National Agency for Medicines and 
Medical Devices with i) a formal 
role in healthcare products 
regulation process AND ii) 
experience in regulatory affairs as 
well as knowledge of national 
regulations  
N=2 Romanian representatives with 
a role or official position within 
EMA OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=4 Representatives of i) a 
Romanian Health 
Technology Assessment 
Organization or a 
reimbursement agency; OR 
ii) who are involved in the 
evaluation of a health 
technology OR in the 
prescription drugs and 
health care reimbursement 
decision-making 
procedures. 
Target disease: Cardiovascular 
Diseases  
N=1 Romanian representative of 
one of the main (Romanian) 
Cardiovascular diseases patient 
organisations 
N=1 Patient i) aged ≥ 18; ii) 
recent (<6months) cardiovascular 
event  
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with a cardiovascular 
disease; iii) more than 2 years 
post-event 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with a cardiovascular 
disease; iii) more than 5 years 
post-event 
Target disease: 
Cardiovascular Diseases  
N=4 Cardiologists OR 
Cardiothoracic surgeons 
OR Primary care 
providers OR physicians 
working with CVD 
patients OR physicians 
as part of a medical 
team caring for CVD 
patients in Romania 
N=4 persons working 




in the drug life cycle 
OR patient preference 
methods 
n=2/3 persons whose 
activities are focused 
on pharmaceuticals  
n=1/2 persons whose 
activities are focused 





N=2 Representatives of Italian 
Medicines Agency (AIFA) with i) a 
formal role in healthcare products 
regulation process AND ii) 
experience in regulatory affairs as 
well as knowledge of national 
regulations 
N=2 Italian representatives with a 
role or official position within EMA 
OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=4 Representatives of i) 
an Italian Health 
Technology Assessment 
Organization or an Italian 
reimbursement agency; OR 
ii) who are involved in the 
evaluation of a health 
technology OR in the 
prescription drugs and 
health care reimbursement 
decision-making 
procedures. 
Target disease: lung cancer 
N=1 Italian representative of one 
of the main (Italian) cancer 
patient organisations 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with lung cancer 
within 3 months; and iii) in 
treatment 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with lung cancer 
within 1 year; and iii) in 
treatment 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with lung cancer iii) 
more than 5 years post-diagnosis; 
and iv) out of treatment 
Target disease: lung 
cancer 
N=4 Oncologists OR 
Surgeon OR Primary 
care providers OR 
physicians OR working 
with lung cancer 
patients OR physicians 
as part of a medical 
team caring for lung 
cancer patients in Italy 
N=4 persons working 




in the drug life cycle 
OR patient preference 
methods 
n=2/3 persons whose 
activities are focused 
on pharmaceuticals  
n=1/2 persons whose 
activities are focused 




N=2 Representatives of Medicines 
& Healthcare Products Regulatory 
Agency with i) a formal role in 
healthcare products regulation 
process AND ii) experience in 
regulatory affairs as well as 
knowledge of national regulations 
N=2 UK representatives with a role 
or official position within EMA OR 
ii) collaborations and/or interactions 
with European regulatory agencies 
for the Evaluation of Medicinal 
Products AND ii) knowledge of 
European legislation 
N=4 Representatives of i) 
an UK Health Technology 
Assessment Organization 
or a reimbursement agency 
OR ii) who are involved in 
the evaluation of a health 
technology OR in the 
prescription drugs and 
health care reimbursement 
decision-making 
procedures 
Target disease: muscular 
dystrophy 
N=1 UK representative of one of 
the main (UK) muscular 
dystrophy patient organisations 
N=1 Patient newly diagnosed 
(<6months) with muscular 
dystrophy; i) aged ≥ 18 OR ii) 
caregiver if patient is younger 
than 18 or cognitive impaired  
N=2 Patient diagnosed with 
muscular dystrophy; i) aged ≥ 18 
OR ii) caregiver if patient is 
younger than 18 or cognitive 
impaired 








primary care provider 
working with 
Neuromuscular 
Dystrophy patients OR 
physicians as part of 
medical team caring for 
Neuromuscular 
Dystrophy patients in 
the UK 
N=4 persons working 




in the drug life cycle 
OR patient preference 
methods 
n=2/3 persons whose 
activities are focused 
on pharmaceuticals  
n=1/2 persons whose 
activities are focused 
on medical devices 
* Ensure a mix of males and females whenever possible 
1 Ensure the inclusion of bodies with differing scope and budget responsibilities 
2 Ensure the inclusion of both physicians of university and local hospitals 
3 Includes consultants for industry/representatives of general associations of pharmaceutical industry. Ensure the inclusion of 












Appendix 3.2: Recruitment Protocol: Netherlands, Germany, France, US 













N=1 Representative of Medicines 
Evaluation Board (CBG) with i) a 
formal role in healthcare products 
regulation process AND ii) 
experience in regulatory affairs as 
well as knowledge of national 
regulations  
N=1 Dutch Representative with a 
role or official position within EMA 
OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=2 Representatives of 
i) a Dutch Health 
Technology Assessment 
Organization or a 
reimbursement agency; 
OR ii) who are involved 
in the evaluation of a 
health technology OR in 
the prescription drugs 
and health care 
reimbursement decision-
making procedures. 
Target disease: muscular 
dystrophy 
N=1 Dutch representative of 
one of the main (Dutch) 
muscular dystrophy patient 
organisations 
N=1 Patient diagnosed with 
muscular dystrophy; i) aged ≥ 
18 OR ii) caregiver if patient 
is younger than 18 or 
cognitive impaired 








primary care provider 
working with 
Neuromuscular 
Dystrophy patients OR 
physicians as part of 
medical team caring for 
Neuromuscular 
Dystrophy patients in 
the Netherlands 




the drug life cycle OR 
patient preference methods 
n=1/2 persons whose 
activities are focused 
on pharmaceuticals  
n=0/1 persons whose 
activities are focused 








N=1 Representative of Federal 
Institute for Drugs and Medical 
Devices (BfArM) or Paul-Ehrlich-
Institut (PEI) - with i) a formal role 
in healthcare products regulation 
process AND ii) experience in 
regulatory affairs as well as 
knowledge of national regulations  
N=1 German representative with a 
role or official position within EMA 
OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=2 Representatives of 
i) a German Health 
Technology Assessment 
Organization or a 
reimbursement agency; 
OR ii) who are involved 
in the evaluation of a 
health technology OR in 
the prescription drugs 
and health care 
reimbursement decision-
making procedures. 
Target disease: Rheumatoid 
Arthritis 
N=1 German representative of 
one of the main (German) 
Rheumatoid Arthritis patient 
advocacy organisations 
N=1 Patient over 18 on at 




OR primary care 
provider OR physicians 
working with 
Rheumatoid Arthritis 
patients OR physicians 
part of a medical team 
caring for Rheumatoid 
Arthritis patients in 
Germany 




the drug life cycle OR 
patient preference methods 
n=1/2 persons whose 
activities are focused 
on pharmaceuticals  
n=0/1 persons whose 
activities are focused 






N=1 Representative of French 
National Agency of Medicine and 
Health Products Safety (ANSM)  
with i) a formal role in healthcare 
products regulation process AND ii) 
experience in regulatory affairs as 
well as knowledge of national 
regulations  
N=1 French representative with a 
role or official position within EMA 
OR ii) collaborations and/or 
interactions with European 
regulatory agencies for the 
Evaluation of Medicinal Products 
AND ii) knowledge of European 
legislation 
N=2 Representatives of 
i) a French Health 
Technology Assessment 
Organization or a 
reimbursement agency; 
OR ii) who are involved 
in the evaluation of a 
health technology OR in 
the prescription drugs 
and health care 
reimbursement decision-
making procedures. 
Target disease: lung cancer 
N=1 French representative of 
one of the main (French) 
cancer patient organisations 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with lung cancer 
iii) more than 5 years post-
diagnosis; and iv) out of 
treatment 
Target disease: lung 
cancer 
N=2 Oncologists OR 
surgeon OR Primary 
care providers OR 
physicians OR working 
with lung cancer 
patients OR physicians 
as part of a medical 
team caring for lung 
cancer patients in France 




the drug life cycle OR 
patient preference methods 
n=1/2 persons whose 
activities are focused 
on pharmaceuticals  
n=0/1 persons whose 
activities are focused 




N=1 Representative of US Food and 
Drug Administration (FDA) FDA 
from the Center for Drug 
Evaluation and Research (CDER) 
or the Center for Biologics 
Evaluation and Research (CBER)  
N=1 Representative of US Food and 
Drug Administration (FDA) from 
the Center for Devices and 
Radiological Health (CDRH). 
N=2 Representatives of 
i) an American Health 
Technology Assessment 
Organization or a 
reimbursement agency; 
OR ii) who are involved 
in the evaluation of a 
health technology OR in 
the prescription drugs 
and health care 
reimbursement decision-
making procedures. 
Target disease: Cardiovascular 
diseases 
N=1 US representative of one 
of the main Cardiovascular 
diseases patient organisations 
(in the USA) 
N=1 Patient i) aged ≥ 18; ii) 
diagnosed with a 
cardiovascular disease; iii) 
more than 2 years post-event 
Target disease: 
Cardiovascular diseases 
N=2 Cardiologists OR 
Cardiothoracic surgeons 
OR Primary care 
providers OR physicians 
working with CVD 
patients OR physicians 
as part of a medical 
team caring for CVD 
patients in the US 





the drug life cycle OR 
patient preference methods 
n=1/2 persons whose 
activities are focused 
on pharmaceuticals  
n=0/1 persons whose 
activities are focused 
on medical devices 
 
* Ensure a mix of males and females whenever possible 
1 Ensure the inclusion of bodies with differing scope and budget responsibilities 
2 Ensure the inclusion of both physicians of university and local hospitals 
3 Includes consultants for industry/representatives of general associations of pharmaceutical industry. Ensure the inclusion of 









Appendix 3.3: Coding list applied to transcripts  
  
Organization 
Expertise - Staff 
Financial resources 
Study duration 
Patient preference study design 
Ethics - Good science rules compliance 
Objective - RQ - Perspective (individual PP vs group PP vs caregiver PP) 
Patient centeredness in PP studies 
Patient population (including age, sex, type, duration of illness) 
Heterogeneity 
Participant recruitment process 
Representativeness - Generalisability 
Preference exploration elicitation instrument design 
Attributes 
Cognitive Complexity - cognitive ability - learning tools or instruments 
Number of Attributes 
Question framing 
Preference exploration- elicitation method selection 
Outcome Measurements (including risk tolerance, uncertainty, stated preferences, tradeoffs) 
Validity - Reproducibility 
Use of the results from patient preference studies 
Not useful 
Useful 
Processes currently being used 
HTA & reimbursement (including Economic evaluation, Cost-effectiveness analysis, Cost-benefit analysis, 
Cost-utility analysis, PRO identification, Outcomes weighing, QALY estimation) 
Industry 
Clinical development (including Clinical trial design, Patient Relevant Outcomes (PRO) identification, 
Treatment arm selection, Product design validation, Patient trade-off understanding) 
Pre-clinical development (including Product design validation) 
Research and discovery (including Ideation, Unmet medical need identification, Prototyping, Product 
design adaptation) 
Marketing Authorization (including Benefit-risk assessment, Benefits and risks weighing, Patient trade-off 
understanding, Subpopulation identification, Early access, Labelling optimization) 
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Methods for exploring and eliciting patient preferences in the medical 
product lifecycle: a literature review 
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Preference studies are becoming increasingly important within the medical product decision-making context. 
Currently, there is limited understanding of the range of methods to gain insights into patient preferences. We 
developed a compendium and taxonomy of preference exploration (qualitative) and elicitation (quantitative) methods 
by conducting a systematic literature review to identify these methods. This review was followed by analyzing prior 
preference method reviews, to cross-validate our results, and consulting intercontinental experts, to confirm our 
outcomes. This resulted in the identification of 32 unique preference methods. The developed compendium and 
taxonomy can serve as an important resource for assessing these methods and helping to determine which are most 








There is an emerging consensus that the patient perspective should be incorporated within decisions in the medical 
product lifecycle (MPLC) [1, 2, 3, 4], where the medical product lifecycle in this study is defined as the lifecycles of 
drugs, biologics and medical devices. Broadly encouraging the involvement of patients has, therefore, become 
increasingly important [5, 6]. Taking the patient voice into consideration has not only become increasingly important 
for companies that develop new medical products but also for the authorities that assess, regulate and decide which 
products are effective, safe, well-tolerated and cost-effective [7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. 
To incorporate the patient voice, patient preferences need to be explicitly explored or elicited through revealed- or 
stated-preference methods. In this paper, preference exploration methods are defined as qualitative methods that 
collect descriptive data through participant or phenomenon observation, examining the subjective experiences and 
decisions made by participants. Elicitation methods are defined as quantitative methods collecting quantifiable data 
for hypothesis testing and other statistical analyses. Whereas the use of revealed-preference methods still represents a 
methodological challenge in health, many different methods exist to assess stated preferences of patients [17, 18]. An 
up-to-date compendium of different stated-preference methods to explore or elicit patient preferences within the 
MPLC is missing. 
 
There have been few publications on what methods can be used to assess patient preferences in a scientific way, in 
the context of the MPLC specifically. In 2001, Ryan et al. [19] provided an overview of methods known at the time 
for eliciting public preferences for healthcare. In 2015, the Medical Device Innovation Consortium (MDIC) developed 
an overview of different preference elicitation methods as part of their framework on incorporation of patient 
preferences into regulatory assessments of medical devices [20]. Although both publications made useful 
contributions, the study from Ryan et al. [19] does not reflect methods developed since 2001, and the study from the 
MDIC [20] did not include preference exploration methods or use a systematic approach for identifying preference 
elicitation methods. Therefore, the aim of our study was to develop an up-to-date compendium and taxonomy of 
exploration and elicitation preference methods within the MPLC context. This will be an important step to further 
drive the incorporation of patient preferences forward, in addition to the study of van Overbeeke et al. [6], and in 
developing guidance on when and how to assess patient preferences scientifically in the context of decision-making 
in the MPLC. 
 
Compendium of preference methods 
 
A systematic literature review was conducted, followed by an analysis of prior reviews by Ryan et al. [19] and from 
the MDIC [20] and expert consultations with international preference experts, to identify all potential preference 
exploration and elicitation methods within the context of the MPLC. In this paper, a broad definition of a preference 
method was used: any method that enabled us to gain insight into a patient’s relative desirability or acceptability of 
specified alternatives; or choices among treatment alternatives or outcomes; or other attributes that differ among 
alternative health interventions [7]. Ultimately, 208 papers were analyzed during the systematic literature review to 
identify preference exploration and elicitation methods within the context of the MPLC. More information about the 
approach used in the systematic literature review is provided in Appendix 4.1.  
 
We identified 19 different methods: five exploration methods and 14 elicitation methods, in the systematic literature 
review. The most frequently cited exploration methods included focus groups (n = 29, 13.9%) and (semi-)structured 
individual interviews (n = 47, 22.6%), whereas most cited elicitation method papers included discrete choice 
experiments (n = 57, 27.4%) and the visual analog scale (n = 12, 5.8%). Contingent valuation (n = 11, 5.3%), standard 
gamble (n = 11, 5.3%) and time trade-off (n = 11, 5.3%) were also frequently included in the analyzed papers. Four 
studies included best–worst scaling type 1,2 (n = 4, 2%). 
 
Through the analysis of the preference method reviews of Ryan et al. [19] and the MDIC [20], and after condensing 
several of these methods, we identified 23 preference exploration and elicitation methods. This selection included nine 
preference exploration and 14 elicitation methods. From these 23 preference methods, 13 methods were also identified 
in our systematic literature review (56%). The expert consultations confirmed the methods identified in the systematic 
literature review and in the analysis of prior preference method reviews. Also, consensus was reached on including 
four additional elicitation methods. The expert consultations also resulted in the exclusion of methods focusing on 
scale-related (e.g., Likert scales) or decision-making framework-related (e.g., multicriteria decision analysis) 
techniques, because these techniques were regarded as inconsistent with our definition of a preference method. As 
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described above, we identified 19 methods through the systematic literature review, the 23 methods through the 
analysis of previously conducted reviews and the four additional methods via expert consultations. In total, 32 unique 
preference methods were identified: ten exploration and 22 elicitation methods. Table 1 summarizes and briefly 
describes these methods. 
 
Table 1: Overview of identified methods 
Method Description Refs 
Exploration methods   
Citizens’ juriesb Group of individuals discussing issues on the basis of evidence provided by two trained moderators 24, 25 
Complaints proceduresb Method in which stakeholders can register complaints to be investigated by experts 26, 27 
Concept mappingb 
Method that utilizes small groups of participants responding to various topics or issues, while 
ensuring each respondent is given equal opportunity to express their opinions and address other 
group dynamic issues 
28, 29 
Delphi methoda, b 
Structured, iterative forecasting method involving a panel of experts who provide anonymous 
responses to questionnaires with the opportunity to revise their responses when the anonymous 
summary of response from the prior round is revealed 
30, 31 
Dyadic interviewa, b 
Method that utilizes two participants in a single interview, responding to open-ended questions asked 
by an interviewer to identify how a product, service or opportunity is perceived 
32, 33 
Focus groupa, b 
Method that utilizes a group of interacting individuals that provide information about a specific issue 
to identify how a product, service or opportunity is perceived 
34, 35 
In depth – individual 
interviewa, b 
Interview technique that allows for an intensive discussion with one interviewee to explore their 
perspectives on a particular topic or theme, to gain a deeper understanding of this particular topic or 
theme. Often only a limited amount of questions or themes are prepared by the interviewer, and the 




Method that utilizes a group process that involves making decisions by vote and ranking responses 
given by members of the group 
38, 39 
Public meetingsb 
Method to gain public opinions on particular issues by allowing general members of the public to 
attend and voice their responses 
40, 41 
(Semi-)structured 
individual interviewa, b 
Interview technique that allows new ideas to be brought up during the interview as a result of what 
the interviewee says in a semi-structured setting, whereas in the structured setting the interviewer 
strictly sticks to an interview guide and does not ask questions based on the response of the 
interviewee 
42, 43 
Elicitation methods   
Adaptive conjoint 
analysisa 
Method similar to regular conjoint analysis, but with adaptive conjoint choice tasks based on the 
earlier choices made within the survey, in theory allowing the survey to focus attention on those 
attributes or levels of those attributes that have the most influence on the choices of that individual. 
Unlike discrete choice experiments this method is founded in the theory of conjoint measurement 
(CM), which is more focused on the behavior of number systems instead of the behavior of human 
preferences 
44, 45, 81 
Allocation of pointsb 
Method that involves asking respondents to rate their conditions on scales, while knowing the 
weights which they attach to different criteria, indicating the relative importance of particular areas 




Method in which responders assess the relative importance of pairs of attributes (treatment 
endpoints, properties, criteria, items, objects, etc.) toward achieving a goal, where these responses 
are used to compute a weight for each attribute 
20, 48 
Best–worst scaling (types 
1, 2, 3)a, b 
Involves respondents answering surveys that include lists of attributes or profiles and being asked to 
indicate the best (or most appealing/important) and the worst (or least appealing/important) of them. 
This method consists of three types: in type 1 a set of attributes is showed that might not reflect the 
characteristics of any particular treatment, of which the respondent picks the best and worst. Type 2 
involves a situation in which the attributes collectively characterize a particular profile and the 
respondent chooses the best and worst. In type 3 three or more profiles are shown and the respondent 
selects the best and worst profiles 
20, 49, 50 
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Method Description Refs 
Constant sum scalingc 
Constant sum scaling consists of a comparative scale where respondents are asked to allocate a fixed 
amount (or constant sum) of points, dollars or anything among a set of objects according to a 
criterion 
51, 52 
Contingent valuationa, b 
Method to determine the willingness to pay (WTP), where individuals are presented with a choice 
between not having the commodity valued and having the commodity but forgoing a certain amount 
of money. The money being that they are willing to forgo to have the commodity is their WTP for 
that commodity. WTP can be calculated directly using a threshold or indirectly using a discrete 
choice experiment for example 
53, 54 
Control preference scalea 
The control preferences scale (CPS) is a method to determine the degree of control a patient wants 
regarding medical treatment. The preference orders are analyzed using unfolding theory to determine 
the distribution of preferences in different populations and the effect of covariates on consumer 
preferences 
55, 56, 57 
Discrete choice 
experimenta, b 
Method that utilizes an attribute-based measure of benefit, during which individuals are offered a 
series of hypothetical choice situations (i.e., choice sets), from which they are asked to choose 
between two or more profiles. There are numerous variants of discrete choice experiments. In 
contrast to conjoint analysis, this method relies on a theory of the behavior of human preferences [for 
example random utility theory (RUM)] 
58, 59, 60, 
81 
Measure of valueb 
Method used to identify the optimal bundle of services to be provided given resource constraints. 
Individuals are asked to allocate a fixed amount of resources between different services. These 




Instrument that allows participants to prioritize outcomes making use of a specific tool according to 
the ‘trade-off’ principle, implying that they are willing to compromise on the less important 
outcomes 
[62] 
Person trade-offa, b 
An extension of the time trade-off. With person trade-off an individual evaluates the health effects of 




Method that determines the maximal change in one attribute respondents are willing to accept to 
achieve a given change in another attribute 
20, 65 
Q-methodologyc 
Method that uses a specially designed response grid to present respondents with a set of statements 




Method that involves a scoring and ranking process based on decision analysis technique, involving 
the definition of options in terms of qualitative categories, then deriving a numeric point estimate and 
finally solving a maximization problem with given constraints 
[68] 
Repertory grid methoda 
Method used for eliciting personal constructs (i.e., what people think about a given topic). To 
identify preferences overlapping and rating techniques are used 
69, 70 
Self-explicated conjointc 
Method that asks explicitly about the preference for each attribute rather than the preference of 
several 
[71] 
Standard gamblea, b 
Method in which respondents are asked to choose between a certain outcome and a gamble that 
might result in either a better outcome with a probability P or a worse outcome than the original with 
a probability 1-P 
72, 73 
Starting known efficacya 
Method similar to (probabilistic) threshold techniques, but with a specific known starting point. This 
method is specifically used within the context of the medical product lifecycle 
[74] 
Swing weightingb 
Method for setting the weights in which a decision-relevant range is specified for each attribute, and 
the impact of ‘swinging’ the attribute through that entire range of values is assigned a weight relative 
to the impact of swinging the attribute with the largest weight 
19, 20 
Test trade-offc 
Method that can be regarded as an extension of the time trade-off that is specifically used to evaluate 
a new biomarker by using risks (instead of time) as the equilibrating mechanism 
75, 76 
Time trade-offa, b 
Method that presents individuals with a choice between living for a period in a specified, but less 
than perfect, state versus having a healthier life for a period of time, where time is varied until the 
respondent is indifferent to the alternatives 
20, 77, 78 
Visual analog scalea, b 
A self-reporting instrument consisting of a line of predetermined length that separates extreme 
boundaries of the phenomenon being measured 
79, 80 
In total 32 unique methods were identified. a Identified in systematic review (19 methods); b Identified through analysis of previous preference 




Taxonomy of preference methods 
 
There are many ways to group preference methods. In this study, we grouped the identified methods according to their 
manner of data collection and the similarities in their method of analysis. This grouping was not intended to be a 
formal lexicon but primarily served as a taxonomy to organize results and to develop a compendium of preference 
exploration and elicitation methods. Preference exploration methods can be grouped according to the number of 
participants the method utilizes in one session (Fig. 1). (Semi-)structured individual interviews, in-depth interviews 
and complaints procedures use interviews with one participant (n = 1) in a single setting or session. The Delphi 
method, focus groups, dyadic interviews, public meetings, nominal group technique and citizen juries typically direct 
questions to more than one participant (n >1) in a single setting. Concept mapping can employ either individual or 
group settings for data collection (n ≥1). 
 
Preference elicitation methods can be grouped into four distinct groups (Fig. 2), with methods from left to right being 
able to answer a smaller subset of research questions [a discrete choice experiment (DCE) is for example able to 
provide willingness-to-pay (WTP) information and probability scores whereas contingent valuation provides WTP 
information only]. First, discrete choice-based methods typically examine the importance of trade-offs between 
attributes and their alternatives through a series of choice sets that present (hypothetical) alternatives. Second, ranking 
(or related) methods were classified based on the use of ranking exercises to capture the order of alternatives or 
attributes within a presented set. Third, indifference techniques are methods that vary the value of one attribute in one 
of the alternatives until the participant is indifferent, or has no preference, between alternatives. Finally, rating (or 
related) methods are methods based on their utilization of comparative rating approaches, often allowing participants 
to express the strength of their preferences along a labeled scale. 
 
Trends in the use of preference methods 
With the systematic literature review, spanning 37 years of literature, we observed an overall upwards trend in the 
number of MPLC patient preference studies per year. The mean number of preference studies increased from 1.1 per 
year to 6.5 per year to 20.3 per year. This is for the periods 1980–2000, 2001–2010 and 2011–2016, respectively 
(Appendix 4.2). We also observed that our included papers originated from all over the world, covering five different 
continents (Table 2). The majority (73%) of papers were from North America (n = 90) and Europe (n = 62). 
 
Table 2: Background information of identified patient preference methods in the systematic review focusing on the 
medical product lifecycle 
Method Frequency Continents of origin Study numbers 
n = 19 n = 208a (%) Continents (frequency)a n = 208 
Exploration methods    
Delphi method 3 (1.4) Asia (2), North America (1) 24, 107, 308 
Dyadic interview 1 (0.5) Africa (1) 269 
Focus group 29 (13.9) 
Africa (1), Asia (2), 
Australia/Oceania (3), Europe (15), 
North America (8) 
2, 14, 17, 18, 43, 45, 71, 72, 84, 97, 109, 116, 119, 
121, 211, 220, 222, 236, 253, 269, 282, 283, 286, 290, 
294, 300, 308, 313, 317 
In depth – individual 
interview 
9 (4.3) 
Asia (1), Australia/Oceania (1), 
Europe (3), North America (4) 




Africa (2), Asia (6), 
Australia/Oceania (6), Europe (18), 
North America (15) 
2, 9, 17, 18, 21, 30, 41, 43, 57, 58, 65, 67, 87, 94, 100, 
101, 120, 129, 141, 153, 162, 164, 184, 193, 198, 205, 
211, 215, 217, 222, 226, 229, 230, 232, 239, 267, 268, 
269, 272, 280, 284, 285, 286, 302, 306, 310, 323 
Elicitation methods    
Adaptive conjoint analysis 3 (1.4) North America (3) 88, 89, 243 
Analytic hierarchy process 1 (0.5) Europe (1) 221 
Best-worst scaling (types 1, 
2,3) 
4 (1.9) 
Asia (1), Australia/Oceania (1), 
North America (2) 
133, 180, 189, 300 
73 
 
Method Frequency Continents of origin Study numbers 
Contingent valuation 11 (5.3) 
Asia (2), Australia/Oceania (1), 
North America (2) 
29, 35, 144, 148, 155, 166, 167, 180, 199, 244, 298 
Control preference scale 3 (1.4) Asia (1), North America (2) 147, 175, 316 
Discrete choice experiment 57 (27.4) 
Africa (1), Asia (7), 
Australia/Oceania (6), Europe (15), 
North America (28) 
19, 25, 26, 34, 42, 48, 57, 66, 73, 79, 80, 90, 100, 101, 
109, 114, 117, 119, 122, 133, 134, 154, 155, 160, 161, 
163, 166, 179, 180, 184, 192, 194, 200, 212, 213, 215, 
218, 219, 222, 227, 229, 234, 238, 239, 243, 246, 247, 
249, 257, 264, 266, 272, 281, 309, 311, 312, 313 
Outcome prioritization tool 1 (0.5) Europe (1) 304 
Person trade-off 1 (0.5) Europe (1) 274 
Repertory grid method 1 (0.5) Europe (1) 255 
Standard gamble 11 (5.3) 
Asia (1), Australia/Oceania (1), 
Europe (2), North America (7) 
34, 42, 155, 180, 195, 200, 209, 219, 237, 277, 312 
Starting known efficacy 1 (0.5) North America (1) 201 
(Probabilistic) threshold 
technique 
2 (1.0) North America (2) 42, 172 
Time trade-off 11 (5.3) 
Australia/Oceania (1), Europe (2), 
North America (8) 
33, 34, 78, 155, 180, 200, 209, 219, 237, 277, 318 
Visual analog scale 12 (5.8) 
Asia (2), Europe (3), North 
America (7) 
93, 115, 168, 171, 178, 195, 208, 223, 278, 281, 287, 
314 
a Included countries per continent: Africa – Kenya, South Africa; Asia – China, Iran, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand, 
Turkey; Australia/Oceania – Australia; Europe – France, Germany, UK, Hungary, The Netherlands, Norway, Spain; North America – Canada, 
USA. 
 









Figure 2: Grouping of preference elicitation (quantitative) methods into four groups: discrete choice based, ranking, 
indifference and rating methods. 
 
 
Analyzing the separate use of preference exploration and elicitation methods over time, we observed a trend of 
preference exploration methods being used more frequently in recent years. We did not consider the period 1980–
2005 because this period only included a few data points to compute representative percentages. For the period 2002–
2006, 33.3% of the papers used a preference exploration method to gain insights into patient preferences (computed 
as the frequency of an exploration or elicitation method in each individual paper). This increased to 48.8% in the 
period 2007–2011 and to 45.8% for 2012–2016. Among preference exploration methods, the proportion of studies 
that used focus groups increased from 23% in the period 2002–2006 to 35% in the period 2012–2016. The proportion 
of (semi-)structured individual interviews remained more or less constant with 55% in the period 2002–2006 and 52% 
in the period 2012–2016, whereas in-depth individual interviews decreased from 23% in 2002–2006 to 8% in 2012–
2016. Over time, we also observed more diversity within the group of preference exploration methods. The Delphi 
method and dyadic interviews began appearing in 2007. 
 
Among preference elicitation methods, we observed that the number of papers that made use of a discrete choice 
experiment increased from 38% in 2002–2006 to 58% in 2012–2016. Papers that included a visual analog scale 
decreased from 16% to 3%, and contingent valuation showed a similar trend (17% to 9%). Standard gamble and time 
trade-off showed an upward trend, from 5% and 4% in 2002–2006 to 9% and 6% in 2012–2016, respectively. Overall, 
we observed that, over time, a more diverse group of preference elicitation methods was used. 
 
Comparison of sources 
 
The results of this study were partly in line with the results found by Ryan et al. (2001) and the MDIC (2015) 19, 20. 
Fifty-six percent (13 out of 23) of methods reported by Ryan et al. [19] and/or the MDIC [20] were identified in our 
systematic literature review. The differences arise because: (i) the search in this study focused specifically on methods 
to obtain patient preferences for drugs and medical devices, whereas Ryan et al. [19] focused on public views on the 
provision of healthcare; (ii) MDIC [20] excluded preference exploration methods; and (iii) the MDIC [20] effort did 
not use a systematic approach for identifying methods. The taxonomy of preference methods proposed in this study is 
also in line with results from Mt-Isa et al. [21], Zhang et al. [22] and Gonzalez et al. [23], in which elicitation methods 
were grouped by rating, ranking and trade-off (which included choice-based methods) techniques, although many 




Results from our study’s systematic literature review (19 preference methods identified) showed that most reviewed 
papers used focus groups, (semi-)structured individual interviews, discrete choice experiments or the visual analog 
scale to gain insights into patient preferences. Most of these studies were conducted in North America or Europe. We 
also showed that the mean number of patient preference studies for drugs and medical devices increased over time. 
Furthermore, this study showed that, for preference exploration and elicitation methods, a more diverse mix of 




In this study we developed an up-to-date compendium and taxonomy of preference exploration and elicitation methods 
in the context of the MPLC. The systematic review (19 methods), analysis of prior conducted preference method 
reviews (23 methods) and expert consultations (four methods) contributed to this compendium. In total, 32 unique 
methods were identified. Preference exploration methods were grouped in three main groups, whereas the preference 
elicitation methods were grouped in four main groups. Because choosing which method to use will depend on the 
MPLC phase and what the measured preferences are being used for, future research might focus on determining which 
methods are most appropriate to explore or elicit patient preferences, and under what circumstances, throughout the 
different phases in the MPLC. In addition, it might be of interest for future research to focus on the specific 
combinations of preference exploration and elicitation methods used in mixed-method studies, and the reasoning 
behind such study designs. 
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Appendix 4.1 Methods used in the study 
A.1 Systematic literature review 
The systematic literature review (Figure A) was conducted in accordance with standard guidelines [A1], searching for 
relevant peer-reviewed papers from 1980 until 2016 in six different scientific databases: Cochrane Library, Econlit, 
Embase, PubMed, PsycInfo and Scopus. We used broad search terms to minimize the chance of missing methods. The 
following search query was developed to search for papers in the databases Cochrane Library, Econlit, Embase, 
PubMed, PsycInfo and Scopus (this query is based on the PubMed database and was translated to other databases 
when necessary): 
((patient[tiab] OR patients[tiab] OR client[tiab] OR clients[tiab] OR citizen[tiab] OR citizens[tiab] OR consumer[tiab] OR 
consumers[tiab] OR public[tiab] OR general population[tiab]) AND (Preference[tiab] OR Preferences[tiab] OR Acceptability[tiab] 
OR utility[tiab] OR utilities[tiab] OR desirability[tiab]) AND (method[tiab] OR methods[tiab] OR methodology[tiab] OR 
methodologies[tiab] OR technique[tiab] OR techniques[tiab] OR measurement[tiab] OR measurements[tiab] OR instrument[tiab] 
OR instruments[tiab] OR tool[tiab] OR tools[tiab] OR measure[tiab] OR measures[tiab] AND (elicitation[tiab] OR 
elicitations[tiab] OR measuring[tiab] OR determine[tiab] OR determining[tiab] OR explore[tiab]) AND (drug[tiab] OR drugs[tiab] 
OR pharmaceutical[tiab] OR pharmaceuticals[tiab] OR medicine[tiab] OR medicines[tiab] OR medication[tiab] OR 
medications[tiab] OR “medical device”[tiab] OR “medical devices”[tiab] OR “medical instrument”[tiab] OR “medical 
instruments”[tiab])) AND ("loattrfull text"[sb] AND ("1980/01/01"[PDAT] : "2016/12/31"[PDAT]) AND "humans"[MeSH 
Terms] AND English[lang]).  
 
Studies were included if they focused on technical/methodological aspects of preference exploration or 
elicitation methods (including papers focused on reviews or protocols) or were related to a (technical) application 
study, drugs or medical devices, patient (or caregivers) preferences, and if the full text was available in English. Papers 
were excluded if they included instruments specifically developed for the quality-adjusted life year (QALY) 
framework (e.g. EQ-5D, HUI, SF-36) and no specific preference method was used to generate QALY weights, since 
these methods are generally not able to gain insights into patient preferences outside of the QALY framework. Papers 
were screened and analyzed independently by two reviewers (VS and CW) based on the aforementioned inclusion 
criteria. Differences were discussed between both reviewers to reach consensus, and a third reviewer (JV or EBG) 
was consulted when consensus could not be reached.  
A total of 12,136 references were identified from the beginning of 1980 until the end of 2016 (Figure A). 
From these references, 4,572 papers met the inclusion criteria and remained for title and abstract screening. The title 
and abstract screening excluded another 4,249 papers based on the inclusion criteria. Hence, 323 full-text papers were 
screened for eligibility. A total of 115 papers were excluded since they did not meet the inclusion criteria, did not 
mention a preference method, or were focused on scale related and/or decision-making framework related techniques.  
The 208 included papers comprised of 5 systematic literature reviews, 18 technical and/or methodological papers, and 
185 (technical) application studies. 
A.2 Analysis of prior reviews 
Prior reviews by Ryan et al. [A2] and from the MDIC [A3] were analyzed for additional preference methods. These 
reviews were analyzed independently by two reviewers (VS and CW), and a third (JV or EBG) reviewer was consulted 
when there were differences and consensus could not be reached. These activities served as a cross-validation for our 
results from the systematic literature review.  
 
A.3 Expert consultation rounds 
To account for publication lag and to confirm our results, international experts (n=24) in the field of health preferences 
and/or medical decision-making were consulted. In this final step, experts were consulted via e-mail, phone interviews 
or in person (e.g. during the 7th Meeting of the International Academy of Health Preference Research (IAHPR)) to 
critically assess our list of identified methods, and the grouping of the identified methods, until data saturation was 
reached. The experts were from three different continents and had various, specialized areas of expertise in health 
preferences and/or medical decision-making. 
 
A.4 Strengths and weaknesses  
The current study has several strengths. First, the systematic literature review, followed by an analysis of prior reviews 
and expert consultations, resulted in an updated compendium of methods (identifying 9 methods not reported in 
previously-conducted reviews) to gain insights into patient preferences throughout the MPLC. Using previously-
conducted reviews as validation, and consulting health preference and medical-decision-making experts to confirm 
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our results, is important to build a well-founded and accepted basis across the field of health preference research. 
Secondly, the systematic literature review was conducted independently by two researchers, which had a positive 
effect on reaching a reliable overview of preference exploration and elicitation methods that were applied to drugs 
and medical devices. Thirdly, the identification of both preference exploration and elicitation methods as presented in 
this paper matches the trend in the literature, such as Vass et al. [A4] and Ikenwilo et al. [A5] describing a more 
frequent use of mixed-method approaches to gain more insights into preferences. 
A potential weakness of our study design is that the systematic literature review might have missed possible/promising 
methods to gain insights into patient preferences. To produce a time-efficient and precise review, we limited the 
synonyms for a variety of search terms. However, the impact is likely to be limited given the validation with 
previously-conducted reviews and additional review by international experts with significant experience in health 
preference research. Another weakness is that some methods in this study might be considered specific variants of 
other preference methods (e.g. constant sum scaling, measure of value, outcome prioritization tool, and starting known 
efficacy) and that there may be no consensus across different scientific fields if the method can indeed be considered 
a “preference method” itself (e.g. control preferences scale, test-trade-off and visual analogue scale). However, we 
decided to include these methods in our overview, since the aim of our study was to develop a current compendium 
of both exploration and elicitation preference methods, without excluding methods that were within the scope of our 
study a priori.  
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Background: Incorporating patient preference (PP) information into decision-making has become increasingly 
important to many stakeholders. However, there is little guidance on which patient preference assessment methods, 
including preference exploration (qualitative) and elicitation (quantitative) methods, are most suitable for decision-
making at different stages in the medical product lifecycle (MPLC). This study aimed to use an empirical approach to 
assess which attributes of PP assessment methods are most important, and to identify which methods are most suitable, 
for decision-makers’ needs during different stages in the MPLC. 
 
Methods:  A four-step cumulative approach was taken: 1) Identify important criteria to appraise methods through a 
Q-methodology exercise, 2) Determine numerical weights to ascertain the relative importance of each criterion 
through an analytical hierarchy process, 3) Assess the performance of 33 PP methods by applying these weights, 
consulting international health preference research experts and review of literature, and 4) Compare and rank the 
methods within taxonomy groups reflecting their similar techniques to identify the most promising methods.  
 
Results: The Q-methodology exercise was completed by 54 stakeholders with PP study experience, and the analytical 
hierarchy process was completed by 85 stakeholders with PP study experience. Additionally, 17 health preference 
research experts were consulted to assess the performance of the PP methods. Thirteen promising preference 
exploration and elicitation methods were identified as likely to meet decision-makers’ needs. Additionally, eight other 
methods that decision-makers might consider were identified, although they appeared appropriate only for some stages 
of the MPLC.  
 
Conclusions: This transparent, weighted approach to the comparison of methods supports decision-makers and 






The integration of patient preferences into decision-making is becoming progressively more important throughout the 
medical product life cycle (MPLC) [1]. Patient preference (PP) information is defined by the United States (US) Food 
and Drug Administration (FDA) as: “qualitative or quantitative assessments of the relative desirability or acceptability 
to patients of specified alternatives or choices among outcomes or other attributes that differ among alternative health 
interventions” [2]. The Center for Devices and Radiological Health (CDRH) at the FDA has published guidance [3, 
4, 5] on conducting preference studies and is soliciting research priorities in patient preference studies [6]. The 
European Medicines Agency (EMA) has published similar guidance and intention to investigate PP methodologies 
[7]. Other projects such as the MDIC (Medical Device Innovations Consortium [8] are promoting the importance of 
PP information in benefit-risk assessments, while the National Institute for Health and Care Excellence (NICE) is 
establishing patient preference research partnerships [9].  
Overall, there is a consensus among stakeholders, including industry, health technology assessment (HTA) bodies or 
payers, regulatory authorities, and clinicians, that the use of PP information in decision-making for medical products 
might be beneficial to inform benefit-risk and HTA/payer assessments [10]. Despite this consensus, the results of PP 
studies are currently not integrated into the MPLC systematically. Generally, there is a lack of guidance in current 
literature regarding the choice of PP study methods [11]. As the role of PP information in decision-making increases, 
it is vital that decision-makers are able to select the most appropriate methods suitable for their requirements. 
A total of 33 methods have been identified in contemporary literature [12] as being able to measure patient preferences 
in medical treatments. This includes 10 preference ‘exploration’ methods that collect descriptive data through the 
subjective experiences and decisions of participants (generally qualitative techniques), and 23 preferences ‘elicitation’ 
methods that collect quantifiable data able to be reported through statistical inferences or analysis (generally 
quantitative techniques) (Table 1). An appraisal of these numerous and diverse PP methods will aid in combatting the 
uncertainty that stakeholders face regarding which methods to use.  
There is currently no comprehensive comparison between these methods, nor any generally assessment of which are 
most suitable for particular stages in the MPLC or for particular study design considerations. This study proposes a 
means of choosing between methods eliciting and exploring patient preferences. It aims to 1) identify criteria most 
important for appraising preference PP methods, with relative weights for those criteria and 2) identify PP methods 
most suitable for satisfying decision-makers’ needs in the MPLC.  
 
Table 1: Thirty-three patient preference exploration and elicitation methods (adapted from Soekhai et al. [12])  
 






















In-depth individual interviews 






























s Discrete choice based 
methods 
Adaptive conjoint analysis 
Discrete choice experiment / Best- worst 
scaling (type 3) 
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Allocation of points 
Analytic hierarchy process 
Constant sum scaling 
Measure of value 
Outcome prioritization tool 
Repertory grid method 
Swing weighting 
Visual analogue scale 
Ranking methods 
Best-worst scaling (type 1)b 
Best- worst scaling (type 2)b 
Control preference scale 
Q-methodology 
Qualitative discriminant process 
Self-explicated conjoint 
a Concept mapping can be utilised as a group method, but for the purpose of this method comparison it will be taxonomised as an 
individual method because the success of its data collection is not dependent on the present of multiple participants, unlike the 
other group techniques; b Soekhai et al. [12] condensed Best-worst scaling types 1 and 2 into one method for the systematic review, 




In this study, a four step approach was taken (Figure 1): 1) Identify important criteria to appraise methods through a 
Q-methodology exercise, 2) Determine numerical weights to ascertain the relative importance of each criterion 
through an analytical hierarchy process (AHP), 3) Assess the performance of 33 PP methods by applying these 
weights, consulting international health preference research (HPR) experts and by review of literature, and 4) Compare 
and rank the methods within taxonomy groups [12] reflecting their generally similar techniques to identify the most 
promising methods. This will result in the means of identifying the preference elicitation and exploration methods 
most suitable for decision-makers needs.  
 




Step 1: Q-methodology  
To determine which criteria were most important when selecting a preference exploration or elicitation method in the 
MPLC, 35 initial criteria were developed based on previous studies, including MDIC’s patient-centred benefit-risk 
framework [8] and a systematic review by Ryan et al [13]. These criteria can be found in Table 2. Q-methodology, a 
research technique using a unique ranking system [14, 15, 16] was used to rank these criteria. Q-methodology aims to 
capture the subjectivity of participants’ opinions or preferences by identifying correlations between participants across 
a sample of variables (in this case, the criteria), allowing researchers to contrast different attitudes of participants. It 
is an effective method even with samples under 100 participants. Q-methodology was used to identify similar 
viewpoints across diverse stakeholder groups, and to identify a ‘shortlist’ of the most important attributes from the 
participants’ rankings.  
 
Table 2: Q-methodology results 









A typical survey can be conducted at relatively low costs ✓ ✓   
Data can be collected during quick sessions with participants  ✓ ✓  
Low frequency of sessions required by patients ✓ ✓ ✓  
Relatively quick delivery of preparation, data collection, and analysis ✓ ✓ ✓ ✓ 
A large number of attributes can be explored    ✓ 
Suitable to study preferences in a small sample size ✓ ✓  ✓ 
A low cognitive load on patients ✓ ✓ ✓ ✓ 
Does not need an education tool or preparatory instructions in order 
to enhance participant comprehension 
 ✓ ✓  
Publically acknowledged by your organisation’s guidelines as an 
acceptable method to study preferences 
  ✓ ✓ 
New attributes can be added without making prior results invalid ✓ ✓ ✓  
Can be used to collect data from more than one participant in a single 
session 
  ✓  
The analysis can calculate risk attitudes, like risk tolerance, and 
calculate how value functions bend due to the presence of uncertainty 
in the participant 
✓ ✓ ✓ ✓ 
Explores the reasons behind a preference in detail ✓ ✓ ✓ ✓ 
Can estimate weights for attributes ✓ ✓ ✓ ✓ 
Estimates trade-offs that patients are willing to make among 
attributes 
✓ ✓ ✓ ✓ 
Can quantify heterogeneity in preferences ✓ ✓ ✓ ✓ 
Internal validity can be established ✓ ✓ ✓ ✓ 
External validity can be established ✓ ✓ ✓ ✓ 
Outcomes can refer to a course of health over time (as opposed to a 
constant health state) 
    
Sensitivity analysis is possible     
Can combine quantitative and qualitative methods     
Applies validation tests     
Results can be reproduced by an (independent) researcher for 
reproducibility     
Applies tests for consistency     
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Can be conducted without the need for specialized software (beyond 
Excel) 
    
Can be conducted without programming skills     
Researcher does not need to supervise the data collection     
Does not require hypothetical scenarios     
Attributes and attribute levels can be determined as part of the 
method itself (internal identification) 
    
Data saturation can be achieved relatively quickly     
Does not require model estimations     
Outcomes can be expressed in a particular format (e.g. probability 
scores, marginal rates of substitution, monetary values) 
    
Outcomes can refer to a constant health state (as opposed to a course 
of health over time)     
Uses respondent validation by asking participants to check their data 
or responses     
Validates through triangulation     
✓ Criteria considered important in the Q-methodology, included in the AHP 
 Criteria considered important in the Q-methodology, but not included in the AHP for the following reasons: 1. The criterion 
does not sufficiently discriminate between each method (i.e. every method would perform the same way under the criterion), 2. 
The criterion reflects an element of good study conduct, and not a unique aspect of a method itself, 3. The criterion could be 
absorbed into other similar criteria, in order to avoid the oversaturation of themes.  
  
In a convenience sample, our participants consisted of academics, consultants conducting patient preference research 
for other stakeholders, HTA/payers, industry members, physicians, and patient organisation members, all with PP 
study experience. Participants were recruited from organisations partnered with the PREFER project [10], and also 
outside the project, through snowballing techniques, based on their experience with PP studies. In implementing Q-
methodology, participants were first asked to assign our 35 criteria into three groups (most important, moderately 
important, least important), and then place these criteria on a V-shaped grid [14], visually ranking the criteria from 
most important (on the far right of the V-shape) to least important (on the far left). Participants completed this task 
for four hypothetical scenarios representing different stages of the MPLC, in which patient preferences could be 
required in order to inform a decision including: early development scenarios for products with mechanisms that are 
understood (Scenario A) and not understood (Scenario B), a late phase III scenario (Scenario C), and a post-marketing 
scenario (Scenario D) (see Table 3). 
Participants were invited to participate in the online survey using the online application FlashQ [17] and randomly 
allocated two out of the four hypothetical scenarios. The data were analysed in the qmethod package [18] under R 
3.4.1 software [19].  
 











of action well 
understood) 
Phase 2a results are complete and phase 2b is 
being designed.  The indication and 
population are well-defined.  The clinical and 
commercial teams are discussing the criteria 
and requirements for a target product profile 
(TPP), including which benefits, risks and 
tolerability issues to include and what levels 
of each are the target.  The TPP decision is an 
 
A drug is being developed for a certain population. The 
mechanism of action, meaning the specific biochemical 
interaction by which a drug produces an effect, is well-
understood. The drug has been on the market for years for 
a different condition and its benefit-risk profile is well-
understood in that population. However, this is a novel 









in-house activity for now, with information 
being shared with commercial and clinical 
development teams. The mechanism of 
action is well-understood.  This is a novel 
indication of a treatment that has been on 
the market for years. 
dosing strategy are still being identified in the new 
population and condition.  Phase 2a studies have been 
conducted to demonstrate clinical efficacy. Phase 2b studies 
are being designed to find the optimum dose that has the 
greatest efficacy with minimal side-effects. The internal 
clinical and commercial teams are discussing the criteria and 
requirements for a successful treatment. The preference 
study would be conducted for internal decision-making 






of action is 
not well 
understood) 
Phase 2a results are complete and phase 2b is 
being designed.  The indication and 
population are well-defined.  The clinical and 
commercial teams are discussing the criteria 
and requirements for a target product profile 
(TPP), including which benefits, risks and 
tolerability issues to include and what levels 
of each are the target.  The TPP decision is an 
in-house activity for now, with information 
being shared with commercial and clinical 
development teams. The mechanism of 
action is not understood.  This is novel 
indication. 
 
A drug is being developed for a certain population. The 
mechanism of action, meaning the specific biochemical 
interaction by which a drug produces an effect, is not 
understood. This is a novel indication of the treatment, 
and the benefits, risks, and dosing strategy are still being 
identified. Phase 2a studies have been conducted to 
demonstrate clinical efficacy. Phase 2b studies are being 
designed to find the optimum dose that has the greatest 
efficacy with minimal side-effects. The clinical and 
commercial teams are discussing the criteria and 
requirements for a target product profile (TPP), including 
which benefits, risks and tolerability issues to include and 
what levels of each are the target.  The TPP decision is an in-
house activity for now, with information being shared with 
commercial and clinical development teams. The preference 
study would be conducted for internal decision-making 
on whether or not the medication should advance further 
in development. 
 
C: Late Phase 
III 
Clinical data available for pivotal trials. 
Mechanism of action is understood.  Advisory 
committee/scientific advisory group meeting 
is scheduled.  The goal is to provide data to 
support benefit-risk assessment to health 
authorities for regulatory dossier submission. 
 
 
The benefits and risks dosing strategy of a medical product 
are reasonably well-characterized, as clinical trials in 
patients have been completed to assess efficacy, 
effectiveness, and safety. Mechanism of action is 
understood, (meaning the specific biochemical interaction 
by which a drug produces an effect). There is an advisory 
committee/scientific advisory group meeting scheduled.   
The goal is to provide patient preference data to support 
benefit-risk assessment when submitting dossiers to 




The treatment approved a year ago is now 
discovered from a registry or observational 
data to have a clinical significant side effect.  
Currently, the discussion is all in-house, but 
the signal is likely to lead to a discussion with 
health authorities. 
 
A medical product approved a year ago is now discovered 
from a registry or observational data to have a clinical 
significant side effect.  Currently, the discussion is all in-
house, but the signal is likely to lead to a discussion with 
health authorities. The preference study would be used to 
complement the clinical data by providing the patient’s 
perspective on benefit-risks. 
 
 
Step 2: Analytical Hierarchy Process 
To determine the relative importance of the criteria identified during Step 1, four Analytic Hierarchy Process (AHP) 
exercises were executed using Expert Choice 5.70 software [20]. AHP is a preference elicitation method which 
assesses the relative importance of attributes, with respect to achieving a goal, through pairwise comparisons. A block 
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design [21] was used to reduce the number of pairwise comparisons, and therefore, the burden on each respondent. In 
each comparison, a participant indicates preference between two criteria and the strength of that preference on a 7-
point scale [22, 23]. Based on these evaluations, a numerical weight can be derived for each attribute that reflects the 
relative importance of the criteria.  
The same four hypothetical MPLC Scenarios A-D were used in the AHP as the Q-methodology, although the text was 
expanded for clarity, since the Q-methodology software demanded short texts on screen (Table 3). Several criteria 
that scored positively in the Q-methodology were not included in the AHP if the criterion: 1) did not sufficiently 
discriminate between each method (e.g. “results can be reproduced”), 2) reflected an element of good study conduct, 
and not a unique aspect of a method itself (e.g. “applies consistency tests”), 3) could be absorbed into other similar 
criteria, in order to avoid the oversaturation of themes (e.g. “applies validation tests”, which were absorbed into the 
criteria involving internal and external validity). This successfully improved the list of criteria for clarity and brevity, 
decreasing the cognitive burden on participants since the AHP required many pairwise comparisons. Additionally, the 
attribute of collecting data from more than one participant in a single session was expanded into two attributes, one 
regarding group dynamics and one regarding solitary exercises, because many methods are able to do both and we 
needed to determine if one setting was more important than the other in some circumstances.  
A convenience sample of key stakeholders involved with PP studies including academics, consultants, HTA/payers, 
industry members, physicians, patient organisation members, and regulators, were invited to complete the AHP 
exercises online, and were randomly allocated two out of four hypothetical scenarios, including one of the early 
development scenarios, and one of the later scenarios (late phase III or post-marketing). Participants were recruited 
from organisations partnered with the PREFER project [10], and also outside the project, through snowballing 
techniques, based on their experience with PP studies. 
 
Step 3: Method Performance 
This step assessed the performance of each of the 33 preference methods identified by Soekhai et. al. [4] for the criteria 
resulting from Step 2. Performance was based on semi-structured interviews with health preference method experts 
and supplemented, where needed, by peer-reviewed literature [13, 8]. Each expert was asked whether a certain method 
could, as typically applied, meet each criterion. The expert replied with a “Yes”, “No”, “Maybe” or “Unsure” answer, 
and an explanation of their reasoning. Literature was used to complete any missing information, to turn the “Maybe” 
expert answers into definitive “Yes” or “No” by identifying the most common practice in the literature, to help make 
a definitive decision when experts could not reach a consensus or a majority (e.g. three expert answers of “Yes”, “No” 
and “Maybe”), or when expert opinion directly contradicted published literature.  
 
Step 4: Method Comparison 
Each method was awarded assigned a performance score (P) by summing the weights times an indicator function for 
meeting the criteria. This is summarised in Equation 1: 
 
𝑃 =  ∑ 𝑥𝑖
𝑛
𝑖=1 𝑦𝑖             [Equation 1] 
 
where xi was the weight of the criterion (identified in Step 2), yi was an indictor function that equals 1 if the method 
achieves criterion i or 0 if it does not (identified in Step 3),  and n was total number of criteria, and i was the index of 
summation. By combining the weights determined from the AHP with the performance of each method, the 33 
preference exploration and elicitation methods were compared. The higher the preference score, the more important 
criteria the method was able to meet.   
 
The performance of the methods were compared within their designated taxonomy groups (Table 1) as defined by 
Soekhai et al [12] to compare methods with similar approaches to data collection and analysis. Exploration and 
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elicitation methods were compared separately because they are used under different circumstances to address different 
research questions and a significant number of the criteria (e.g. estimating trade-offs) were only suited for elicitation 
methods and would result in an undervaluation of all exploration methods. Additionally, methods were compared in 
their taxonomy groups in order to examine similar methods that may seek to answer similar research questions.  
 
The method comparison was supplemented with information about the method’s publication frequency in peer-
reviewed journals as applied to patient preferences, calculated from the systematic review of Soekhai et al [12]. This 
was included after it was noted that several methods have not had any publications in the past few decades while 
others have had limited or no application to healthcare research. The methods’ publication frequency in peer-reviewed 
journals within the topic of patient preferences revealed that a total of 22 out of 33 of the methods had their most 
recent article concerning patient preferences published between 2012 and 2016. Several methods, such as measure of 
value, have not had any publications within healthcare contexts in the past few decades. Two methods, repertory grid 
method and starting known efficacy, were last published in 2005 and 1996, respectively. The remaining methods were 
not detected through systematic review. Other methods have had limited or no application to healthcare research, but 
experts have identified their potential (e.g. qualitative discriminant process [13]). Publication frequency was not used 
as a criterion used in Steps 1-3 because it would have been impossible for our participants and experts to know 




Step 1: Q-methodology  
Out of 116 international stakeholders invited to participate, 54 participants (Appendix 5.1) completed at least one of 
the four online Q-methodology exercises and had their responses statistically analysed for similar viewpoints. Of the 
35 initial criteria, 18 were identified as being most important for selecting a patient preference exploration or elicitation 
method each of the four hypothetical scenarios in the MPLC (see Table 3). These criteria obtained a positive average 
score (≥ 0.0) across all respondent groups with similar viewpoints, meaning the participants consistently ranked these 
criteria on the ‘important’ side of the grid. The results indicated that not all method criteria were important, or even 
relevant, for addressing stakeholder needs at different stages of the MPLC. For example, the cost of a preference study 
was thought to be an important criterion in both early development scenarios of the Q-methodology. However, it 
ranked low during the post-marketing scenario, and even lower in the phase III scenario, with six participants giving 
it the lowest possible ranking position.   
 
Step 2: Analytical Hierarchy Process 
Out of 210 international stakeholders invited to participate, 85 participants (Appendix 5.1) completed at least one of 
their two designated exercises. Thirty-seven participants also completed the Q-methodology in step 1, although this 
had different objectives and was completed 4 months earlier. Our results showed that the relative importance of each 
criterion, as expressed by derived weights, is different for the particular stage in the MPLC where it will be performed, 
and the anticipated needs of the decision-maker that are specific to the scenario (Table 4). Establishing validity and 
reliability, as well as ensuring a low patient burden, received the highest weights in every stage of the MPLC. Cost, 
study duration, and sample size were very important in early development, particularly when the mechanism of action 
was known (Scenario A), although cost was less important than the other two when the mechanism was not known 
(Scenario B). Additionally, early stages demanded the exploration of reasons behind a preference in qualitative detail. 
Establishing and quantifying heterogeneity became more important in later stages, particularly during phase III. Also 
in this stage, the ability to estimate trade-offs was particularly important, more so than any other stage. Post-marketing 
had similar priorities to phase III, but the criteria of study duration and sample size were included in this Scenario D 
survey, and received a significant share of the total weights. 
90 
 











Cost 12.38 10.36   
Sample Size 11.76 12.91  14.01 
Study duration (time needed) 
 
12.10 13.18  14.36 
Low frequency of sessions 5.45 4.21 - - 
A low cognitive load on patients 8.21 4.35 - - 
Quick sessions with participants - 2.04 - - 
Complexity of instructions to participants - 3.78  - 
Group dynamic with participants - - 1.95 - 
No interaction between participants (Solitarily exercise) - - 3.80 - 
Ease to which new attributes can be added without making 
prior results invalid 
2.91 2.75 2.92 - 
Estimating weights for attributes 4.60 3.59 6.45 4.04 
Estimating trade-offs between attributes 5.48 6.18 9.31 5.98 
8 or more attributes can be explored - - - 1.89 
Degree to which internal validation methods can be 
incorporated 
7.16 8.87 12.89 7.57 
Degree to which external validity is established 10.15 8.00 11.72 11.62 
Exploring the reasons behind a preference in qualitative 
detail 
8.00 9.01 6.09 4.91 
Public acknowledgement by your organisation as an 
acceptable method to study preferences 
- - 6.15 4.27 
Quantifying heterogeneity in preferences 6.94 6.62 13.2 9.02 
Calculating of risk attitudes (like risk tolerance vs. risk 
aversion) due to uncertainty in the value of an attribute 
4.87 4.18 8.36 6.85 
 
 
Step 3: Method Performance 
The performance of each method under the criteria was determined by consulting international preference method 
experts (n=17) (Table 5). Six methods (complaints procedures, concept mapping, measure of value, starting known 
efficacy, outcome prioritization tool, and qualitative discriminant process) were informed exclusively by literature 
because no method expert could be contacted at the time of analysis. A sensitivity analysis was conducted if there was 
ultimately no clear consensus. There was a lack of consensus among the experts for the performance of best-worst 
scaling type 1, the performance of (probabilistic) threshold technique, and whether most methods could be performed 
in a group setting, so literature was consulted as a tie-breaker, and to determine how the methods performed typically, 

































































































































































































































































































































































































































































































































































































































































































 ✓ ✓ ✓ ✓a ✓  b a  ✓  ✓  ✓ ✓ ✓ ✓  
Allocation of points ✓ ✓ ✓ ✓ ✓ ✓  a ✓ ✓a ✓ ✓   ✓ ✓ ✓ ✓  
Analytical Hierarchy 
Process 
✓b ✓b ✓ ✓ ✓b ✓ b b ✓  ✓ ✓b ✓  ✓ ✓ ✓ ✓  
Best-Worst Scaling 
type 1 
✓b ✓ ✓ ✓a ✓ ✓ ✓  ✓  ✓ b   ✓  ✓ ✓  
Best-Worst Scaling 
type 2 
✓b ✓ ✓ ✓a ✓ ✓ b  ✓  ✓ b   ✓  ✓ ✓  
Constant sum scaling ✓ ✓ ✓ ✓ ✓  ✓ ✓ a  ✓ b   ✓ ✓ ✓b ✓  
Contingent valuation ✓ ✓ ✓ ✓   ✓ ✓ ✓  ✓ ✓   ✓ ✓ ✓ ✓  
Control preferences 
scale 
✓ ✓ ✓ ✓   ✓  ✓  ✓ a     ✓ ✓  
Discrete Choice 
Experiment /  Best-
Worst Scaling type 3 
 ✓ ✓ ✓     ✓  ✓  ✓  ✓ ✓ ✓ ✓  
Measure of Value* ✓  ✓ ✓ ✓ ✓ ✓ ✓    ✓      ✓  
Outcome prioritization 
tool* 
✓ ✓ ✓ ✓  ✓ ✓ ✓  ✓ ✓    ✓  ✓ ✓  
Person Trade-off ✓ ✓ ✓ ✓  b ✓  ✓  ✓ ✓     ✓ ✓  
(Probabilistic) threshold 
technique 
✓b ✓b ✓ ✓b  ✓ ✓  ✓ ✓ ✓  ✓  ✓ ✓ ✓ ✓  
Q-methodology ✓  ✓ ✓ ✓ ✓ ✓  ✓  ✓ ✓  ✓a ✓  ✓ ✓  
Qualitative discriminant 
process* 
✓  ✓ ✓ ✓ ✓     ✓    ✓  ✓ ✓  
Repertory grid method ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓a      ✓  
Self-explicated conjoint a ✓ ✓ ✓ a a a a a  ✓  ✓  ✓ ✓ ✓ ✓  
Standard Gamble ✓ ✓ ✓ ✓  ✓ a a ✓ ✓ ✓ a ✓  ✓ ✓ ✓ ✓  
Starting Known 
Efficacy* 
✓ ✓ ✓ ✓  ✓    ✓ ✓  ✓  ✓ ✓ ✓ ✓  
Swing weighting ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ ✓  
Test Trade-off ✓ ✓ ✓ ✓  ✓ ✓    ✓ a   ✓ ✓ ✓ ✓  
Time Trade-off ✓ ✓ ✓ ✓  ✓ a a ✓ ✓ ✓ a ✓a  ✓ ✓ ✓ ✓  






















 Citizens’ juries ✓    ✓ ✓    ✓  ✓  ✓    ✓  
Complaints procedures ✓ ✓ ✓ ✓ ✓  ✓ ✓   ✓   ✓    ✓  
Concept mapping ✓   ✓ ✓ ✓    ✓ ✓ ✓  ✓    ✓  
Delphi method ✓    ✓ ✓   ✓ ✓  ✓  ✓    ✓  
Dyadic interview ✓  ✓ ✓ ✓ ✓ ✓ ✓  ✓  ✓  ✓    ✓  
Focus group ✓  ✓  ✓ ✓ ✓ ✓ ✓ ✓  ✓  ✓    ✓  
In-depth individual 
interview 
✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓    ✓  
Nominal group 
technique 
✓   ✓ ✓ ✓   ✓   ✓  ✓ ✓   ✓  
Public meetings ✓  ✓ ✓ ✓  ✓ ✓  ✓  ✓  ✓    ✓  
(Semi) structured 
individual interview 
✓ ✓ ✓  ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓    ✓  
✓ = meets criterion;  = does not meet criterion; Grey= indicates a lack of unanimous consensus among the experts;  
*Informed exclusively by literature, and not expert interviews;  
a Literature conflicted with experts; b No clear majority. Literature broke the tie 
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Step 4: Method Comparison 
The performance of each method was closely examined by comparing their scores for the different stages of the 
MPLC, compared to other methods’ scores within the same taxonomy group (Figure 2). Publication frequency was 
also considered when assessing the method’s performance, after it was noted that several methods have not had any 
publications over the past 20 years, or have had limited application in healthcare research. Therefore, this additional 
information helped contextualise the performance of the methods in a real-world context.  
 
Figure 2: Method comparison 
 
A total of 13 elicitation and exploration methods were identified as promising, meaning they are most likely to meet 
most decision-makers’ needs during all stages of the MPLC. These methods obtained the highest overall scores for all 
stages of the MPLC, relative to other methods within the same taxonomy group. For the exploration methods, these 
include focus groups, in-depth interviews, and semi-structured interviews (Figure 3). For the elicitation methods, these 
include discrete choice experiments / best-worst scaling type 3 (DCE/BWS3), adaptive conjoint analysis, 
(probabilistic) threshold technique, standard gamble, time trade-off, best-worst scaling type 1 (BWS1), best-worst 
scaling type 2 (BWS2), swing weighting, visual analogue scale, and analytical hierarchy process (AHP) (Figure 3). 
Rather than identifying only one overall highest scorer, we identified several instances of more than one promising 
method within the same taxonomy group.  
Additionally, eight other methods were identified that may have potential but only for some of the MPLC stages, or 
might have some publication frequency issues of which decision-makers must be aware before selecting these 
methods. This does not necessarily mean that the method would never be successful, but decision-makers need to 
balance the identified benefits and risks. For exploration methods, these are nominal group technique, public meetings, 
and dyadic interviews. For elicitation methods, these include test trade-off, starting known efficacy, Q-methodology, 





Group exploration methods 
Group exploration methods collect data from more than one participant in a single session [24, 25, 26]. Most of these 
methods performed better during early development than in later stages. Dyadic interviews, focus groups, nominal 
group technique, and public meetings were the highest performing group exploration methods likely to meet most 
decision-makers’ needs during all stages of the MPLC. However, dyadic interviews were not detected through 
systematic review [12]. Focus groups, on the other hand, performed strongly across all stages and were the most well-
published group method [12]. Nominal group technique appears promising only for early development and post-
marketing. Public meetings appear promising for early development and late phase III. Despite a low publication 
frequency, this method is frequently employed by the FDA during early development as a method of patient 
engagement [27]. However, this method has been criticised for a lack of robustness [28]. All group methods did not 
perform very well in late phase III; probably because this phase had criteria reflecting decision-makers’ needs for 
quantitative PP. Delphi method and citizens’ juries did not perform as well across all phases, because they had 
relatively higher cognitive burdens, more sessions for patients, and a longer study duration. However, the Delphi 
method has a relatively strong publication frequency [12]. In all, focus groups appeared to be the most promising 
group exploration method likely to meet most decision-makers’ needs during all stages of the MPLC. Nominal group 
technique, public meetings, and dyadic interviews are also potential group exploration methods because they can 
achieve some decision-makers’ needs during particular stages of the MPLC.   
Individual exploration methods 
Individual exploration methods collect data from one participant in a single session [29, 30]. In-depth interviews and 
semi-structured interviews were the highest performing methods in this category. Concept mapping and complaints 
procedures did not perform as well, and their performance was derived exclusively from literature. Therefore, in-depth 
interviews and semi-structured interviews appeared to be the most promising group exploration methods. No potential 
methods were identified in this group.  
Discrete choice based elicitation methods 
Discrete choice based elicitation methods examine the relative importance of trade-offs between attributes and their 
alternatives through a series of hypothetical choices [52, 53]. Although there were only two methods in this category, 
both discrete choice experiments / best-worst scaling type 3 (DCE/BWS3) and adaptive conjoint analysis both 
performed highly, both inside their group and relatively across all methods. Adaptive conjoint analysis has some well-
published theoretical concerns, both structural and statistical [33, 34] that decision makers should be aware of before 
selecting it, as well as a lower publication frequency compared to DCE/BWS3. Nonetheless, DCE/BWS3 and adaptive 
conjoint analysis appear to be the most promising discrete choice based elicitation methods.  
Indifference elicitation methods 
Indifference elicitation methods use techniques that examines a participant’s preferences for one attribute or 
alternative over another, until the participant is indifferent or has no preference [35, 36]. (Probabilistic) threshold 
technique, standard gamble, and time trade-off performed the best out of this group. Test trade-off could be promising 
in early development when the mechanism of action is known, and post-marketing, but this method could not be 
detected through systematic review [12]. Starting known efficacy also appeared promising for early development 
stages, although this result was based on literature, and not expert interviews. Contingent valuation does not perform 
as well compared to the other methods, despite a positive publication frequency. It appears to be a promising method 
during phase III, possibly due to its ability to satisfy vital criteria for this stage: estimating weights for attributes and 
trade-offs between attributes whilst still maintaining a relatively low cognitive burden. Person trade-off did not 
perform well for any stage, possibly because of its sample size requirements and limitations for what its outcomes can 
estimate. Both these methods also had the least amount of expert consensus (see Table 5). In summary, (probabilistic) 
threshold technique, standard gamble, and time trade-off appeared to be the most promising indifference elicitation 
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methods likely to meet most decision-makers’ needs during all stages of the MPLC. Additionally, test trade-off and 
starting known efficacy could also be potential methods during particular stages of the MPLC.  
Rating elicitation methods 
Rating elicitation methods use comparative rating approaches [37, 38]. Swing weighting, visual analogue scale (VAS), 
and analytical hierarchy process (AHP) performed the best out of this group. AHP was evaluated as a (rating) 
elicitation method in this study (see Figure 1), in addition to being used as part of the methodology itself (Step 2). 
Interestingly, swing weighting performed the best out of all elicitation methods, across all groups. Constant sum 
scaling performed well for late phase III, but it could not be detected through systematic review [12]. Outcome 
prioritization tool appears to be promising for early development and post-marketing, but its performance was 
informed exclusively by literature and not expert interviews. Allocation of points, constant sum scaling, and repertory 
grid method performed worse than other methods in the group. This is because they did not satisfy several important 
criteria (such as calculating risk attitudes) and their publication frequency was lower than the others. Measure of value 
could not be detected through systematic review [12]. In summary, swing weighting, VAS and AHP appear to be the 
most promising rating elicitation methods likely to meet most decision-makers’ needs during all stages of the MPLC. 
Additionally, outcome prioritization tool could also be a potential method, as could constant sum scaling during phase 
III.  
Ranking elicitation methods 
Ranking elicitation methods use ranking exercises [39, 40]. Best-worst scaling type 1 (BWS1), best-worst scaling type 
2 (BWS2), and Q-methodology performed the best out of this group. However, Q-methodology was not detected 
through systematic review [12], probably due to it being a relatively new method in healthcare research. Qualitative 
discriminant process could be promising in early development when the mechanism of action is known, although it 
was also not detected through systematic review, and its performance was informed exclusively by literature and not 
expert interviews. Additionally, other reviews have noted its lack of application to healthcare research [13]. Self-
explicated conjoint analysis could not be detected through systematic review and did not perform as well as the other 
ranking methods [12]. Control preferences scale could be promising for late phase III, despite a moderately low 
publication score, although it performed consistently low for the other stages. This is likely because the method has 
had few applications in healthcare, let alone patient preferences [13]. In summary, BWS1 and BWS2 appear to be the 
promising ranking elicitation methods most likely to meet most decision-makers’ needs during all stages of the MPLC. 
Additionally, Q-methodology could also be a potential method if decision-makers are willing to compromise on its 
rate of publication in recent years.  
 
Discussion 
Through a four-step approach, this study identified 13 exploration and elicitation methods most suitable for patient 
preference studies at different stages of the MPLC. By applying the numerical weights calculated for each important 
criterion in this study, decision-makers can potentially be aided when selecting a method. A total of 13 elicitation and 
exploration methods were identified as promising, meaning they are most likely to meet most decision-makers’ needs 
during all stages of the MPLC (Figure 2). For the exploration methods, these include focus groups, in-depth interviews, 
and semi-structured interviews (Figure 3). For the elicitation methods, these include DCE/BWS3, adaptive conjoint 
analysis, (probabilistic) threshold technique, standard gamble, time trade-off, BWS1, BWS2, swing weighting, visual 









Strengths and limitations 
There is currently no comprehensive overview of how to directly compare patient preference methods or how to 
determine which are more suitable for decision-makers’ needs. Decision-makers would benefit from having such 
information to improve the systematic inclusion of patient preferences throughout the MPLC. The key strength of this 
study is its empirical approach with the direct comparison of many diverse methods and the significant contribution 
by international health preference experts. Other appraisals of patient preference methods have been conducted [13] 
[41], although we have attempted to be more systematic, quantitative, and up-to-date. Another strength is its 
transparency, incorporating several tools for examining method performance, including the criteria and weights 
established by a Q-methodology, and an AHP.  
There are limitations to our sample. Although our response rate was lower than expected, both the Q-methodology 
and the AHP do not require large sample sizes. Therefore, we were still able to conduct a meaningful statistical analysis 
with n=54 and n=85 participants, respectively.  In terms of representativeness, these results may not be generalizable 
to the larger sample of preference methodologists.  There were significantly more industry members and academics 
in both the Q-methodology and AHP, with an under-representation of HTA/payer representatives and regulators. 
These latter two groups could have made a significant contribution by sharing insights into the requirements of patient 
preference study design during health technology assessments or during market authorisation. Most patient 
organization representatives and physicians did not fulfil the requirements of having patient preference method 
experience or have sufficient understanding of MPLC decision-contexts and were therefore not included in the 
analysed data. The methodological and technical focus of this appraisal meant that actual experience with these 
methods was crucial.. Despite limitations of our sample, the  international diversity of all cohorts was significant and 
a relatively high consensus was achieved among them in terms of the identification of more promising preference 
methods in each taxonomy category.  
All four of the MPLC scenarios created for both the Q-methodology and AHP relate strongly to industry decision 
points. They were written in a way to be accessible to persons with little pharmaceutical development experience, and 
they contained a variety of possible situations (e.g. certainty or uncertainty concerning the product, internal or external 
submissions, and early or late stages in development) applicable to other MPLC decision points not tested in this task, 
such as specific HTA/payer or regulatory decision points. The scenarios were not meant to stand in as proxy for 
decision-maker objectives and research questions; there is a range of potential research questions that decision-makers 
could seek to answer at each stage. However, they do offer insight into some real-world decision-points. For example, 
we included a scenario in which the goal is to provide patient preference data to support benefit-risk assessment when 
submitting dossiers to regulators or HTA bodies. We examined which needs were most important to decision-makers 
during this situation (reflected in our criteria) and identified the methods most likely to meet these needs during this 
specific situation, and help create a successful dossier submission.  
The incorporation of method taxonomies helps decision-makers identify the most suitable method that would best aim 
to answer their research question. However, this study does not intend to assist decision-makers with determining the 
taxonomy group that is most appropriate to answer a specific research question; this is out of scope for this study.   
It is not as accurate to compare the weights of the same attribute in different scenarios directly because there were 
different numbers of attributes in each scenario. As the Q-methodology indicated, not all method criteria were 
important, or even relevant, at every stage of the MPLC. Evaluating every criterion from the original list of 35 through 
an AHP would have been a highly burdensome pairwise comparison exercise. It was not possible to re-combine the 
criteria identified through the Q-methodology into one large AHP survey, because it would have defeated the purpose 
of identifying MPLC-specific criteria. For example, the cost of a preference study was thought to be an important 
criterion in both early development scenarios but very unimportant in later stages. Therefore, it would be illogical, 
and unnecessary participant burden, to use this criterion in an attribute for Scenarios C and D during the AHP.  
For the AHP, a relatively common practice is to check the consistency of each judgement made by participants to 
ensure a reasonable level of consistency in terms of proportionality and transitivity [42]. However, given the large 
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size of data to be analysed, and the number of judgements made across all the scenarios, it was not feasible to check 
the consistency of every judgement. This could be a beneficial addition to future sensitivity analysis. Several academic 
studies have indicated that weight derivation from pairwise comparisons is much more accurate than direct weighting 
[43], although three participants commented that the 7-point scale of the AHP was unnecessarily large. Additionally, 
the quantification of a “low” survey cost, a “small” sample size, or a “short” study duration are highly subjective, and 
we cannot control participant perceptions of these quantities. However, we instructed participants to not focus on a 
specific amount, but rather ask how important this concept (e.g. cost) is, in general, at this stage.  
The application of the AHP weights to the method performance was a complex process, and the construction of the 
performance grid (Table 5) was an ambitious task. A total of 17 international experts were contacted over a period of 
5 months. It was originally planned to have at least 3 different experts contribute to each method, cross-verifying the 
data. However, this was not always feasible, meaning additional literature was consulted to fill the gaps. Disagreement 
from experts in this innovative field is not unexpected, and this study provided a platform for an engaged discussion.  
Some of our consulted experts argued that reducing a method’s capabilities to a binary “yes” or “no” answer eliminates 
shades of grey. In many cases, a method is capable of being conducted a particular way under certain circumstances 
(e.g. using a very small sample size, although this may compromise reliability and reproducibility). In these cases, we 
decided to examine what was typical or common practice for the method, instead of what the method could achieve 
in the hypothetical sense. This is one of the key motivations for augmenting these scores with the literature results, as 
it demonstrated how this method has been observed to behave in the field of preference elicitation or exploration.  
Although tested in a relatively small setting, this novel approach warrants further development in the future. Even if 
a method obtains a low performance score using our approach, it does not necessarily mean that it could never meet a 
decision maker’s needs in the right circumstances. It is possible to repeat variations of these four-steps with different 
samples of participants (e.g. industry members exclusively) and different MPLC scenarios or in order to determine 
stakeholder-specific criteria, creating a tailored short list of suitable methods for their unique situation (e.g. informing 
cost-effectiveness ratios).This study ultimately reflects one example of how this approach be accomplished. By 
utilising the steps included in this study, either individually or as a whole, decision-makers have a tool for selecting 
an exploration or elicitation method most suited to their needs. Future research building upon this study could help 
develop a decision-tree for different stakeholders to give guidance of which method is most useful for a certain 
research question. Other research should investigate whether patient preference data should be directly incorporated 




This study aimed to develop criteria to characterise and appraise preference exploration and elicitation methods, and 
create a comprehensive overview based on empirical evidence of how these methods compare to one another within 
the MPLC. A total of 13 elicitation and exploration methods were identified as suitable and most likely to meet most 
decision-makers’ needs during all stages of the MPLC. Additionally, we identified eight methods that could have 
potential for some of these stages, although we have identified potential issues of which decision-makers should be 
aware before selecting these methods. Our rigorous, quantitative review of preference methods provides guidance for 
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Appendix 5.1: Participant demographics and stakeholder affiliation 
 
Participant demographics and stakeholder affiliation (Q-methodology and AHP) 





































AC 8 4 7 3 16 28 20 17 
CO 2 1 1 1 3 1 1 5 
HT 1 1 0 1 1 0 0 1 
IN 22 19 20 19 16 14 11 22 
PH 1 2 1 2 1 1 2 0 
PO 2 0 2 0 1 0 1 0 
RE 0 0 0 0 0 1 1 0 







BE 5 0 3 0 4 0 0 4 
CH 2 4 1 4 1 2 1 2 
DE 5 5 4 5 5 7 4 8 
IT 2 1 2 0 2 0 2 0 
NL 3 1 3 1 7 7 9 5 
SE 2 1 2 2 0 3 1 1 
UK 5 5 3 5 4 9 7 6 
US 11 11 9 10 15 14 12 15 
FR 0 0 0 0 0 1 0 1 
O** 1 0 4 1 1 5 1 4 
 
 
AC = academia; CO = consultant; HT = health technology assessment body or payer; IN = industry; PH = physicians; PO = patient 
organisation members; RE = regulators; O = Other; BE = Belgium; CH = Switzerland; DE = Germany; IT = Italy; NL = 
Netherlands; SE = Sweden; UK = United Kingdom; US = United States; FR = France; AHP = Analytical hierarchy process 
*Other includes: Independent research organisation, International organisation, and University hospital 
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Background: Integrating patient preferences in Health Technology Assessment (HTA) is argued to improve uptake, 
adherence, and patient satisfaction. However, how to elicit and incorporate these preferences in HTA in a systematic 
and scientifically valid manner is subject to debate. 
Objective: This article provides a systematic review of the challenges to integrating patient preferences in HTA that 
have been raised in the literature about patient preferences in HTA. 
Methods: A systematic review of articles published between 2013 and 2017 addressing challenges to the integration 
of patient preferences in HTA was conducted in 7 databases. All issues with respect to the integration of patient 
preferences in HTA were extracted and divided into 5 categories: conceptual, normative, procedural, methodological, 
and practical issues. The issues were ranked according to how often they were mentioned. 
Results: Of 2147 retrieved articles, 67 were included in the analysis. Thirty-seven unique research issues were 
identified. In the majority of the articles, methodological issues were posed (82%), followed by procedural (73%), 
normative (51%), practical (24%), and conceptual (9%) issues. Frequently posed methodological issues concerned 
preference heterogeneity and choice of method. Common procedural issues concerned how to evaluate the impact of 
preference studies and their degree of being evidence based. 
Conclusions: This article provides an overview of issues with respect to the integration of patient preferences in HTA 
procedures. Most issues were of a methodological or procedural nature; yet, the large number of different issues points 
to the overall importance of further researching the different aspects concerned with patient preferences in HTA. 






Health Technology Assessment (HTA) informs reimbursement and coverage decisions on how to allocate healthcare 
resources to different health technologies by carefully assessing the costs and benefits of health interventions [1]. With 
the increasing focus on patient preferences in clinical practice guidelines [2, 3, 4], academic research [5, 6], and 
regulatory decision making [7, 8, 9], it is important that HTA not fall behind [10]. The US Food and Drug 
Administration defines patient preference information as “qualitative or quantitative assessments of the relative 
desirability or acceptability to patients of specified alternatives or choices among outcomes or other attributes that 
differ among alternative health interventions” [11]. In this context, qualitative assessments usually refer to exploring 
patient preferences and quantitative assessments for eliciting patient preferences. Not aligning the assessment of health 
intervention costs and benefits with patient preferences can cause adherence to be very different than expected, and it 
can explain why many health interventions that have developed throughout the medical product life cycle end up not 
being used [12]. Other arguments for integrating patient preferences in HTA are that it is considered ethical to listen 
to the patient voice [13, 14], it will increase patient satisfaction [14, 15], and that HTA decision making will be more 
informed and more transparent with the inclusion of patient-relevant value judgments and experiential data 
[13, 14, 15, 16, 17]. 
Although the US Food and Drug Administration has provided guidance on how to use patient preference information 
in benefit-risk assessments [11], HTA is still lagging behind. Patients are increasingly being involved in the HTA 
decision-making process [18, 19], but how to elicit and incorporate patient preferences in a systematic and 
scientifically valid manner is still subject to debate. For example, Weernink et al. [20] could not find a method that 
performed well from a statistical and patient burden point of view. Janssen et al. [21] suggested further researching 
validity and reliability tests for quantitative preference methods. Facey et al. [22] discussed whether and how 
qualitative, and quantitative, patient preference studies could be considered robust scientific evidence. Hansen and 
Lee [17] questioned the validity of qualitative research methods. In a recently published editorial, Mott [10] stated 
that HTA needs “substantive changes” to catch up with regulatory decision making in the incorporation of patient 
preferences. He mainly questioned how to weigh patient preference information in current HTA procedures. Facey 
et al. [23] highlighted the “substantial challenges to realizing the goal of informing evidence-based patient-centered 
policy.” The variety of open questions concerning patient preferences in HTA raised by different researchers suggests 
the need for a comprehensive overview of all challenges in the field. Therefore, the objective of this article is to 
provide a systematic review of the challenges to integrating patient preferences in HTA raised by literature. By doing 




To identify open questions concerning the use of patient preferences in HTA, the following study design was used. 
First, literature about patient preferences in HTA was identified. Second, the study characteristics of the included 
literature were elicited. Third, issues related to the integration of patient preferences in HTA, as raised in the literature, 
were derived. Last, the issues were categorized according to thematic differences and similarities. The results were 
analyzed on 3 different levels of categorization, namely from broad to specific: “categories,” “topics,” and “issues.” 








Figure 1: Study design 
The 3 different levels of categorization, from broad to specific, were “categories,” “topics,” and “issues.” Elicited 
issues were subdivided into topics; topics (and their issues) were also subdivided into categories. 
 
Identification of Literature 
To identify literature about patient preferences in HTA, we conducted a systematic review using the databases Embase, 
Medline Ovid, Web of Science, Scopus, Cochrane CENTRAL, CINAHL EBSCOhost, and Google Scholar. The 
search terms can be found in Appendix 7.1. 
Articles were deemed eligible if they met the following 6 inclusion criteria. The studies had to concern patient 
preferences, had to concern HTA, and had to discuss at least 1 issue concerning the integration of patient preferences 
in HTA. Further, the articles had to be English-language articles, the full text had to be available, and the articles had 
to be published between 2013 and 2017 because recent publication is inherent to providing a contemporary overview. 
After excluding duplicates and articles outside the relevant publication years, 2 of the researchers (S.H. and C.W.) 
independently reviewed the remaining titles and abstracts for eligibility. If at least 1 of the researchers determined that 
an article met the eligibility criteria based on title and abstract screening, a full-text screening was done by the 
researchers. If no consensus could be reached about the eligibility of the full text, a third researcher (E.B.G.) was 
consulted. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Statement [24]. 
Description of Study Characteristics 
For all eligible articles, 6 study characteristics were extracted. Extracted data included the country in which the first 
author was employed, whether the study was a theoretical or applied study, the medical context (ie, general or disease-
specific) in which the study was conducted, and whether the article concerned qualitative (exploring) or quantitative 
(eliciting) patient preferences. In addition, we extracted which type of stakeholders raised the issue (eg, respondents 
or the authors) and for which type of stakeholders the issue was relevant (eg, patients, HTA bodies, or academics). 
Data were extracted by 1 researcher, after which 2 other researchers validated the findings. 
Elicitation of Issues 
Issues concerning the integration of patient preferences in HTA were extracted from the literature in the broadest sense 
(ie, questions, concerns, barriers, facilitators, and areas for further research). All study-specific elements were deleted 
from the extracted issues to allow for comparison of the issues across studies. Data were extracted by 1 researcher, 
followed by confirmation of 2 other researchers. 
Categorization of Issues 
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Two researchers (S.H. and C.W.) performed a 3-level categorization of the elicited issues, and a third researcher was 
consulted if no consensus could be reached. The 3 different levels, from broad to specific, were “categories,” “topics,” 
and “issues.” Issues were subdivided into topics; topics (and their issues) were also subdivided into categories. Again, 
an illustration of the study design is presented in Figure 1. To enhance consistency of the categorization process, we 
defined, before analysis, whether a research issue would fall into only 1 category or topic, respectively. Consensus 
thus had to be reached on which category or topic best described the issue. As in Utens et al. [25], we used the 
following 5 categories as the broadest level of categorization: conceptual, normative, procedural, methodological, and 
practical issues. Conceptual issues relate to the definition and characterization of patient preferences. Normative issues 
concern which members of society should have their preferences elicited. Procedural issues relate to how to integrate 
patient preferences into the existing procedures of HTA. Methodological issues address establishing good and accurate 
research practice on the topic. Practical issues address all other concerns of a practical nature such as time and money 
constraints. The topics were the second level of categorization. Unlike the categories, topics were not predefined and 
were established using backward induction. The issues were grouped according to thematic similarities and 
differences; the exact name of the topic was determined after the issues were grouped. Included in the third level of 
categorization were the issues themselves. The categorized data were analyzed in 2 different ways. First, to give insight 
into the variety of issues in each category and topic, respectively, the number of issues in each category or topic (as 
% of the total number of issues) was established. Second, to measure frequency of occurrence of the issues, the number 
of articles that mentioned each issue (as % of total number of articles) was analyzed. 
 
Results 
Identification of Literature 
The database search identified 2147 articles, of which 375 unique articles published in 2013 to 2017 were screened. 



















Figure 2: Study selection 
 
 
Description of Study Characteristics 
For most of the articles containing issues regarding patient preference in HTA, the first authors worked on behalf of 
organizations/universities in Canada (n = 13; 19%), the United Kingdom (n = 13; 19%), and Germany (n = 10; 15%) 
(Table 1). Other common countries of origin were the United States (n = 8; 12%), Australia (n = 7; 10%), and The 
Netherlands (n = 6; 9%). Three quarters of the articles (51 of 67 articles) discussed the integration of patient 
preferences in HTA theoretically rather than actually conducting a preference study. Almost two thirds of the articles 
(n = 44) concerned a general medical context rather than a disease-specific context. Thirty-one articles concerned the 
qualitative elicitation of preferences (46%), whereas 17 concerned quantitative preference elicitation (25%), 9 
concerned both (13%), and 10 did not specify (15%). 
 
Table 1: Study characteristics - summary 
Item  N=67 1 % 2 
Country of origin Canada 13 19% 
 United Kingdom 13 19% 
 Germany 10 15% 
 United States 8 12% 
 Australia 7 10% 
 The Netherlands 6 9% 
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Item  N=67 1 % 2 
 Other 10 15% 
Type of study Theoretical 51 76% 
 Application 15 22% 
 Both 1 1% 
Medical context General 44 66% 
 Disease-specific 23 34% 
Preference elicitation Qualitative 31 46% 
 Quantitative 17 25% 
 Both 9 13% 
 Not defined 10 15% 
Issue raised by stakeholder Authors and cited authors 52 78% 
 Respondents: HTA professionals 5 7% 
 Respondents: Patients 4 6% 
 Respondents: Other 6 9% 
Issue relevant for stakeholder  HTA professionals and academics 34 51% 
 HTA professionals 23 34% 
 Other 10 15% 
1 Absolute number of articles ; 2 Relative number of articles (as % of total of 67 articles). Percentages may not add to 100 because of rounding 
error.  
Many of the research issues were raised by the authors or authors cited in the articles (n = 52; 78%). The vast majority 
of first authors (73%) worked in academia; the remainder worked for a variety of organizations (eg, patient 
organizations, HTA agencies, and private consultants). In the remainder of articles where study respondents were 
specifically asked about the advancement of patient preference integration in HTA (n = 15, 22%), respondents were 
HTA professionals (n = 5), patients (n = 4), and a variety of other respondents (eg, healthcare professionals, caregivers, 
and policy makers, n = 6). Most of the issues were relevant for HTA professionals and academics (n = 34; 51%). Other 
issues were relevant for HTA professionals only (n = 23; 34%) or for a variety of HTA professionals, clinical guideline 
developers, patients, patient organizations, or clinicians (n = 10; 15%). Table 1 summarizes these study 
characteristics; a more elaborate overview of the study characteristics per article is presented in Appendix 7.2. 
Categorization of Issues 
Across the 5 categories of identified issues, 16 topics and 37 unique research issues were identified from the total 
selection of articles. The issues were the most specific level of categorization. These were subdivided into topics. In 
turn, the topics were subdivided into categories. Table 2 presents a broad overview of the research categories and 
topics. Table 3 presents the most specific level, namely, the issues. The analysis of the 3 levels of categorization is 










Table 2: Relative occurrence of issues, per category of issues and per topic of issues. 
Category Topic # issues # mentions 
  N=37 1 % 2 N=671 %2 
Conceptual  1 3% 6 9% 
 Taxonomy 1 3% 6 9% 
Normative  5 14% 34 51% 
 Whose preferences 4 11% 26 39% 
 Relevance of preferences 1 3% 11 16% 
Procedural  9 24% 49 73% 
 Weight 3 8% 21 31% 
 Impact 1 3% 21 31% 
 Patient education 3 8% 20 30% 
 Evidence-based 1 3% 17 25% 
 HTA stage 1 3% 16 24% 
Methodological  18 49% 55 82% 
 Choice of method 3 8% 30 45% 
 Internal validity 3 8% 24 36% 
 Generalizability 4 11% 19 28% 
 Sample selection 1 3% 15 22% 
 External validity 2 5% 9 13% 
 Patient characteristics 2 5% 8 12% 
 Reliability 3 8% 7 10% 
Practical  4 11% 16 24% 
 Resources 4 11% 16 24% 
1 Absolute number of issues identified and absolute number of articles mentioning each issue; 2 Relative number of issues (as % of 37 issues) and 
relative number of articles mentioning each issue (as % of 67 articles). Percentages might not add up to 100% because most studies mentioned 
multiple issues or because of rounding error. 
 
Table 3: Three-level categorization and relative occurrence of issues. 
Category Topic # Issue N=671 %2 Article(s)  
Conceptual       
 Taxonomy 1. How should we define patient preferences and 
subsequently find and retrieve patient preference 
studies? 
6 9% [26-29, 37, 50] 
       
Normative       
 Whose 
preferences 
1. Do preferences of representatives of patient 
organizations/advocacies represent preferences of a 
broader set of individuals? 
13 19% [22, 30, 31, 44, 53, 
58, 60, 63, 65, 83-
86] 
  2. Whose preferences should be elicited (e.g. patients with 
or without treatment experience, carers, patient 
representatives)?  
12 18% [26, 32, 34, 35, 44-
46, 65, 69, 83, 85, 
87]  
  3. Are patient preferences influenced by external factors 
(e.g. media, family or pharmaceutical companies)? 




Category Topic # Issue N=671 %2 Article(s)  
  4. How can preferences from various samples (e.g. 
clinicians, carers and patients) be synthesized to be of 
value as a whole? 
3 4% [47, 54, 87] 
 Relevance 1. What are patient relevant outcomes (i.e. health vs. 




[14, 26, 37, 47-49, 
59, 66, 82, 88, 89]  
       
Procedural       
 Weight 1. How should preference studies be evaluated in 
comparison/addition to clinical and economic evaluation 
studies? 
15 22% [14, 26, 28, 30, 32, 
37, 39, 40, 65, 66, 
83, 85, 86, 90, 91] 
  2. How can preference studies add to or replace the QALY 
paradigm? 
5 7% [14, 33, 37, 52, 76] 
  3. How should ethical issues concerning patient 
preferences be weighed in HTA?  
4 6% [13, 43, 64, 86] 
 Impact 1. How can we evaluate the impact of patient preferences 
studies on HTA decision-making? 
21 31% 
 
[14, 22, 26, 29, 30, 
32, 34-36, 38, 44, 
50, 53, 54, 58, 63, 
69, 81, 83, 86, 92] 
 Patient 
education 
1. How can patients be sufficiently trained to perform HTA 
studies?  
14 21% [22, 30, 31, 44, 53, 
56, 60, 64, 65, 69, 
83, 86, 89, 93]  
  2. How can communication between researchers and 
patients be aligned in preference studies? 
6 9% [22, 30, 31, 83, 86, 
89] 
  3. How should patients and caregivers be informed about 
HTA studies and the possibility to be involved? 
12 19% [38, 47, 53, 54, 65, 
66, 69, 82, 83, 86, 
93, 94]  
 Evidence-based 1. How is and should the quality and transparency of 
patient preference studies be assessed to be considered 
robust scientific evidence? 
17 25% 
 
[14, 22, 29, 34, 39, 
44, 47, 50-52, 59, 
60, 64, 65, 76, 85, 
93] 
 HTA stage 1. In which context and stage of HTA should preferences 
be used to inform decision-making? 
16 24% 
 
[26, 30, 31, 35, 47, 
49, 53-55, 63, 66, 
85, 88, 90, 92, 93]  
       
Methodological       
 Choice of 
method 
1. Which methods are preferable for eliciting preferences? 29 43% [14, 26-28, 30, 32, 
33, 35, 37-41, 46, 
52, 53, 60, 62, 65, 
69, 76, 82, 85, 87, 
92, 93, 95-97]  
  2. When should we use quantitative (eliciting) vs. 
qualitative (exploring) research methods for patient 
preference studies? 
3 4% [14, 26, 27] 
  3. Which methods to elicit patient preferences are 
preferable in which stage of HTA?  
2 3% [30, 63]  
 Internal 
validity 
1. How do preferences on an individual level differ from 
those on a collective level (i.e. preference 
heterogeneity)?  
18 27% [22, 33, 37, 39-41, 
45, 48, 56, 57, 59, 
66, 86, 89, 91, 97-
99] 
  2. How does framing affect preferences? 4 6% [27, 32, 41, 67]  
  3. How can validity of preference studies be tested? 1 1% [48] 
 Reliability 1. How stable are preferences over time? 4 6% [14, 48, 49, 82]  
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Category Topic # Issue N=671 %2 Article(s)  
  2. How consistent are individuals in preference studies, 
how does this affect results and how should inconsistent 
responses be handled? 
3 4% [22, 41, 48] 
  3. How should uncertainty in patient preferences be 
modelled? 
1 1% [32] 
 Generalizability 1. How representative are preferences from the recruited 
sample for the entire population? 
9 13% [22, 29, 35, 48, 60, 
65, 69, 86, 87]  
  2. Can preference studies be transferred across diseases and 
contexts (i.e. as a generic instrument)? 
7 10% [14, 26, 34, 40, 47, 
52, 82] 
  3. Can preference studies be transferred across 
countries/socio-cultural groups? 
4 6% [39, 48, 60, 94]  
  4. How representative are preferences for a singular 
intervention compared to when it is administered 
alongside other interventions? 
2 3% [49, 82] 
 Sample 
selection 
1. How (i.e. via which channels and based on which 
characteristics) should the sample be selected? 
15 22% [29-31, 42, 44, 47, 
53, 54, 60, 65, 67, 
69, 83, 92, 100]  
 External 
validity 
1. What is the external validity of preference studies and 
how can this be improved? 
5 7% [22, 41, 60, 67, 99] 
  2. How can we merge real-world data (e.g. adherence data) 
and stated preference studies? 
4 6% [14, 49, 50, 57] 
 Patient 
characteristics 
1. Which sociodemographic patient characteristics (e.g. 
gender, age, education, income, family, risk attitude and 
beliefs) affect preferences and how should we tailor 
these subgroups? 
6 9% [31, 39, 47, 56, 57, 
99] 
  2. Which disease-specific patient characteristics (e.g. stage 
and severity of illness) affect preferences and how 
should we tailor these subgroups? 
6 9% [47, 56, 57, 82, 98, 
99] 
       
Practical       
 Resources 1. How can cost constraints of preference studies be 
overcome? 
13 19% [26, 31, 38, 42-44, 
54, 55, 58-60, 69, 
86]  
  2. How can time constraints of preference studies be 
overcome? 
11 16% [26, 30, 31, 42-44, 
55, 60, 69, 86, 100]  
 
 
 3. How can staff/expertise constraints of preference studies 
be overcome (who should perform preference studies)? 
6 9% [26, 30, 43, 68, 69, 
86] 
  4. How can location constraints of preference studies be 
overcome? 
1 1% [31] 
QALY indicates quality adjusted life year; HTA, Health Technology Assessment. 
1 Absolute number of articles; 2 Relative number of articles mentioning each issue (as % of 67 articles). Percentages do not add up to 100% because 
most studies mentioned multiple issues or because of rounding error. 
 
Categories of identified issues 
Of the 37 issues, 1 was conceptual (3%), 5 were normative (14%), 9 were procedural (24%), 18 were methodological 
(49%), and 4 were of a practical nature (11%) (Fig. 3). In terms of how often the issues were mentioned, 
methodological issues arose relatively often in the literature—namely, in 55 of 67 articles (82%). Procedural issues 
were also mentioned frequently (n = 49; 73%). Normative issues were raised relatively less frequently (n = 34; 51%), 
followed by practical issues (n = 16; 24%) and conceptual issues (n = 6; 9%). 
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Figure 3: Relative occurrence of issues, per category of issues. 
 
 
Topics of identified issues 
The 16 research topics that were extracted can be found in Table 2. Each of these topics contains between 1 and 4 
issues. The establishment of a taxonomy for patient preference studies was the only conceptual topic that was raised. 
It was raised in 6 of the 67 articles (9%; eg, Utens et al. [25], Brooker et al. [26], and DeJean et al. [27]). Normative 
topics included whose preferences to elicit and the relevance of preference studies to patients. Whose preferences to 
elicit was mentioned most—namely, in 26 of the 67 articles (39%; eg, Rashid et al. [28], Gagnon et al. [29], and Buck 
et al. [30]). Procedural topics concerned what weight to give patient preferences in current HTA procedures, how to 
evaluate impact, how to educate patients in preparation for preference studies, whether and how patient preferences 
are evidence based, and in which HTA stage to incorporate patient preferences. The most often mentioned procedural 
topics were how to weight preference studies in comparison to or in addition to current ethical, clinical, and cost-
effectiveness (quality adjusted life year [QALY]) procedures (n = 21; 31%; eg, Dirksen [14], Mühlbacher and 
Kaczynski [31], and Mühlbacher and Sadler [32]) and how to evaluate the impact of preference studies on HTA 
decision making (n = 21; 31%; eg, Dipankui et al. [33], Kreis and Schmidt [34], and Abelson et al. [35]). 
Methodological topics concerned choice of method, internal and external validity, reliability, generalizability, and 
which patient characteristics affect preferences and how. The most prevailing methodological topic was choice of 
method (n = 30; 45%; eg, Utens et al. [36], Wortley et al. [37], and Brereton et al. [38]), followed by internal validity 
(n = 24; 36%; eg, Brooker et al. [26], Wahlster et al. [39] and Danner et al. [40]). The only practical topic that was 
raised concerned resource constraints in conducting preference studies, which was mentioned in 16 of the 67 articles 
(24%; eg, Utens et al. [25], Hailey et al. [41], and Single et al. [42]). 
Issues 
Table 3 gives an overview of the 37 unique research issues and their frequency of being mentioned. The most 
frequently posed normative issues concerned whether the preferences of representatives of patient organizations 
represent the preferences of a broader set of individuals (n = 13; 19%; eg, Rashid et al. [28], Gagnon et al. [29], and 
Buck et al. [30]) as well as whose preferences should be elicited (n = 12; 18%; eg, Kreis et al. [43], Mott and 
Najafzadeh [44], and Thokala et al. [45]) and whether patient-relevant outcomes and processes should be accounted 
for in preference studies and how this should be done (n = 11; 16%; eg, Evers et al. [46], Mühlbacher et al. [47], and 
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Berglas et al. [48]). The most frequently posed issue of a procedural nature was how to evaluate the impact of 
preference studies (n = 21; 31%; eg, Dipankui et al. [33], Kreis and Schmidt [34], and Abelson et al. [35]), followed 
by whether preference studies can be considered robust scientific evidence (n = 17; 25%; eg, Iskrov and Stefanov 
[49], Moreira [50], and Tordrup et al. [51]) and in which HTA stage to incorporate them (n = 16; 24%; eg, Hämeen-
Anttila et al. [52], Weeks et al. [53], and Husereau et al.54). The most frequently raised methodological issues were 
about which methods to use for preference elicitation (n = 29; 43%; eg, Utens et al. [36], Wortley et al. [37], and 
Brereton et al. [38]) and about heterogeneity in preferences (n = 18; 27%; eg, Wahlster et al. [39], Di Paolo et al. 
[55], and Doctor and MacEwan [56]). The most frequently mentioned practical issues with conducting preference 
studies were cost constraints (n = 13; 19%; eg, Wortley et al. [37], Mossman et al. [57], and Kievit et al. [58]) and 
time constraints (n = 11; 16%; eg, Buck et al. [30], Brereton et al. [59], and Scott and Wale [60]). 
 
Discussion 
In this study, from a selection of 67 articles, we identified 37 unique research issues that concern the integration of 
patient preferences in HTA. In most of the articles, methodological issues were raised (82%), followed by procedural 
(73%), normative (51%), practical (24%), and conceptual (9%) issues. Frequently posed methodological issues were 
about preference heterogeneity and choice of method. Common procedural issues concerned how to evaluate the 
impact of preference studies and their degree of being evidence based. 
The relatively large number of unique issues shows that patient preference integration is by and large a relevant topic 
to be researched. This review includes theoretical and applied studies and includes studies in numerous medical 
contexts from various countries. Furthermore, the identified issues relate to qualitative (exploring) and quantitative 
(eliciting) preference methods that might vary in rigorousness and addressability depending on the research question 
concerning patient preferences in HTA. Given the variety of study characteristics, this review provides a 
comprehensive research agenda that is relevant for multiple stakeholders. The issues in the articles were relevant for 
HTA professionals, academic researchers, clinical guideline developers, patients, patient organizations, and/or 
clinicians. Nonetheless, the majority of the issues were raised by academic authors of the articles, and the articles 
provide little guidance on how to address the issues. Hence, we believe that to reach consensus on the way forward, 
involvement, coordination, and collaboration among the different stakeholders is warranted. 
The issues identified in this review are very much in line with non-HTA specific literature [9, 12] in which experts 
generally argue for the use of patient preferences in healthcare research. According to Ostermann et al. [12], important 
issues are internal and external validity, reliability, and preference heterogeneity in addition to evidence-based 
prediction of uptake and adherence. In a research agenda concerning regulatory review of medical devices, Levitan 
et al. [9] stated that validity and reliability, the choice of method, sample selection, patient-relevant outcomes and 
processes, framing, patient education, and correcting for patient characteristics were important issues to consider. 
Within the HTA context, Mott [10] prioritized issues about weighting patient preferences in current HTA procedures. 
He discussed whether patient preferences should be incorporated within the QALY or beyond the QALY and proposed 
multiple-criteria decision analysis as a new methodological approach to HTA. The challenges mentioned by Facey 
et al. [23] include the impact of preference studies on HTA decisions, time and cost constraints, and how to weight 
preference studies alongside clinical and cost-effectiveness studies. The authors also strongly highlighted the need for 
patient preference studies to be evidence based. Despite the fact that the previously mentioned authors differed in their 
prioritization of issues, all of the issues in their articles were also identified in our review, advocating its inclusiveness. 
Some aspects of this review require discussion. A first limitation is that articles outside the scope of our definitions 
may have been overlooked for various reasons. As mentioned in some of the included articles 
[25, 26, 27, 28, 36, 49], patient preferences are not clearly defined, and therefore studies concerning this topic are not 
easily retrievable. Furthermore, the integration of public preferences is sometimes discussed alongside the integration 
of patient preferences [28, 30, 34, 35, 44, 53, 61, 62, 63, 64, 65, 66, 67, 68]. Although it is an important issue to 
address, it was not an explicit goal of this research to take a stance on or provide an overview of whether to use patient, 
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public, or both preferences in HTA. For an overview of arguments for and against public and patient preferences in 
health valuation, other literature [10, 69, 70, 71, 72, 73, 74] can be consulted. Other reasons for potentially having 
overlooked important research questions that are inherent to reviewing literature are publication lag or bias and the 
inclusion of only English-language articles. 
Second, the process of categorization should be interpreted with caution. For pragmatic reasons, study characteristics 
and issues were extracted by 1 researcher, followed by confirmation by 2 other researchers. The categorization of 
issues was performed by 2 researchers, followed by confirmation by a third researcher, yet the issues were subjectively 
categorized to put them into context. There could be discrepancies between what was originally meant by authors of 
the articles included in the analysis, how we interpreted the issues, and how other researchers would interpret them. 
In addition, we interpreted frequency of occurrence as a way to measure priority. The broader the issue, the more it is 
likely to occur; so it is possible that issues unintentionally became weighted according to their specificity in the 
extraction process. The current categorization is by no means intended to be definitive. However, it is a systematically 
retrieved overview and, we believe, an informative descriptive basis for a more extensive prioritization of issues to 
advance the integration of patient preferences in HTA. Other interesting research that goes beyond the scope of this 
article could be in-depth analysis about how knowledge accumulated on a particular issue or topic as listed in this 
review. In addition, it might be interesting to research how particular issues or topics trend together. 
Thirdly, it should be noted that HTA studies vary in the degree to which patient preferences are meaningful. According 
to the articles included in this systematic review, integrating patient preferences in HTA is mostly relevant for the 
following situations: when there is no 1 treatment that is considered superior [14, 25, 26]. when the benefits of 
interventions are only marginal [14], when uncertainty of the treatment outcome is high [4], when there are multiple 
alternatives that vary largely in terms of risk-benefit trade-offs [4], when preferences of patients are expected to be 
very heterogeneous [4], and when the treatment concerns a rare disease that would benefit from early HTA [46]. 
Based on the literature and our interpretation of the data, we recommend 2 areas for further research that are 
fundamental to the advancement of integrating patient preferences in HTA. First, as addressed in articles included in 
this review [14, 32, 36, 51, 75] and beyond [10, 69, 76], the discussion as to whether patient preferences should be 
incorporated within the QALY or beyond the QALY is essential to the integration of patient preferences in HTA. 
Second, in agreement with articles included in this review [32, 45] and broader literature [7, 10, 19, 77, 78, 79], we 
recommend exploration of the possibilities of using multiple-criteria decision analysis to integrate patient preferences. 
Both of these procedural matters relate to normative changes to current HTA procedures, hence warranting further 
research. Other normative issues, such as whose preferences to incorporate in HTA, concern a choice rather than 
further research. To address the entire spectrum of issues identified in this review, especially the normative issues, 
better communication, collaboration, and consensus among the different stakeholders is required [80, 81]. 
 
Conclusion 
In line with the increasing use of patient preferences in various medical contexts, the integration of patient preferences 
in HTA is expected to contribute to better decision making and to increase uptake, adherence, and patient satisfaction. 
So, what is next for patient preferences in HTA? Methodological and procedural issues were mentioned most; yet, the 
large number of different issues advocates the overall importance of a multi-stakeholder and holistic approach to the 
integration of patient preferences in HTA. By providing a contemporary overview of issues in the literature, this 
review is an important first step toward the integration of patient preferences in HTA in a systematic and scientifically 
valid manner. The next step requires coordination and collaboration among the different stakeholders to reach 
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Appendix 7.1: Database search terms 
 
Embase 
('patient preference'/de OR 'patient participation'/de OR 'patient engagement'/de OR 'patient attitude'/de OR 'attitude 
to health'/de OR 'consumer attitude'/de OR 'patient decision making'/de OR (((patient* OR client* OR consumer* OR 
user*) NEAR/3 (preference* OR participat* OR involvement* OR engage* OR choice* OR perspective* OR utilit* 
OR acceptab* OR desirab* OR tradeoff* OR trade-off* OR decision* OR attitude* OR voice*))):ab,ti) AND 
('biomedical technology assessment'/de OR (((biomedical OR health OR healthcare OR medical) NEAR/3 technolog* 
NEAR/3 (assessment* OR decision*)) OR hta):ab,ti) NOT [Conference Abstract]/lim AND [english]/lim 
 
Medline Ovid 
 (Patient Preference/ OR Patient Participation/ OR Patient Acceptance of Health Care/ OR Attitude to Health/ OR 
(((patient* OR client* OR consumer* OR user*) ADJ3 (preference* OR participat* OR involvement* OR engage* 
OR choice* OR perspective* OR utilit* OR acceptab* OR desirab* OR tradeoff* OR trade-off* OR decision* OR 
attitude* OR voice*))).ab,ti.) AND (Technology Assessment, Biomedical/ OR (((biomedical OR health OR healthcare 
OR medical) ADJ3 technolog* ADJ3 (assessment* OR decision*)) OR hta).ab,ti.) AND english.la. 
 
Cochrane CENTRAL 
 ((((patient* OR client* OR consumer* OR user*) NEAR/3 (preference* OR participat* OR involvement* OR 
engage* OR choice* OR perspective* OR utilit* OR acceptab* OR desirab* OR tradeoff* OR trade-off* OR 
decision* OR attitude* OR voice*))):ab,ti) AND ((((biomedical OR health OR healthcare OR medical) NEAR/3 
technolog* NEAR/3 (assessment* OR decision*)) OR hta):ab,ti)  
 
Web of Science 
TS=(((((patient* OR client* OR consumer* OR user*) NEAR/2 (preference* OR participat* OR involvement* OR 
engage* OR choice* OR perspective* OR utilit* OR acceptab* OR desirab* OR tradeoff* OR trade-off* OR 
decision* OR attitude* OR voice*)))) AND ((((biomedical OR health OR healthcare OR medical) NEAR/2 
technolog* NEAR/2 (assessment* OR decision*)) OR hta)) ) AND DT=(article) AND LA=(english) 
 
Scopus 
TITLE-ABS-KEY(((((patient* OR client* OR consumer* OR user*) W/2 (preference* OR participat* OR 
involvement* OR engage* OR choice* OR perspective* OR utilit* OR acceptab* OR desirab* OR tradeoff* OR 
trade-off* OR decision* OR attitude* OR voice*)))) AND ((((biomedical OR health OR healthcare OR medical) W/2 
technolog* W/2 (assessment* OR decision*)) OR hta)) ) AND DocType(ar) AND Language(english) 
 
CINAHL EBSCOhost  
(MH Consumer Participation+ OR MH Attitude to Health OR TI (((patient* OR client* OR consumer* OR user*) N2 
(preference* OR participat* OR involvement* OR engage* OR choice* OR perspective* OR utilit* OR acceptab* 
OR desirab* OR tradeoff* OR trade-off* OR decision* OR attitude* OR voice*))) OR AB (((patient* OR client* OR 
consumer* OR user*) N2 (preference* OR participat* OR involvement* OR engage* OR choice* OR perspective* 
OR utilit* OR acceptab* OR desirab* OR tradeoff* OR trade-off* OR decision* OR attitude* OR voice*)))) AND 
(TI (((biomedical OR health OR healthcare OR medical) N2 technolog* N2 (assessment* OR decision*)) OR hta) OR 
AB (((biomedical OR health OR healthcare OR medical) N2 technolog* N2 (assessment* OR decision*)) OR hta)) 














Appendix 7.2: Study characteristics – per article 




RQ posed for  
Abelson et al. (2016) [36] Canada Theory General Qualitative Authors HTA professionals 
Beresniak et al. (2015) [76] France Theory General Quantitative Authors HTA professionals and 
academics 
Berglas et al. (2016) [49] Canada Application General Qualitative Authors HTA professionals 
Brereton et al. (2017) [39] UK Theory Palliative care & 
general 
Qualitative Authors HTA professionals and 
academics 
Brereton et al. (2017) [60] UK Application Palliative care & 
general 
Qualitative Authors HTA professionals and 
academics 
Brooker et al. (2013) [27] Canada Application COPD 
ventilation 
Quantitative Authors and 
cited authors 
HTA professionals and 
academics 
Buck et al. (2014) [31] UK Theory General Qualitative Respondents 
and authors 
HTA professionals 
Burke et al. (2014) [90] US Theory General N/D Authors HTA professionals, 
clinicians and patients 
Cassels (2016) [84] Canada Theory General Qualitative Authors HTA professionals 
Chen (2014) [100] US Theory Oncology N/D Authors HTA professionals and 
academics 
Dalle Fratte et al. (2015) [62] Italy Application HPV and general Qualitative Authors HTA professionals 
Danner et al. (2016) [41] Germany Application Age-Related 
Macular 
Degeneration 
Quantitative Authors Academics 
DeJean et al. (2016) [28] Canada Theory General Qualitative Authors HTA professionals and 
academics 
Di Paolo et al. (2017) [56] Italy Theory General Qualitative Authors HTA professionals 
Dipankui et al. (2015) [34] Canada Application General Qualitative Respondents 
and authors 
HTA professionals and 
academics 
Dirksen (2014) [14] NL Theory General Qualitative Authors and 
cited authors 
HTA professionals and 
academics 
Doctor and MacEwan (2017) 
[57] 
US Theory General N/D Authors HTA professionals and 
academics 
Douglas et al. (2015) [63] Canada Theory Orphan drugs Qualitative Authors HTA professionals 
Drummond et al. (2013) [93] US Theory General Mixed Authors HTA professionals 
Ducey et al. (2017) [64] Canada Theory General Qualitative Respondents 
and authors 
HTA professionals and 
academics 
Evers et al. (2016) [47] NL Theory Rare diseases Qualitative Authors HTA professionals and 
academics 
Facey et al. (2014) [98] Scotland Theory Rare diseases Qualitative Authors and 
cited authors 
HTA professionals 
Gagnon et al. (2014) [81] Canada Applications Early HTA Qualitative Authors HTA professionals 
Gagnon et al. (2014) [30] Canada Theory General Qualitative Respondents 
and authors 
HTA professionals 
Gagnon et al. (2015) [83] Canada Theory General Qualitative Respondents 
and authors 
HTA professionals 
Hailey et al. (2013) [42] Australia Theory General Mixed Respondents 
and authors 
HTA professionals and 
academics 
Hämeen-Anttila et al. (2016) 
[53] 
Finland Theory General Qualitative Respondents 
and authors 
HTA professionals and 
academics 
Husereau et al. (2016) [55] Canada Theory General Qualitative Authors HTA professionals 
Iskrov and Stefanov (2016) 
[50] 
Bulgaria Theory General Quantitative Authors HTA professionals and 
academics 
Janssen et al. (2017) [22] US Theory General Authors Authors and 
cited authors 
Academics 
Janssen et al. (2016) [87] Germany Application Hemodialysis Mixed Respondents 
and authors 
HTA professionals and 
academics 
Kennedy-Martin et al. (2015) 
[95] 
UK Theory Diabetic kidney 
disease 
Quantitative Authors HTA professionals and 
academics 
Kievit et al. (2017) [59] NL Theory General Qualitative Authors HTA professionals and 
academics 
Kleme et al. (2014) [92] Finland Theory General Qualitative Authors HTA professionals 
Kreis et al. (2013) [44] Germany Theory General Qualitative Respondents 
and authors 
HTA professionals and 
academics 
Kreis and Schmidt (2013) 
[35] 
Germany Theory General Qualitative Authors HTA professionals 
Li and Ngorsuraches (2014) 
[94] 
US Theory General N/D Authors HTA professionals 
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RQ posed for  
Lopes et al. (2016) [65] Australia Theory General Qualitative Respondents 
and authors 
HTA professionals 
Low (2015) [88] UK Theory General Qualitative Authors Patients and patient 
organizations 
MacLeod et al. (2016) [66] Australia Theory General Qualitative Authors HTA professionals and 
academics 
Moreira (2015) [51] UK Theory Alzheimer Qualitative Authors HTA professionals and 
academics 
Morel and Cano (2017) [82] Belgium Theory Rare diseases Mixed Authors HTA professionals and 
academics 






HTA professionals and 
academics 
Mossman et al. (2017) [58] Belgium Theory General N/D Authors and 
cited authors 
HTA professionals and 
academics 
Mott and Najafzadeh (2016) 
[45] 
UK Application Anticoagulant 
therapy and 
general 
Quantitative Authors HTA professionals and 
academics 
Mühlbacher (2015) [91] Germany Theory General Quantitative Authors HTA professionals and 
academics 
Mühlbacher et al. (2016) [99] Germany Application Acute Coronary 
Syndrome 
Quantitative Authors HTA professionals and 
academics 





HTA professionals and 
academics 
Mühlbacher et al. (2016) [85] Germany Theory General Quantitative Authors HTA professionals and 
academics 
Mühlbacher and Kaczynski 
(2016) [32] 
Germany Theory General Quantitative Authors Academics 
Mühlbacher and Sadler 
(2017) [33] 
Germany Application Hepatitis C Quantitative Authors HTA professionals and 
academics 
Narbutas et al. (2017) [89] Lithuania Theory Cancer care N/D Authors HTA professionals 
Payakachat et al. (2015) [96] US Theory General Quantitative Authors Academics 
Rashid et al. (2017) [29] UK Theory General Mixed Authors HTA professionals and 
clinical guideline 
developers 
Regier et al. (2014) [68] US Theory Oncology N/D Authors HTA professionals 
Scott et al. (2017) [86] Australia Theory General Qualitative Authors HTA professionals and 
patient organizations 
Single et al. (2016) [43] Australia Theory General Qualitative Authors HTA professionals 
Thokala et al. (2016) [46] UK Theory General Quantitative Authors HTA professionals and 
academics 
Tordrup et al. (2014) [52] UK Application General Quantitative Authors HTA professionals and 
academics 










Wahlster et al. (2017) [40] UK Theory and 
application 
Palliative care & 
general 
Both Authors HTA professionals 
Wale et al. (2017) [13] UK Theory General Both  Authors HTA professionals 
Weeks et al. (2017) [54] Canada Theory General Qualitative Respondents HTA professionals and 
academics 
Weernink et al. (2017) [97] NL Application Parkinson's 
Disease 
Quantitative Authors HTA professionals and 
academics 
Whitty (2013) [69] Australia Theory General N/D Respondents 
and authors 
HTA professionals and 
academics 





















This thesis examines critically how patient preference studies are performed, and how this can affect their systematic 
integration into the medical product lifecycle (MPLC). In this chapter, the main findings for each objective will first 
be presented. Next, the scientific and societal implications of these findings will be discussed, alongside contemporary 
theories.  This chapter ends with recommendations for future research.   
 
I. Main Findings 
Objective 1: To examine the current systematic integration of patient preference studies into the medical product 
lifecycle (MPLC), as well as barriers and opportunities to their inclusion. 
The integration of patient preferences throughout the MPLC is a significant step in the goal to strengthen patient-
centric healthcare. This thesis served to examine the current status of patient preferences throughout the MPLC from 
different stakeholder perspectives, and to identify obstacles facing their systematic integration. Overall, it was 
observed that although industry, regulators, HTA bodies, and payers are exploring the use of patient preferences in 
their decision-making processes, the completion and assessment of patient preference studies is limited. 
First, the current decision decision-making processes and decision-points throughout the MPLC for industry, 
regulatory authorities, and HTA/payers were identified (Chapter 1). It was also identified that patient preferences are 
not systematically integrated into any of the 15 identified decision-points, although their potential integration is 
believed by all stakeholders to be greatly beneficial. For industry this includes: 1) selecting and prioritising targets 
and leads, 2) prioritising studies (in early clinical development), 3) prioritising assets (in early clinical development), 
4) optimising and prioritising assets (in late clinical development), 5) regulatory submission and launch, 6) managing 
MPLC and prioritise opportunities. For regulators: this includes 1) submission and validation, 2) scientific opinion, 3) 
commission decision. For HTA/reimbursement this includes: 1) filtration, 2) prioritisation, 3) appraisal, 4) post-
approval filtration, 5) post-approval prioritisation, 6) post-approval appraisal. Secondly, a systematic literature search 
was performed to identify factors and situations influencing the value of patient preference studies, as well as current 
applications throughout the MPLC (Chapter 2). The main factors that contribute to the value of patient preference 
studies related to the degree of careful organisation, design, and conduct of studies, as well as the appropriate 
communication and use of results. It was identified that the use of patient preferences could increase if regulatory 
authorities and HTA/payers would better inform industry about whether and how they would use patient preferences 
in their processes, or state in what situations they find patient preferences most valuable. Although current use of 
patient preferences is limited, there are significant possible applications in discovery, clinical development, marketing 
authorisation, HTA, and post-marketing phases. Thirdly, a qualitative investigation was conducted that identified 16 
critical factors and three situation types (i.e. circumstances) that affect the value and ability of patient preference 
studies to be used in decision-making along the MPLC (Chapter 3).  These critical factors related to: study 
organisation (expertise, financial resources, study duration, ethics and good practices, patient centeredness), study 
design (examining patient and/or other preferences, ensuring representativeness, matching method to research 
question, matching method to MPLC stage, validity and reliability, cognitive burden, patient education, attribute 
development), and study conduct (patients’ ability/willingness to participate and preference heterogeneity). The 
situation types affecting the use of PPS results were related to stakeholder acceptance, market situations, and 
clinical situations. Industry representatives spoke positively about increasing the integration of patient preferences to 
inform decision-making throughout the MPLC, especially in the development of new medical products when patient 
preferences provide real-world context which can inform decision-makers. Regulatory representatives and 
HTA/payers expressed that there is currently a limited acceptance for patient preferences within their decision-making 
processes since there is no recognised nor structured way to include and/or value such information against other criteria 
they use for decision-making. 
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The manner of systematic and scientific integration of patient preferences into HTA appraisal is subject to debate, as 
this part of the thesis demonstrated. A systematic review identified the challenges to integrating patient preferences in 
HTA (Chapter 7), with 37 unique research issues being identified, including methodological, procedural, normative, 
practical, and conceptual issues. The HTA appraisal is a vital decision-point in the MPLC through which patient 
preference studies have been integrated into dossier submissions in the past. According to this chapter, integrating 
patient preferences in HTA are mostly relevant when no singular treatment is considered superior, when the benefits 
of interventions in terms of improving length and quality of life are only marginal, when uncertainty of the treatment 
outcomes is high, when multiple alternatives vary largely in terms of benefit-risk trade-offs, when the preferences are 
expected to be highly heterogeneous, or when the treatment concerns a rare disease that would benefit from HTA.  
 
Objective 2: To appraise different preference exploration and elicitation methods and their suitability to meet 
decision-makers (i.e. regulators, industry, and health technology assessment (HTA) bodies) needs across the 
MPLC. 
One of the most pressing questions when examining patient preference studies is which methods and tools can be used 
to successfully examine patient preferences, how these methods compare to one another, and which are best suited to 
different situations along the MPLC. This thesis aimed to answer these questions.  
First, through a systematic review and international expert interviews, 33 unique preference exploration (qualitative) 
and elicitation (quantitative) methods were identified in peer-reviewed publications over a period of 36 years (Chapter 
4). These methods were grouped into a descriptive taxonomy as individual and/or group techniques, and discrete 
choice-, threshold-, rating-, ranking related-based techniques. There is an overall upwards trend in the number of 
preference studies being published per year, indicating that this is a significantly developing area of scientific research. 
Secondly, in order to identify which methods are most promising to inform decision-making at different decision-
points in the MPLC, representatives of key stakeholder groups (i.e. academia, HTA body or payer, industry, 
physicians, patient organisation members, regulators and health preference research consultants) identified important 
criteria, and subsequently weights, by which to characterise and appraise preference methods according to what is 
most important to them when selecting a method (Chapter 5). Thirteen promising preference exploration (qualitative) 
and elicitation (quantitative) methods were identified as likely to meet decision-makers’ needs at any stage of the 
MPLC. These include focus groups, in-depth interviews, semi-structured interviews, adaptive conjoint analysis, 
discrete-choice experiments / best-worst scaling type 3, (probabilistic) threshold technique, standard gamble, time 
trade-off, best-worst scaling type 1, best-worst scaling type 2, analytical hierarchy process, swing weighting, and 
visual analogue scale. Eight other methods were identified that could have potential, although only for some stages, 
or have a low peer-reviewed publication frequency that decision-makers must consider. These include nominal group 
technique, public meetings, dyadic interviews, test trade-off, starting known efficacy, Q-methodology, outcome 
prioritisation tool, and constant sum scaling.   
 
Objective 3: To critically examine different elicitation methods through empirical evidence by comparing their 
executions and results within the same patient population.  
Two of the methods that were identified as most promising in Chapter 5 were examined more closely in a patient 
preference case study in order to scrutinize their execution and the impact that patient preference data can have towards 
patient-centric decision-making. In Chapter 6, a discrete choice experiment (DCE) and swing-weighting (SW) 
exercise were compared in the same study eliciting preferences for glucose-monitoring devices in a population of 
diabetes patients. Both the DCE and SW point allocation identified the same most important attribute to diabetes 
patients when selecting a glucose-monitoring device. Preference outcomes in both methods were unaffected by the 
order in which they were completed. However, the weights derived from the SW were almost evenly distributed 
regardless of a calculation through point allocation or using the rank order centroid (ROC) method. The SW point 
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allocation had a 1.4-fold difference between the most and least important attribute, while the DCE had a 14.9-fold 
difference. The DCE was better received by participants, and obtained more detailed insights for all attribute-levels, 
making it the preferred method over the SW in this case study. 
 
II. Scientific and Societal Implications  
The systematic integration of patient preferences throughout the medical product lifecycle 
The positive effects for including patient preferences throughout the MPLC are evident by numerous recent studies. 
Patient-oriented product development results in a more targeted and faster development, as well as improved clinical 
trial realisation [1, 2]. Medical devices should also benefit from patient preference information, as current literature 
suggests patient preference information should be seen as additional data during development and submission [66, 67, 
68]. Patient-centric decision-making not only results in better transparency and accountability of medical product 
development, but may also result in better outcomes for patients, improved quality of research and study outcomes 
more relevant to patients, more products developed in line with patients’ needs, and increasing overall well-being [69, 
70, 71].  
Some decision criteria already allow for patient preference information to be incorporated more readily than others, 
but patient preference information is currently not routinely considered one of the requirements for decision-making. 
Information is lacking about when and how to use patient preferences into decision points, with stakeholder-specific 
implementation problems facing industry, regulators, and HTA/payers.  
The integration of patient preference information into industry decision-making appears readily feasible. However, 
patient-based evidence is still not included sufficiently in submission dossiers [1]. The pharmaceutical industry reports 
that it needs more regulatory guidance on how to conduct patient preference studies that will be considered together 
with other evidence in marketing authorisation [9]. Patient input has become a significant commitment for the US 
Food and Drug Administration (FDA), as they have issued guidance for its use and transparency in decision-making. 
In 2012, the FDA initiated a Patient-Focused Drug Development initiative [73] with the aim of gathering patient 
perspectives regarding available treatments in a systematic away. Additionally, the FDA Center for Devices and 
Radiological Health (CDRH)  recommended that “patient tolerance for risk and perspective on benefit” be considered 
in regulatory approval applications, especially the risks that are acceptable in exchange for a probable benefit, from 
the patients’ perspective [11, 12].  
The European Medicines Agency (EMA) similarly values the perspectives of patients and are committed to 
encouraging patient input throughout medicine development and product reviews [76]. The organisation has a history 
of engaging with patient preference studies in order to examine patients’ willingness-to-accept risks and benefits, 
values, including the trade-off between various side-effects and efficacy [14, 7]. However, patient representation 
usually comes in the form of a few patients sitting on advisory boards or decision-making committees [1]. Both EMA 
and FDA play an important role in providing guidance to industry and HTA/payers on how to best incorporate patient 
preference information in future assessments [78, 79]. There is a general consensus that patient preference information 
cannot be the sole justification behind a decision, and must be evaluated alongside effectiveness evidence and legal 
considerations [7]. These regulatory requirements for patient preference studies remains unclear or vague [17]. For 
example, regulatory guidelines such as those issued by the CDRH, require patient preference data to satisfy many 
standards of scientific evidence [7]. However, the ability of current methodologies to meet these requirements is 
unclear [17]. Indeed, industry leaders have called for better methodological standardisation [9]. 
Patient preferences have an opportune means of access during HTA/payer decision-points, particularly during 
appraisal when criteria for decision-making include the consideration of the disease burden and social impact on 
patients, as identified in Chapter 1. Mechanisms exist to collect preferences from patients that help identify and select 
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potential HTA/payer topics that are most important or pressing (Chapter 1), which is supported supported by 
examples of HTA/payers formally reviewing patient preferences as part of dossiers in the past ten years [11]. However, 
the integration of patient preferences at this decision point remains challenging, and often, controversial. HTA/payer 
bodies still prioritise patient involvement in the form of individual representatives, and critics claim that examples of 
HTA/payer bodies actually reviewing patient preference data or allowing product labels to integrate this data are far 
too infrequent [1]. The missions of various HTA/payer bodies varies, but most will have the objective of procuring 
the best ‘value for money’ due to the rising demand for the equitable allocation of limited financial resources [18]. 
This value includes not only the patient perspective, but also aims to align the societal, health-system, and industry 
perspective [19]. A significant issue is the question of whose preferences for health states should be used. It was 
observed that there is often a misconception among HTA/payer representatives that patient preferences are sufficiently 
accommodated through quality-adjusted life years (QALYs), despite their calculation frequently incorporating public 
preferences, and not patient preferences (Chapter 1). Indeed, preferences are derived more commonly from the 
general public, justified by the idea that these preferences reflect the societal perspective, and those who pay for 
healthcare services is most healthcare systems [20]. On the other hand, patients have the best understanding of the 
experience of their own health states, compared to asking the general public to imagine it. Some health economists 
support the idea that QALYs should integrate both patient and public preferences [20].  
Overall, greater discussion and collaboration is required between key stakeholders, especially through 
recommendations from regulators and HTA/payers in order to consolidate efforts to integrate patient preference 
information. Recommendations are needed regarding the amount of weight assigned to patient preferences relative to 
other criteria such as efficacy, clinical effectiveness, cost-effectiveness, and safety, and whether this should be adapted 
on a case-by-case basis depending on the severity or mortality of the disease. Recommendations are also needed to 
inform all decision-makers about how best to capture patient preferences, which methods to use, who should best 
conduct patient preference studies in order to avoid potential bias, how to interpret the results, and satisfy particular 
decision criteria for each decision-point. 
 
Measuring patient preferences throughout the medical product lifecycle 
Other publications concerning which methods can be used to measure patient preferences are either significantly 
outdated [84] or ignore exploration methods all together [22]. Exploration methods should not be underestimated in 
their ability to develop the understanding of patient experiences and preferences through an inductive ‘ground up’ 
approach [23]. Qualitative methodologies rely on subjective experiences and perspectives of participants in order to 
observe phenomena with context and detail. This is particularly relevant for identifying unmet needs and the feasibility 
of various medical products fitting into a patient’s life, especially during discovery and ideation phases of product 
development [7]. Mixed method approaches are suggested to be a more robust, complete technique for early drug 
development, with quantitative research being ‘built’ on robust qualitative insights, although this depends on the 
particular methods used [1]. The way that elicitation methods quantify benefit-risk trade-offs are more practical for 
reporting the preferences of large patient populations, and they facilitate direct comparisons for drug approval 
decisions [24]. The FDA benefit-risk assessment framework, which identifies key decision factors such as severity of 
the condition, current treatment options, benefit, risk, and risk mitigating safety concerns, recommends characterising 
the available patient preference data as quantitatively as possible [25].  
More diverse preference elicitation methods are being used now than in earlier years (Chapter 4). The diversity of 
preference elicitation methods has led to uncertainty regarding how these methods compare. An important step is 
identifying the manner of their data collection and the similarities during data collection. It is not appropriate or 
accurate to directly compare all elicitation methods to exploration methods as though they are equivalent techniques 
due to the differences in presentation, framing, and analysis [18]. The taxonomy developed in Chapter 4 revealed 
consensus with other proposals [26, 27, 28], although there are many different ways through which methods can be 
grouped. A question often posed, is which methods are better suited for different stages of the MPLC [17]. This is 
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especially relevant when it has been recommended that chosen methods should be “designed to fit within existing 
processes of decision-making” in order for it to not cause delays or disruptions [18]. The output of some methods, 
such as the DCE, are helpful when directly comparing the determinants of preferences for healthcare interventions or 
products, but the relative utilities derived from the method are intervention-specific and cannot be compared across 
different diseases or products. Although uptake rates and willingness-to-pay can be helpful for cost-effectiveness 
analysis and budget impact analysis, these methods do not directly solve the issue of limited resource allocation. It 
has been proposed that preference weights of preference elicitation methods, such as the DCE or the analytic hierarchy 
process (AHP), be integrated as value measurements into a multi-criteria decision analysis (MCDA) for successful 
healthcare decision-making [29].  
Another question is which methods are better suited for different disease populations [17]. For example, incorporating 
the preferences of rare disease patients into decision-making is particularly valuable, especially when there are limited 
treatment options or severe risk profiles [30]. One category of questions posed by the MDIC when evaluating patient 
preference methods relates to sample sizes, including the minimum sample size needed to detect preferences 
sufficiently, without compromising representativeness and generalisability [22]. Therefore, this necessitates methods 
that can deliver robust, valid results with a small sample size, which this thesis identified 25 capable of doing, after a 
critical appraisal and collation (Chapter 5).  
The issue of choosing a method has often been described as a trade-off in itself between the cognitive burden for 
participants and the possibilities for analysis [31]. Only 17 out of the 33 methods appraised in Chapter 5 were 
described by health preference researchers as being suitable for a low cognitive burden. A lower cognitive burden in 
a method has a positive effect on data quality and accuracy, as well as increasing the overall response rate [32]. A 
difficult cognitive task can result in measurement error [33], and the CDRH guidance recommends minimal cognitive 
bias in order for the data to be relevant and credible for regulatory decisions [11].  
Crucially, there is no one-size-fits-all approach for selecting an appropriate method, especially when needing to answer 
a specific research question. All methods come with advantages and disadvantages. However, it is exceptionally 
important that methods meet multiple decision-makers’ needs, not merely the needs of the stakeholder group 
performing the study. It has been suggested that selected preference elicitation or exploration methods should be pre-
agreed upon by the pharmaceutical companies, the regulator, and by any pertinent patient groups [18]. Therefore, the 
thirteen most promising methods, identified in Chapter 5 to meet all stakeholder needs throughout the MPLC, require 
closer examination through head-to-head studies.  
  
Empirical evidence examining patient preference exploration and elicitation methods 
It has often been asked whether different methods lead to the same conclusions when answering the same research 
question [17]. This a pressing issue that would help decision-makers decide which methods would be best suited for 
their research questions, and worth investing significant time and resources. For example, previous literature 
comparing a discrete-choice experiment (DCE) and swing-weighting (SW), two methods identified in Chapter 5 as 
most promising, has been lacking [34, 35]. 
Rating methods, such a SW, are often regarded as the simplest approach to eliciting patient preferences since they do 
not force trade-offs [36]. In fact, rating methods are not observed to be easy cognitive tasks due to the involvement of 
a predetermined numerical scale, and the complexity of applying it against multiple attributes [37]. Incorporating point 
allocation into SW is often praised for allowing respondents to judge attributes by the strength of their own preference, 
‘provid[ing] information on relative importance, whilst remaining relatively uncomplicated’ [18]. However, there does 
not appear to be consensus about how the point allocation should be administered, and other SW techniques ask 
participants to designate a proportion of 100 points, meaning all attribute weights must add up to 100 [36]. In case of 
seven attributes, this would provide an unnecessary numerical burden if participants had to monitor the total sum score 
while awarding points. Methods such as SW have fundamental methodological weaknesses, due to their tendency to 
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discriminate poorly among attributes, causing any values to have insufficient variability [33]. If participants report 
that all attributes were important, which they are allowed to do due to the absence of pairwise comparisons, this can 
discriminate poorly among the attributes, causing the weights to be evenly distributed [33, 38].  
It has been theorised that direct pairwise comparisons in a DCE are easier for patients than a direct numerical 
assessment of relative value present in SW [34]. Essentially, it is easier to say which of two attributes is more 
important, rather than trying to quantify how much more important it is [102]. The value of trade-off information 
obtained through direct comparisons of attributes cannot be underestimated, and for this reason choice-based methods 
are often favoured over ranking and rating methods [84]. DCEs ‘decompose’ treatment or medical product alternatives 
into specific attributes describing the element that are most influential to patient decisions, making it possible to 
quantify preferences [33]. The total utility-difference between two alternatives, or between an alternative and the status 
quo, can be calculated and it becomes possible to determine potential uptake rates and market shares based on 
combinations of attributes associated with different treatment profiles [33].  
From the researcher’s perspective, the DCE may appear more complex compared to the SW in terms of design and 
analysis; however, the DCE is in fact the simpler method to understand and complete from the respondent’s 
perspective. A SW might still be a viable alternative in cases when the number of attributes cannot be feasibly 
integrated into a DCE [32], or when a sample size is too small for a DCE, such as in the case of rare diseases [41]. 
Future research should examine DCE and SW in more head-to-head studies with different populations, different 
medical products treatments, and different decision contexts in order to examine if the same weight distribution occurs. 
Variations of the SW point allocation should be examined, reducing the number of attributes, or forbidding attributes 
being allocated the same number of points. This would help conclude whether point allocation adds meaningful 
quantitative insight into preferences, or merely adds cognitive burden to respondents. 
  
III. Future Scientific Challenges 
There are several future challenges to the systematic integration of patient preferences into the MPLC which have 
emerged from this thesis, but the two most pressing ones related to the successful integration of HTA/payer decision 
points, and the unresolved methodological problems regarding patient elicitation preference methods.  
Firstly, patient preferences have a significant opportunity to be integrated into HTA/payer dossiers, but their success 
is limited or lagging behind. It has been suggested that ‘substantive changes’ are needed in order for HTA/payers to 
catch up with regulatory decision-making in this area, with the main focus being on how to weight patient preference 
information in assessment procedures [42]. As mentioned in the previous section regarding scientific and societal 
implication, an issue in need of resolution is the debate regarding public versus patient preferences in health economic 
evaluations [43, 44]. Further exploration of QALYs calculated exclusively through patient preferences and QALYs 
calculated through both patient and public preferences is needed. Moreover, an important topic of discussion concerns 
whether patient preferences should be incorporated within the QALY or alongside it. Studies have been conducted to 
anchor preference elicitation methods such as time trade-off, standard gamble, and even DCEs, to a QALY scale [45]. 
However, current value measures like QALYs, EuroQol five dimensions (EQ-5D) [46], and other Quality of Life 
measures do not sufficiently cover the patient perspective, and do not encompass the same values as patient preference 
information [32]. For example, they only describe the benefit of generic quality-of-life dimensions rather than all 
factors that are important to specific patients [47], or they frequently incorporate public utility values for quality of 
life attributes, as opposed to patient utilities for treatment outcomes [48]. A possible resolution is to include outcome 
measures beyond the QALY. QALYs only capture a subset of benefits that could be created by a healthcare 
intervention of product, and neglect other important elements which could be used in economic assessments including 
"reduction in uncertainty, fear of contagion, insurance value, severity of disease, value of hope, real option value, 
equity, and scientific spillovers" [49]. Therefore, future research should be conducted to investigate how patient 
preference studies can add to, or even replace, the QALY paradigm, in order to sufficiently secure their place in 
HTA/payer decision-points.  
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Secondly, this thesis has critically evaluated the current preference elicitation and exploration methods that have been 
used in studies for the past 30 years. Indeed, methodological issues were the most cited challenge to their successful 
integration into HTA overall (Chapter 7), not only regarding the choice of method but also how to address preference 
heterogeneity, compare multiple alternatives with a variety of different benefit-risk profiles, and accommodate small 
sample sizes from a rare disease population. Although matching the optimal method to the study’s research question 
is vital, the lack of standard methods being employed across the MPLC makes it difficult to compare studies across 
disease types, limiting their value for HTA/payer reimbursement decisions [42]. Therefore, it must be examined 
whether, and how, different weights or values obtained through different methods can be directly compared to one 
other. More head-to-head comparisons within the patient preference studies are needed in order to sufficiently resolve 
several methodological questions and to determine the best standard practices for various situations in the MPLC. 
Other limitations of the various elicitation and exploration methods must be examined, including the potential for 
innumeracy, respondents resorting to heuristic or cognitive shortcuts due to excessive burden, the handling of variation 
among subgroups, measurement error, and hypothetical bias [24].  
 
IV. Overall Conclusion 
Patient preferences are a significant concept within the field of health research. They are critical for the successful 
development, regulation, and reimbursement of medical products and creating patient centric decision-making within 
the MPLC. However, it cannot be ignored that there are multiple systemic challenges towards their integration into 
the MPLC, with many of them hinging on greater clarity being needed by key stakeholders, before they can be 
successfully incorporated into decision-making. 
Patient preferences can be measured through a variety of different preference elicitation and exploration methods and 
decision-makers are eager to discover which methods would suit their needs, and be the most acceptable for market 
authorisation submissions or HTA/payer reimbursement decisions. Although there is no ‘gold-standard’ patient 
preference elicitation or exploration method, some methods have more promising features, and are probably more 
likely to meet decision-makers needs across the MPLC. This includes preference elicitation methods such as the DCE 
and SW. However, it is important that future research examines more methods head-to-head, both in terms of their 
precision and patient acceptability, as it was revealed during a patient preference study that a DCE was the superior 
method to the SW.  
In conclusion, patient preferences have significant contribution to the development, regulation, and reimbursement of 
medical products. In addition to encouraging treatments that are effective, safe, and cost-effective, the incorporation 
of the patient voice is essential to improving lives. The development of methodologically sound patient preference 
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Patient preferences refer to the idea that patients evaluate elements of healthcare based upon their experiences, values, 
and attitudes, and these preferences can influence their healthcare decisions. These elements can include the relative 
benefits, harms, costs, and important outcomes resulting from different medical treatments, products situations, and 
decisions. According to the Federal Drug Association (FDA), patient preference information is defined as information 
resulting from “assessments of the relative desirability or acceptability to patients of specified alternatives or choices 
among outcomes or other attributes that differ among alternative health interventions”.  
Patient preference information can be identified through both qualitative and quantitative research methods, including 
social surveys, experiments, case studies, interviews, and other forms of participant observation.  However, it is still 
unclear what constitutes a methodologically sound patient-preference study, and how different methods compare to 
one another. This is especially relevant for determining how the functions of their methodologies can influence the 
manner in which data is obtained, analysed, and reported. In order for patient preference studies to be sufficiently 
acknowledged within the field of healthcare research, and for their role in the MPLC to be enhanced, greater clarity 
is needed concerning how patient preference information is investigated.  
Benefit-risk assessments are often described as the ‘foundation’ for medical product decision-making and patient 
preferences can significantly contribute towards their input. Other applications for patient preferences include the 
identification of new medical products, identifying unmet medical needs, regulatory approval submissions, and health 
technology assessments. A complete overview of the influence and impact of patient preference information at every 
stage of the medical product lifecycle (MPLC) is necessary to determine when it can have the greatest effect and to 
whom. Additionally, this would help determine where patient preference information is needed, but not currently 
implemented, and which phases stand to benefit from this vital information.   
This thesis aims to critically examine how patient preference studies are performed, and how this can affect their 
systematic integration into the MPLC. These aims can be specified in three detailed objectives:  
1. To examine the current systematic integration of patient preference studies into the MPLC, as well as barriers 
and opportunities to their inclusion 
2. To appraise different preference exploration and elicitation methods and their suitability to meet decision-makers 
needs across the MPLC 
3. To critically examine different elicitation methods through empirical evidence by comparing their executions 
and results within the same patient population  
 
Part I: The Systematic Integration of Patient Preferences throughout the Medical Product Lifecycle  
Through a scoping literature review, semi-structured interviews with representatives from seven European countries 
and the US (n=70), and validation meetings, the current decision-making processes and decision-points throughout 
the medical product lifecycle (MPLC) for industry, regulatory authorities, and health technology assessment 
(HTA)/payers were identified (Chapter 1). A critical decision point is an identified fixed moment where a decision 
influences the course of the medical product development, authorisation or reimbursement process. Six critical 
decision-points for industry decision-making, three for regulatory decision-making, and six for HTA/payers decision-
making were identified in the MPLC as having the potential to integrate patient preference information. For industry 
this includes: 1) selecting and prioritising targets and leads, 2) prioritising studies, 3) prioritising assets, 4) optimising 
and prioritising assets, 5) regulatory submission and launch, 6) managing MPLC and prioritise opportunities. For 
regulators: this includes 1) submission and validation, 2) scientific opinion, 3) commission decision. For 
HTA/reimbursement this includes: 1) filtration, 2) prioritisation, 3) appraisal, 4) post-approval filtration, 5) post-
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approval prioritisation, 6) post-approval appraisal. Stakeholder groups agreed that patient preference information is  
not systematically integrated, either as obligatory information or pre-set criteria, but would benefit all 15 decision-
points in the future. This indicates that all decision-points for all stakeholders have the potential to integrate patient 
preferences. Ultimately, continued discussion between key stakeholders is needed to successfully implement patient 
preference information into decision-making. These critical factors related to: study organisation (expertise, financial 
resources, study duration, ethics and good practices, patient centeredness), study design (examining patient and/or 
other preferences, ensuring representativeness, matching method to research question, matching method to MPLC 
stage, validity and reliability, cognitive burden, patient education, attribute development), and study conduct (patients’ 
ability/willingness to participate and preference heterogeneity). The situation types affecting the use of patient 
preference study results were related to stakeholder acceptance, market situations, and clinical situations. 
Industry, regulators, HTA bodies, and payers are exploring the use of patient preferences in their decision-making 
processes; however, the completion and assessment of patient preference studies is limited (Chapter 2). A systematic 
literature search was performed to identify factors and situations influencing the value of patient preference studies, 
as well as applications throughout the medical product lifecycle. The main factors that contribute to the value of patient 
preference studies, identified in 113 publications, related to the degree of careful organisation, design, and conduct of 
studies, as well as the appropriate communication and use of results. Although current use of patient preferences is 
limited, we identified possible applications in discovery, clinical development, marketing authorisation, HTA, and 
postmarketing phases. 
This was followed by a qualitative investigation which included a scoping review, 143 semi-structured interviews, 
and eight focus groups with stakeholders in seven European Union countries and the United States (Chapter 3). 
Sixteen critical factors and three situation types (i.e. circumstances) were identified that affect their value and ability 
to be used in decision-making along the MPLC. The factors influencing the value of patient preference studies for 
decision-making that were identified related to: study organisation, study design, and study conduct. Three types of 
situations affecting the use of patient preference results were identified that related to stakeholder acceptance of patient 
preference information, market situations in which a decision needs to be made, and clinical situations surrounding 
the decision. Industry representatives spoke positively about increasing the integration of patient preference 
information to inform decision-making throughout the MPLC, especially in the development of a new medical 
products when patient preference information can provide real-world context which can inform decision-makers. 
Regulatory representatives and HTA/payers expressed that there is currently a limited acceptance for patient 
preference information within their decision-making processes since there is currently no recognized nor structured 
way to include and/or value such information against other criteria they use for decision-making.  
 
Part II: Measuring Patient Preferences throughout the Medical Product Lifecycle  
Through a systematic review and international expert interviews, 32 unique preference exploration (qualitative) and 
elicitation (quantitative) methods were identified in peer-reviewed publications over a period of 36 years (Chapter 
4). These methods were grouped into a descriptive taxonomy as individual and/or group techniques, and discrete 
choice-, threshold-, rating-, ranking related-based techniques. 
One of the most pressing questions when examining patient preference studies is which methods and tools can be used 
to successfully examine patient preferences.  In order to identify which methods are most promising to inform 
decision-making at different decision points in the MPLC, representatives of key stakeholder groups identified 
important criteria, and subsequently weights, by which to characterise and appraise preference methods according to 
what is most important to them when selecting a method (Chapter 5). Thirteen promising preference exploration 
(qualitative) and elicitation (quantitative) methods were identified as likely to meet decision-makers’ needs at any 
stage of the MPLC. This includes focus groups, in-depth interviews, semi-structured interviews, discrete choice 
experiments/best-worst scaling type 3, adaptive conjoint analysis, (probabilistic) threshold technique, standard 
gamble, time trade-off, best-worst scaling type 1, best-worst scaling type 2, swing weighting, visual analogue scale, 
156 
 
and analytical hierarchy process. Additionally, eight other methods were identified that could have potential, although 
only for some stages, or have a low peer-reviewed publication frequency that decision-makers must consider. There 
is no one-size-fits-all approach for selecting an appropriate method, especially when needing to answer a specific 
research question. However, the critically evaluated and collated methods have been observed to be most successful 
when implemented. 
 
Part III: Empirical Evidence Examining Patient Preference Exploration and Elicitation Methods 
There are few studies directly comparing a discrete-choice experiment (DCE) with swing-weighting (SW) and more 
head-to-head studies are needed to directly compare preference elicitation methods in order to determine whether they 
lead to the same conclusions when answering the same research question. In Chapter 6, a DCE was compared with a 
SW by eliciting preference for glucose-monitoring devices in a population of 459 diabetes patients. Both methods 
identified that cost was the most important attribute when selecting a device, followed by the precision of the device. 
However, the weights derived from the SW, regardless of a calculation through point allocation or rank order centroid 
(ROC) method, were almost evenly distributed between the attributes. However, the DCE had a 14.9-fold difference 
between the most and least important attribute, while the SW had a 1.4-fold difference. The DCE was better received 
by participants, and generated larger weight differences between each attribute level, making it the more informative 
method in our case study. This method comparison provides further evidence of the degree of method suitability and 
trustworthiness of these methods for measuring preferences for decision-making.  
 
Part IV: The Future of Patient Preferences in HTA 
A systematic review of 2,147 retrieved articles was performed to identify the challenges to integrating patient 
preferences in HTA (Chapter 7). Thirty-seven unique research issues were identified. In the majority of articles, 
methodological issues were posed (82%), followed by procedural (73%), normative (51%), practical (24%), and 
conceptual (9%) issues. Frequently posed methodological issues concerned preference heterogeneity and choice of 
method. Common procedural issues concerned how to evaluate the impact of preference studies and their degree of 
being evidence based. 
 
General Discussion and Conclusions 
Patient preferences are a significant concept within the field of health research. They are critical for the successful 
development, regulation, and reimbursement of medical products and creating patient centric decision-making within 
the MPLC. However, it cannot be ignored that there are multiple systemic challenges towards their integration into 
the MPLC, with many of them hinging on greater clarity being needed by key stakeholders, before they can be 
successfully incorporated into decision-making. 
Patient preferences can be measured through a variety of different preference elicitation and exploration methods and 
decision-makers are eager to discover which methods would suit their needs, and be the most acceptable during market 
authorisation submissions or during HTA/payer reimbursement decisions. Although there is no ‘gold-standard’ patient 
preference elicitation or exploration method, some methods have more promising features, and are probably more 
likely to meet decision-makers needs across the MPLC. This includes preference elicitation methods such as the DCE 
and SW. However, it is important that future research examines more methods head-to-head, both in terms of their 
precision and patient acceptability, as it was revealed during a patient preference study that a DCE was the superior 
method to the SW.  
In conclusion, patient preferences have significant contribution to the development, regulation, and reimbursement of 
medical products. In addition to encouraging treatments that are effective, safe, and cost-effective, the incorporation 
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of the patient voice is essential to improving lives. The development of methodologically sound patient preference 





Many invaluable people have been involved with the creation of this dissertation. Firstly, I would like to thank my 
promoter, Prof. Dr. Maureen P.M.H. Rutten-van Mölken and co-promotors Dr. Esther W. de Bekker-Grob. During 
the past 4 years, I have learnt so much from the both of you. I am grateful for the opportunity that you gave me to 
pursue this research.  
 
Esther, thank you for the unbelievable academic and emotional support over the past 4 years. It was an honour to have 
the opportunity to learn from you. Your passion, knowledge, and dedication is inspirational. Thank you for always 
making time for me and always having the patience to explain even minute details of econometrics to me. Thank you 
for taking a chance me 4 years ago and helping us start a new life in Rotterdam.  
 
Maureen, thank you for believing in my abilities four years ago, and for all the support and time you have given. 
Thank you for supporting the diabetes project and always offering exceptional expertise and patience.  
 
Jorien, thank you for becoming a surrogate supervisor to me over the past few years. Your expertise was invaluable 
and appreciated at every turn. Thank you for being so approachable for giving advice and supporting the diabetes 
study so much.  
 
Thank you especially to my co-authors, Eline van Overbeeke, Karin Schölin Bywall, Samare P.I. Huls, Ian P. Smith, 
Ardine de Wit, Rosanne Janssens, Selena Russo, Irina Cleemput, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, 
Isabelle Huys, Meredith Smith, Richard Hermann, Mattias Englbrecht, Axel J. Hueber, Alina Comaneuscu, Sarah 
Harding, Jonathan Mauer, Stephen Watt, Vaishali Patadia, Rachael DiSantostefano, Cathy Anne Pinto, Steven 
Simoens, Job van Exel, and Carin A. Uyl-de Groot. It has been an honour being able to work with you and thank you 
for your knowledge and exceptional efforts.  
 
This thesis would not be possible without the support from the Patient Preferences in Benefit-Risk Assessments during 
the Drug Life Cycle (PREFER) project, which receives funding from the Innovative Medicines Initiative. For the 
research in this thesis, I would like to thank all members of the PREFER project for their input and support. I would 
like to thank the following for their expertise: Mario Mendoza (Pfizer), Suchitra Iyer (Agency for Healthcare Research 
and Quality), Harald Enzmann (EMA), Francesco Pignatti (EMA), Iordanis Gravanis (EMA), Telba Irony (FDA), 
Laura Lee Johnson (FDA), Anindita Saha (FDA), Frank Breitenbücher (TÜV Rheinland LGA Products GmbH), 
Tomas Byström (Swedish Medical Product Agency), Judith Gulpers (Erasmus University Rotterdam), Filip Mussen 
(Janssen Research & Development), Mats G Hansson (Uppsala University), Ulrik Kihlbom (Uppsala University), 
Sheila Dickinson (Novartis), Michel Goldman (I3h Institute, Université libre de Bruxelles), Jenny Sharpe (Muscular 
Dystrophy UK), Nikoletta Nikolenko (Newcastle University), Isabelle Manneh-Vangramberen (European Cancer 
Patients Coalition), Hanns Lochmuller (Newcastle University), Nigel Cook (Novartis), Ardine de Wit (University 
Medical Centre, Utrecht University), Ateesha Mohamed (Bayer), Mats Hansson (Uppsala University), Conny Berlin 
(Novartis), Wichor Bramer (Erasmus MC), John Bridges (Johns Hopkins Bloomberg School of Public Health), 
Benjamin Craig (International Academy of Health Preference Research), J.M. Gonzalez (Duke University), Tarek 
Hammad (EMD Serono), Brett Hauber (RTI Health Solutions), Reed Johnson (Duke University), Stiggelbout (Leiden 
University Medical Center), Mariska Hackert (Erasmus University Rotterdam), Hal Forman (Expert Choice), Andrea 
Beyer (Actelion), Bas Donkers (Erasmus University Rotterdam), Martin Gebel (Bayer), Nigel Cook (Novartis), 
Ateesha Mohamed (Bayer), Jerzy Tyczynski (Abbvie), Zhong Yuan (Janssen), and Cecilia Jimenez Moreno 
(Newcastle University). Special thanks to Guildhawk Ltd (formerly Today Translations) and SurveyEngine for their 
services.  
 
It’s easy to reduce patients to numbers, and to make sweeping conclusions about what we think they would want, or 
what would be most convenient for them to want. Patient preference research really belongs to the patients, and to all 
the vulnerable patients who still feel unheard, disbelieved, or ignored. As researchers and scientists, it is our 
responsibility to give them a voice and be the bridge between the biomedicine (especially when it’s out of reach), and 
their daily lives.   
 
Thank you to the other PhDs who worked next to me (even briefly) in J8-11 and always offered a patient ear to listen, 




I’d like to express gratitude to Dr Nicole Bourque who is dearly missed, and without whom I would not have been 
able to pursue my interest in global health in the first place.  
Thank you to my parents for their continued support of me and my education, even if it means I live on the other side 
of the planet. Thank you to my in-laws for welcoming me into a lovely new family in 2019.  
And to my wife, Emmy Kat, ‘I would not wish any companion in the world but you.’ You have been my superheroine 
since the day we met, and especially on the day we sat down and wrote a pro-and-con list of moving to the Netherlands 
and doing this PhD. I am overwhelmed by the love, support, and courage you have given me every single day, and the 
sacrifices you have made to be with me while I finish this leviathan. On to our next adventure! 
 






List of Publications 
 
2019 
Whichello C*, Overbeeke E*, Janssens R, Schölin Bywall K, Russo S, Veldwijk J, Cleemput I, Juhaeri J, Levitan B, 
Kübler J, Smith M, Hermann R, Englbrecht M, Hueber AJ, Comaneuscu A, Harding S, Simoens S, Huys I, de 
Bekker-Grob EW, “Factors and situations affecting the utility of patient preference studies: semi-structured 
interviews in Europe and the US” Frontiers in Pharmacology: Pharmaceutical Medicine and Outcomes Research, 
2019, 10:1009.  
van Overbeeke E*, Whichello C*, Janssens R, Veldwijk J, Cleemput I, Simoens S, Juhaeri J, Levitan B, Kübler J, de 
Bekker-Grob E, Huys I, “Factors and situations influencing the value of patient preference studies along the medical 
product lifecycle: a literature review” Drug Discovery Today, 2019, 24:1, p. 57-68. 
Soekhai V*, Whichello C*, Levitan B, Veldwijk J, Pinto C, Gonzalez J, Donkers B, van Overbeeke E, Huys, I, Juhaeri 
J and de Bekker-Grob EW, “Compendium of methods for exploring and eliciting patient preferences in the medical 
product and medical device life cycle” Drug Discovery Today, 2019, 24:7, p.1324-1331. 
Huls, SPI, Whichello C, van Exel NJA, Uyl-de Groot, CA, de Bekker-Grob EW, “What is next for patient preferences 
in Health Technology Assessment? A systematic review” Value in Health, 2019, 22:11, p.1318-1328. 
van Overbeeke E, Janssens R, Whichello C, Schölin Bywall K, Sharpe J, Nikolenko N, Phillips B, Guiddi P, 
Pravettoni G, Vergani L, Marton G, Cleemput I, Simoens S, Kubler J, Juhaeri J, Levitan B, de Bekker-Grob EW, 
Veldwijk J, Huys I. “Design, conduct and use of patient preference studies: A multi-method study” Frontiers in 
Pharmacology: Pharmaceutical Medicine and Outcomes Resesarch, 2019, 10:3389.   
Janssens R, Russo S, van Overbeeke E, Whichello C, Harding S, Kubler J, Juhaeri J, Schölin Bywall K, Comanescu 
A, Hueber A, Englbrecht M, Nikolenko N, Pravettoni G, Simoens S, Stevens H, Hermann R, Levitan B, Cleemput 
I, de Bekker-Grob EW, Veldwijk J, Huys I. “Patient preferences in the medical product lifecycle: what do 
stakeholders think? Semi-structured interviews in Europe and the US” The Patient, 2019, 12:5, p.513-526. 
Janssens R, Huys I, van Overbeeke E, Whichello C, Harding S, Kübler J, Juhaeri J, Ciaglia A, Simoens S, Stevens H, 
Smith M, Levitan B, Cleemput I, de Bekker-Grob EW, Veldwijk J. “Opportunities and challenges for the inclusion 
of patient preferences in the medical product life cycle: a systematic review.” BMC Medical Informatics and 
Decision-making, 2019, 19:189.  
2020 
Whichello C, Levitan B, Juhaeri J, Patadia V, DiSantostefano R, Pinto CA, de Bekker-Grob EW. “Appraising patient 
preference methods for decision-making in the medical product lifecycle: An empirical comparison” BMC Medical 
Informatics and Decision Making, 2020, 20:114 
Whichello C*, Schölin Bywall K*, Mauer J, Watt S, Cleemput I, Pinto CA, van Overbeeke E, Huys I, de Bekker-
Grob EW, Hermann R, Veldwijk J, “An overview of critical decision points in the medical product lifecycle: where 
to include patient preference information in the decision-making process?” Health Policy, In Press.  
Whichello C, Smith IP, Veldwijk J, de Wit AG, Rutten-van Molken MPMH, de Bekker-Grob EW. “Discrete choice 
experiment verss swing-weighting: A head-tohead comparison” (submitted to journal Aug 2020).  
 
* Denotes joint first authorship   
161 
 
Portfolio: Summary of PhD training and teaching activities  
 
   
International Conference Presentations  
Oct 2015 Oral presentation IMI PREFER Annual Conference – Basel 
Oct 2017 Oral presentation IMI PREFER Annual Conference – Basel  
May 2018 Oral presentation IMI PREFER Case Study Workshop – Berlin 
May 2018 Oral presentation lolaHESG (Lowlands Health Economists’ Study Group) – Utrecht  
Jun 2018 Oral presentation PSI (Statisticians in the Pharmaceutical Industry) – Amsterdam  
Jun 2018 Oral presentation SMDM (Society for Medical Decision Making) – Leiden  
Aug 2018 Two posters ICPE (International Conference for Pharmacoepidemiology) – Prague  
Oct 2018 
Oral presentation & 
Poster* 
IMI 10th Anniversary Scientific Symposium – Brussels  
Oct 2018 Oral presentation IMI PREFER Annual Conference – Leuven  
Nov 2018 Two posters ISPOR (Int’l Society for Pharmacoecomonics & Outcomes Research) – Barcelona  
May 2019 Oral presentation lolaHESG (Lowlands Health Economists’ Study Group) – Almen  
Jul 2019 Poster IAHPR (International Academy of Health Preference Research) – Basel  
Oct 2019 Oral presentation IMI PREFER Annual Conference – Basel  
Nov 2019 Poster ISPOR (Int’l Society for Pharmacoecomonics & Outcomes Research) – Copenhagen 
 




2018 - Pharmaceutical Pricing and Market Access  
2019 - Measuring Patient Preferences Using Discrete Choice Experiments 
 
2019 - Pharmaceutical Pricing and Market Access 
2020 - Measuring Patient Preferences Using Discrete Choice Experiments 
 








Sep 2017 - Erasmus University Rotterdam 
 
Professionalism and Integrity in Research 
Sept 2017 – Erasmus University Rotterdam 
 
Measuring Patient Preferences Using Discrete Choice Experiments 
Mar 2018 - Erasmus University Rotterdam 
  
Q-methodology   
Nov 2018 - Erasmus University Rotterdam 
  
Choice Modelling & Stated Choice Survey Design 
Nov 2018 - University of Leeds 
 
Group Dynamics in the Classroom  
Mar 2019 - Erasmus University Rotterdam 
 
Brush Up Your SPSS Skills 
Jan 2020 – Erasmus University Rotterdam 
 
Data Analysis in R 














Chiara Lauren Whichello was born on 13 January 1991 in Vienna, Austria to Australian parents. She 
completed the International Baccalaureate Diploma at the American International School of Vienna in 
2009, obtaining 40 points, and was awarded the Principal’s Award for Excellence. She completed a 
Certificate of Higher Education in English Law at the University of Dundee before relocating to Glasgow. 
In 2014, she obtained an MA in Anthropology and Sociology (1st Class Honours) at the University of 
Glasgow, with a particular interest in medical anthropology. During these studies, she also completed an 
internship at the Comprehensive Nuclear-Test-Ban Treaty Organisation in Vienna and worked as an events 
manager in Glasgow. In 2015, she obtained an MSc in Global Health (with Merit) and completed a research 
thesis examining the impact of poor housing conditions and disease vectors upon health and perceptions of 
hygiene in Govanhill, Glasgow. In 2016, she moved to the Netherlands and began her PhD at the Erasmus 
University of Rotterdam in collaboration with The Patient Preferences in Benefit-Risk Assessments during 
the Drug Life Cycle (PREFER) project.  
